https://forbion.com/fr/ 2026-01-14T10:17:26+00:00 https://forbion.com/fr/about-us/ 2025-08-06T11:49:45+00:00 https://forbion.com/fr/about-us/impacting-the-future/ 2025-09-15T12:24:24+00:00 https://forbion.com/fr/about-us/history/ 2025-09-10T09:30:02+00:00 https://forbion.com/fr/about-us/careers/ 2025-07-29T13:42:03+00:00 https://forbion.com/fr/strategies/ 2025-11-05T13:58:59+00:00 https://forbion.com/fr/strategies/human-health/ 2025-09-01T14:00:20+00:00 https://forbion.com/fr/strategies/human-health/formation/ 2025-09-11T09:29:36+00:00 https://forbion.com/fr/strategies/human-health/ventures/ 2025-09-11T16:57:16+00:00 https://forbion.com/fr/strategies/human-health/growth/ 2025-09-11T17:02:21+00:00 https://forbion.com/fr/strategies/planetary-health/ 2025-09-01T14:00:43+00:00 https://forbion.com/fr/strategies/planetary-health/bioeconomy/ 2025-11-05T13:35:33+00:00 https://forbion.com/fr/portfolio/ 2025-12-01T14:12:06+00:00 https://forbion.com/fr/portfolio/beacon-therapeutics/ 2026-03-25T14:02:35+00:00 https://forbion.com/fr/portfolio/amphista-therapeutics/ 2026-03-25T12:24:47+00:00 https://forbion.com/fr/portfolio/azafaros/ 2025-09-19T12:09:54+00:00 https://forbion.com/fr/portfolio/airna/ 2026-03-23T09:43:36+00:00 https://forbion.com/fr/portfolio/am-pharma/ 2026-03-25T14:00:47+00:00 https://forbion.com/fr/portfolio/allecra-therapeutics/ 2025-09-18T09:04:40+00:00 https://forbion.com/fr/portfolio/anaveon/ 2026-03-25T12:25:04+00:00 https://forbion.com/fr/portfolio/aavantgarde-bio/ 2026-03-25T13:53:35+00:00 https://forbion.com/fr/portfolio/achilles-therapeutics/ 2025-09-18T09:03:47+00:00 https://forbion.com/fr/portfolio/bicycle-therapeutics/ 2026-03-24T13:48:02+00:00 https://forbion.com/fr/portfolio/bioinvent/ 2026-03-25T12:26:43+00:00 https://forbion.com/fr/portfolio/calluna-pharma/ 2026-03-25T14:04:59+00:00 https://forbion.com/fr/portfolio/capstan-therapeutics/ 2025-09-18T09:07:31+00:00 https://forbion.com/fr/portfolio/catalym/ 2026-03-25T14:20:30+00:00 https://forbion.com/fr/portfolio/cellcentric/ 2025-09-10T10:42:54+00:00 https://forbion.com/fr/portfolio/citryll/ 2026-03-24T14:09:52+00:00 https://forbion.com/fr/portfolio/complement-therapeutics/ 2026-03-24T14:11:10+00:00 https://forbion.com/fr/portfolio/dyne-therapeutics/ 2025-09-10T10:06:05+00:00 https://forbion.com/fr/portfolio/eeden/ 2026-03-25T12:28:25+00:00 https://forbion.com/fr/portfolio/engene/ 2026-03-24T14:23:39+00:00 https://forbion.com/fr/portfolio/engrail-therapeutics/ 2026-03-24T14:18:10+00:00 https://forbion.com/fr/portfolio/enterprise-therapeutics/ 2026-03-24T14:18:59+00:00 https://forbion.com/fr/portfolio/f2g/ 2026-03-23T10:00:22+00:00 https://forbion.com/fr/portfolio/granite-bio/ 2026-03-25T11:33:27+00:00 https://forbion.com/fr/portfolio/kynexis/ 2026-03-25T11:35:41+00:00 https://forbion.com/fr/portfolio/loqus23-therapeutics/ 2025-09-30T08:23:11+00:00 https://forbion.com/fr/portfolio/maplight-therapeutics/ 2026-03-23T10:05:44+00:00 https://forbion.com/fr/portfolio/marea-therapeutics/ 2026-03-25T11:37:00+00:00 https://forbion.com/fr/portfolio/mestag-therapeutics/ 2026-03-16T12:37:24+00:00 https://forbion.com/fr/portfolio/mosanna-therapeutics/ 2026-03-25T11:38:57+00:00 https://forbion.com/fr/portfolio/navigator-medicines/ 2026-03-25T11:43:29+00:00 https://forbion.com/fr/portfolio/nerre-therapeutics/ 2026-03-25T11:44:39+00:00 https://forbion.com/fr/portfolio/newamsterdam-pharma/ 2026-03-25T12:30:38+00:00 https://forbion.com/fr/portfolio/noema-pharma/ 2026-03-23T10:09:13+00:00 https://forbion.com/fr/portfolio/northsea-therapeutics/ 2025-09-10T10:05:07+00:00 https://forbion.com/fr/portfolio/novameat/ 2026-03-25T12:31:22+00:00 https://forbion.com/fr/portfolio/numab-therapeutics/ 2026-03-25T12:02:32+00:00 https://forbion.com/fr/portfolio/omeicos-therapeutics/ 2026-03-25T12:05:09+00:00 https://forbion.com/fr/portfolio/orbis-medicines/ 2026-03-25T12:11:39+00:00 https://forbion.com/fr/portfolio/pheon-therapeutics/ 2026-03-25T12:32:56+00:00 https://forbion.com/fr/portfolio/precirix/ 2026-03-25T12:14:42+00:00 https://forbion.com/fr/portfolio/prilenia-therapeutics/ 2026-03-25T12:33:34+00:00 https://forbion.com/fr/portfolio/progentos-therapeutics/ 2026-03-25T12:15:41+00:00 https://forbion.com/fr/portfolio/purespring-therapeutics/ 2026-03-25T12:34:53+00:00 https://forbion.com/fr/portfolio/rectify-pharma/ 2026-03-25T12:17:53+00:00 https://forbion.com/fr/portfolio/replimune/ 2026-03-25T12:16:34+00:00 https://forbion.com/fr/portfolio/rycarma-therapeutics/ 2026-03-25T12:19:35+00:00 https://forbion.com/fr/portfolio/seamless-therapeutics/ 2025-09-10T10:09:59+00:00 https://forbion.com/fr/portfolio/solasta-bio/ 2026-03-25T13:18:01+00:00 https://forbion.com/fr/portfolio/synox-therapeutics/ 2026-03-25T12:21:06+00:00 https://forbion.com/fr/portfolio/tessellate-bio/ 2025-09-10T10:37:07+00:00 https://forbion.com/fr/portfolio/vectory/ 2026-03-25T12:21:49+00:00 https://forbion.com/fr/portfolio/verdiva-bio/ 2026-03-23T15:39:09+00:00 https://forbion.com/fr/portfolio/vor-bio/ 2026-03-23T15:43:03+00:00 https://forbion.com/fr/portfolio/abiomed/ 2025-09-18T09:03:09+00:00 https://forbion.com/fr/portfolio/acadia-pharmaceuticals/ 2025-09-18T09:03:21+00:00 https://forbion.com/fr/portfolio/accelerated-technologies/ 2025-09-18T09:03:33+00:00 https://forbion.com/fr/portfolio/acorda-therapeutics/ 2025-09-18T09:03:56+00:00 https://forbion.com/fr/portfolio/aiolos-bio/ 2025-09-18T09:04:08+00:00 https://forbion.com/fr/portfolio/akarna-therapeutics/ 2025-09-18T09:04:20+00:00 https://forbion.com/fr/portfolio/alantos-pharmaceuticals/ 2025-09-18T09:04:30+00:00 https://forbion.com/fr/portfolio/amakem/ 2025-09-18T09:04:54+00:00 https://forbion.com/fr/portfolio/amt/ 2025-09-18T09:05:05+00:00 https://forbion.com/fr/portfolio/ardana/ 2025-09-18T09:05:16+00:00 https://forbion.com/fr/portfolio/argen-x/ 2025-09-18T09:05:29+00:00 https://forbion.com/fr/portfolio/argos-therapeutics/ 2025-09-18T09:05:37+00:00 https://forbion.com/fr/portfolio/ario-pharma/ 2025-09-18T09:05:47+00:00 https://forbion.com/fr/portfolio/armgo-pharma/ 2025-09-18T09:06:05+00:00 https://forbion.com/fr/portfolio/autonomic-technologies-europe/ 2025-09-18T09:06:16+00:00 https://forbion.com/fr/portfolio/bioceros/ 2025-09-18T09:06:26+00:00 https://forbion.com/fr/portfolio/biovex/ 2025-09-18T09:06:38+00:00 https://forbion.com/fr/portfolio/bluebird-bio/ 2025-09-18T09:06:51+00:00 https://forbion.com/fr/portfolio/borean-pharma/ 2025-09-18T09:07:01+00:00 https://forbion.com/fr/portfolio/cellnovo/ 2025-09-18T09:07:45+00:00 https://forbion.com/fr/portfolio/circulite/ 2025-09-18T09:08:01+00:00 https://forbion.com/fr/portfolio/curetis/ 2025-09-18T09:08:23+00:00 https://forbion.com/fr/portfolio/cytheris/ 2025-09-18T09:08:35+00:00 https://forbion.com/fr/portfolio/dezima-pharma/ 2025-09-18T09:08:49+00:00 https://forbion.com/fr/portfolio/escalier-biosciences/ 2025-09-18T09:09:02+00:00 https://forbion.com/fr/portfolio/exosome-diagnostics/ 2025-09-18T09:09:15+00:00 https://forbion.com/fr/portfolio/flowmedica/ 2025-09-18T09:09:26+00:00 https://forbion.com/fr/portfolio/forbion-european-acquisition-corporation/ 2025-09-18T09:09:43+00:00 https://forbion.com/fr/portfolio/fovea/ 2025-09-18T09:09:56+00:00 https://forbion.com/fr/portfolio/galapagos/ 2025-09-18T09:10:09+00:00 https://forbion.com/fr/portfolio/gicare-pharma/ 2025-09-18T09:10:20+00:00 https://forbion.com/fr/portfolio/glycart/ 2025-09-18T09:10:30+00:00 https://forbion.com/fr/portfolio/gotham-therapeutics/ 2025-09-18T09:10:40+00:00 https://forbion.com/fr/portfolio/gyroscope-therapeutics/ 2025-09-18T09:10:53+00:00 https://forbion.com/fr/portfolio/hookipa-biotech/ 2025-09-18T09:11:03+00:00 https://forbion.com/fr/portfolio/impella-cardiosystems/ 2025-09-18T09:11:18+00:00 https://forbion.com/fr/portfolio/inflazome/ 2025-09-18T09:11:29+00:00 https://forbion.com/fr/portfolio/insmed/ 2025-09-18T09:11:45+00:00 https://forbion.com/fr/portfolio/inversago-pharma/ 2025-09-18T09:11:59+00:00 https://forbion.com/fr/portfolio/kandy-therapeutics/ 2025-09-18T09:12:12+00:00 https://forbion.com/fr/portfolio/mariana-oncology/ 2025-09-18T09:12:24+00:00 https://forbion.com/fr/portfolio/milestone-pharmaceuticals-inc/ 2025-09-18T09:12:36+00:00 https://forbion.com/fr/portfolio/mitralign/ 2025-09-18T09:12:53+00:00 https://forbion.com/fr/portfolio/novogi/ 2025-09-18T09:13:04+00:00 https://forbion.com/fr/portfolio/oxitope/ 2025-09-18T09:13:14+00:00 https://forbion.com/fr/portfolio/oxular/ 2025-09-18T09:13:24+00:00 https://forbion.com/fr/portfolio/oxyrane/ 2025-09-18T09:13:34+00:00 https://forbion.com/fr/portfolio/pangenetics/ 2025-09-18T09:13:46+00:00 https://forbion.com/fr/portfolio/pathway-medical-technologies/ 2025-09-18T09:14:00+00:00 https://forbion.com/fr/portfolio/pieris-pharmaceuticals/ 2025-09-18T09:14:12+00:00 https://forbion.com/fr/portfolio/pneumrx/ 2025-09-18T09:14:25+00:00 https://forbion.com/fr/portfolio/promedior/ 2025-09-18T09:14:49+00:00 https://forbion.com/fr/portfolio/pulmagen-therapeutics/ 2025-09-18T09:15:01+00:00 https://forbion.com/fr/portfolio/rigontec/ 2025-09-18T09:15:14+00:00 https://forbion.com/fr/portfolio/rspr-pharma/ 2025-09-18T09:15:27+00:00 https://forbion.com/fr/portfolio/sanifit/ 2025-09-18T09:15:38+00:00 https://forbion.com/fr/portfolio/santaris-pharma/ 2025-09-18T09:16:37+00:00 https://forbion.com/fr/portfolio/staten-biotechnology/ 2025-09-18T09:16:52+00:00 https://forbion.com/fr/portfolio/transave/ 2025-09-18T09:17:03+00:00 https://forbion.com/fr/portfolio/uniqure/ 2025-09-18T09:17:14+00:00 https://forbion.com/fr/portfolio/vectivbio/ 2025-09-18T09:17:24+00:00 https://forbion.com/fr/portfolio/versanis-bio/ 2025-09-18T09:17:35+00:00 https://forbion.com/fr/portfolio/x-cell-medical/ 2025-09-18T09:17:50+00:00 https://forbion.com/fr/portfolio/xention/ 2025-09-18T09:18:02+00:00 https://forbion.com/fr/portfolio/prexton-therapeutics/ 2025-09-18T09:14:36+00:00 https://forbion.com/fr/portfolio/genomines/ 2026-03-23T10:02:00+00:00 https://forbion.com/fr/portfolio/ventures/ 2025-08-28T12:20:35+00:00 https://forbion.com/fr/portfolio/growth/ 2025-09-01T13:59:19+00:00 https://forbion.com/fr/portfolio/bioeconomy/ 2025-08-29T09:06:23+00:00 https://forbion.com/fr/portfolio/yellow-jersey-therapeutics/ 2025-09-18T09:18:22+00:00 https://forbion.com/fr/portfolio/sparrow-pharmaceuticals/ 2026-03-25T12:20:28+00:00 https://forbion.com/fr/portfolio/expedition-therapeutics/ 2026-03-23T09:56:04+00:00 https://forbion.com/fr/portfolio/elevara-medicines/ 2026-03-25T12:28:57+00:00 https://forbion.com/fr/portfolio/pact/ 2026-03-23T14:55:00+00:00 https://forbion.com/fr/portfolio/braveheart-bio/ 2026-03-23T08:54:16+00:00 https://forbion.com/fr/portfolio/gate-bioscience/ 2026-03-24T14:31:52+00:00 https://forbion.com/fr/portfolio/protego/ 2026-03-23T15:12:28+00:00 https://forbion.com/fr/portfolio/corsera-health/ 2026-03-24T14:12:25+00:00 https://forbion.com/fr/portfolio/altesa-biosciences/ 2026-03-23T09:48:44+00:00 https://forbion.com/fr/portfolio/slate-medicines-inc/ 2026-03-25T12:20:02+00:00 https://forbion.com/fr/portfolio/tropic-bio/ 2026-04-01T11:11:14+00:00 https://forbion.com/fr/team/ 2026-03-23T14:03:05+00:00 https://forbion.com/fr/team/alice-vickers-phd/ 2026-01-13T18:30:55+00:00 https://forbion.com/fr/team/audrey-cacaly-msc/ 2025-09-15T11:38:45+00:00 https://forbion.com/fr/team/carlo-incerti-md/ 2025-08-26T13:43:26+00:00 https://forbion.com/fr/team/charlotte-koldeweij-md-phd/ 2025-09-02T13:54:55+00:00 https://forbion.com/fr/team/dirk-kersten/ 2025-07-24T09:02:30+00:00 https://forbion.com/fr/team/dmitrij-hristodorov-phd/ 2025-11-06T13:30:16+00:00 https://forbion.com/fr/team/frank-g-holz-prof/ 2025-09-10T09:55:25+00:00 https://forbion.com/fr/team/geert-jan-mulder-md/ 2025-07-21T16:49:11+00:00 https://forbion.com/fr/team/gijs-van-den-brink-md-phd/ 2025-11-06T13:32:03+00:00 https://forbion.com/fr/team/gilles-van-tienderen-phd/ 2026-01-05T07:39:53+00:00 https://forbion.com/fr/team/holger-reithinger-phd/ 2025-11-06T13:06:53+00:00 https://forbion.com/fr/team/jasper-bos-phd/ 2025-07-21T16:50:19+00:00 https://forbion.com/fr/team/jens-wendland-md/ 2025-09-10T09:52:47+00:00 https://forbion.com/fr/team/john-ford-phd/ 2025-08-28T09:59:12+00:00 https://forbion.com/fr/team/john-jp-kastelein-md-phd-fesc/ 2025-09-09T12:16:56+00:00 https://forbion.com/fr/team/john-montana-phd-mrsa/ 2025-09-10T09:59:48+00:00 https://forbion.com/fr/team/jonathan-mcneill-md/ 2025-09-10T09:57:36+00:00 https://forbion.com/fr/team/kanay-khakhria-md/ 2025-08-26T14:00:04+00:00 https://forbion.com/fr/team/luuk-de-vries-phd/ 2025-09-12T07:50:44+00:00 https://forbion.com/fr/team/marco-boorsma-phd/ 2025-07-21T16:53:42+00:00 https://forbion.com/fr/team/martien-van-osch-msc/ 2026-01-06T09:39:11+00:00 https://forbion.com/fr/team/mathias-vinther-phd/ 2025-10-21T14:59:59+00:00 https://forbion.com/fr/team/matt-cooper-phd/ 2025-11-06T13:06:00+00:00 https://forbion.com/fr/team/melanie-de-almeida-phd/ 2026-01-05T07:39:18+00:00 https://forbion.com/fr/team/michael-hayden-mbchb-phd/ 2025-09-10T09:51:14+00:00 https://forbion.com/fr/team/morgan-haller-msc/ 2025-09-15T11:39:07+00:00 https://forbion.com/fr/team/nanna-lueneborg-phd-mba/ 2025-11-06T13:02:37+00:00 https://forbion.com/fr/team/patrick-round-md/ 2025-09-10T09:56:19+00:00 https://forbion.com/fr/team/patrick-vink-md-mba/ 2025-09-10T09:56:02+00:00 https://forbion.com/fr/team/peter-hoengaard-andersen-dr-med/ 2025-09-10T10:00:08+00:00 https://forbion.com/fr/team/philip-astley-sparke-fsa/ 2025-09-12T10:03:51+00:00 https://forbion.com/fr/team/simon-j-clark-prof/ 2025-09-10T09:55:49+00:00 https://forbion.com/fr/team/regina-salvat-phd/ 2025-09-15T11:39:26+00:00 https://forbion.com/fr/team/robbert-van-de-griendt-msc/ 2025-08-29T14:53:24+00:00 https://forbion.com/fr/team/roberto-hofmann-phd/ 2025-09-02T13:52:39+00:00 https://forbion.com/fr/team/rogier-rooswinkel-phd/ 2025-07-21T17:08:58+00:00 https://forbion.com/fr/team/rory-gummerson/ 2025-11-06T13:32:48+00:00 https://forbion.com/fr/team/sander-slootweg-msc/ 2025-07-21T16:56:50+00:00 https://forbion.com/fr/team/sander-van-deventer-md-phd/ 2025-08-27T10:20:57+00:00 https://forbion.com/fr/team/scott-friedman-md/ 2025-09-10T09:55:38+00:00 https://forbion.com/fr/team/tim-lohoff-phd/ 2025-11-06T12:51:05+00:00 https://forbion.com/fr/team/ton-logtenberg-phd/ 2025-12-03T12:45:05+00:00 https://forbion.com/fr/team/vanessa-carle-phd/ 2026-02-04T14:31:09+00:00 https://forbion.com/fr/team/vincent-loon-msc/ 2025-08-26T14:01:36+00:00 https://forbion.com/fr/team/wouter-joustra-msc/ 2025-07-21T17:00:26+00:00 https://forbion.com/fr/team/yigal-m-pinto-md-phd/ 2025-09-12T13:58:52+00:00 https://forbion.com/fr/team/cyril-lesser-msc-llm/ 2025-07-21T16:47:45+00:00 https://forbion.com/fr/team/devan-sequeira-mba/ 2025-07-21T16:48:42+00:00 https://forbion.com/fr/team/stefan-oschmann/ 2025-09-10T10:00:48+00:00 https://forbion.com/fr/team/per-falholt/ 2025-11-06T13:27:30+00:00 https://forbion.com/fr/team/onno-van-de-stolpe-msc/ 2025-11-06T13:40:17+00:00 https://forbion.com/fr/team/maximillien-souvereyns-msc-mba/ 2025-11-06T12:55:55+00:00 https://forbion.com/fr/team/liz-rodgers/ 2025-09-10T09:51:35+00:00 https://forbion.com/fr/team/joy-faucher/ 2025-11-03T09:05:46+00:00 https://forbion.com/fr/team/joseph-iwasyk-msc/ 2025-11-06T12:56:58+00:00 https://forbion.com/fr/team/floor-saris-msc/ 2025-09-10T10:01:35+00:00 https://forbion.com/fr/team/feike-sijbesma/ 2025-09-10T10:02:31+00:00 https://forbion.com/fr/team/cees-de-jong-md-mba/ 2025-09-10T09:51:47+00:00 https://forbion.com/fr/team/alexander-hoffmann/ 2025-08-27T14:30:06+00:00 https://forbion.com/fr/team/tineke-duijn/ 2025-07-21T16:45:48+00:00 https://forbion.com/fr/team/olga-ziessen/ 2026-01-28T09:22:29+00:00 https://forbion.com/fr/team/marijana-stojanovic/ 2025-07-21T16:41:03+00:00 https://forbion.com/fr/team/danielle-de-magalhaes/ 2025-07-21T16:38:01+00:00 https://forbion.com/fr/team/chelle-tjabring/ 2026-03-25T16:16:22+00:00 https://forbion.com/fr/team/alicia-dortona/ 2025-09-10T10:02:42+00:00 https://forbion.com/fr/team/wilfred-kevelam/ 2025-07-21T16:59:57+00:00 https://forbion.com/fr/team/walter-schram-bec-qc/ 2026-01-05T07:41:18+00:00 https://forbion.com/fr/team/stijn-jochemsen-msc/ 2025-09-11T12:32:39+00:00 https://forbion.com/fr/team/silva-dezelan-phd/ 2025-08-27T10:22:16+00:00 https://forbion.com/fr/team/sabina-osenberg-msc/ 2026-01-05T08:21:22+00:00 https://forbion.com/fr/team/rachelle-young/ 2025-09-22T14:50:22+00:00 https://forbion.com/fr/team/patricia-vonk-msc/ 2025-11-06T13:03:30+00:00 https://forbion.com/fr/team/pascal-van-wees-msc/ 2026-01-05T07:40:30+00:00 https://forbion.com/fr/team/maureen-wouters/ 2025-07-21T16:41:37+00:00 https://forbion.com/fr/team/machteld-groeneveld-llm-emba/ 2026-01-28T10:23:05+00:00 https://forbion.com/fr/team/laura-asbjornsen-llm-mba/ 2025-09-17T09:34:05+00:00 https://forbion.com/fr/team/jennifer-fritzsche-msc/ 2025-07-23T17:23:12+00:00 https://forbion.com/fr/team/iris-veldman-llm/ 2025-07-21T16:39:22+00:00 https://forbion.com/fr/team/josh-brumm/ 2025-09-10T16:11:27+00:00 https://forbion.com/fr/team/marc-van-voorst-tot-voorst/ 2025-11-06T13:33:46+00:00 https://forbion.com/fr/team/francine-macleod/ 2025-11-06T13:36:52+00:00 https://forbion.com/fr/team/nat-kolber/ 2025-11-06T13:39:25+00:00 https://forbion.com/fr/team/vivien-veninga/ 2025-11-07T08:59:23+00:00 https://forbion.com/fr/team/dragana-dragusin/ 2025-11-06T13:35:00+00:00 https://forbion.com/fr/team/jon-edwards/ 2025-12-23T10:54:42+00:00 https://forbion.com/fr/team/carolin-lanfer/ 2025-11-06T12:54:28+00:00 https://forbion.com/fr/team/steen-riisgaard/ 2025-12-03T08:38:32+00:00 https://forbion.com/fr/team/michael-burgess/ 2026-01-13T08:09:31+00:00 https://forbion.com/fr/team/lior-alperovich/ 2026-03-26T10:14:14+00:00 https://forbion.com/fr/team/viktorija-vodilovska/ 2026-03-26T10:14:02+00:00 https://forbion.com/fr/team/sebastien-garnier/ 2026-04-01T11:09:42+00:00 https://forbion.com/fr/team/philippe-van-santen/ 2026-03-26T10:14:32+00:00 https://forbion.com/fr/team/baris-duvan/ 2026-03-27T08:27:51+00:00 https://forbion.com/fr/sustainability/ 2025-09-16T15:17:14+00:00 https://forbion.com/fr/sustainability/human-health/ 2025-06-24T13:46:22+00:00 https://forbion.com/fr/sustainability/human-health/responsible-investment/ 2025-09-03T10:40:38+00:00 https://forbion.com/fr/sustainability/human-health/impact-on-human-health/ 2025-09-15T08:42:14+00:00 https://forbion.com/fr/sustainability/human-health/sfdr/ 2025-08-14T15:21:48+00:00 https://forbion.com/fr/sustainability/planetary-health/ 2025-08-19T12:56:39+00:00 https://forbion.com/fr/sustainability/planetary-health/responsible-investment/ 2025-09-03T10:40:22+00:00 https://forbion.com/fr/sustainability/planetary-health/impact-on-planetary-health/ 2025-09-15T09:48:50+00:00 https://forbion.com/fr/sustainability/planetary-health/sfdr/ 2025-08-14T15:35:33+00:00 https://forbion.com/fr/news-insights/ 2025-09-11T16:56:30+00:00 https://forbion.com/fr/news-insights/news/ 2026-03-12T09:12:40+00:00 https://forbion.com/fr/news-insights/news/ipem-interview-sander-slootweg/ 2025-07-18T14:22:22+00:00 https://forbion.com/fr/news-insights/news/beacon-therapeutics-completes-enrollment-in-registrational-phase-23-vista-trial-of-laru-zova-for-patients-with-xlrp/ 2025-07-28T16:08:05+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-fifth-exit-from-forbion-growth-opportunities-fund-ii-with-the-sale-of-capstan-therapeutics-to-abbvie-for-usd-21-billion/ 2025-07-28T16:12:53+00:00 https://forbion.com/fr/news-insights/news/fda-grants-rmat-designation-for-engene-s-detalimogene-enabling-potential-for-expedited-review-in-high-risk-non-muscle-invasive-bladder-cancer/ 2025-07-28T16:23:29+00:00 https://forbion.com/fr/news-insights/news/vor-bio-announces-175-million-private-placement/ 2025-07-28T16:27:05+00:00 https://forbion.com/fr/news-insights/news/capstan-therapeutics-announces-initiation-of-phase-1-trial-of-lead-in-vivo-car-t-therapy-cptx2309-for-treating-autoimmune-disease/ 2025-07-28T16:36:29+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-80-million-series-a-financing-in-mosanna-therapeutics-to-advance-novel-nighttime-nasal-spray-for-obstructive-sleep-apnea/ 2025-07-28T16:41:10+00:00 https://forbion.com/fr/news-insights/news/orbis-medicines-accelerates-next-generation-oral-macrocycle-platform-with-enhanced-artificial-intelligence-capabilities-of-gefion-supercomputer/ 2025-07-28T16:51:42+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-120-million-investment-in-cellcentric-to-advance-inobrodib-for-treating-multiple-myeloma/ 2025-07-28T16:57:48+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-132m-series-b-oversubscribed-financing-in-azafaros-to-advance-phase-3-clinical-programs-of-innovative-therapies-in-lysosomal-storage-disorders/ 2025-07-28T17:04:38+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-18m-series-a-financing-in-textile-recycling-technology-company-eeden/ 2025-07-28T17:29:26+00:00 https://forbion.com/fr/news-insights/news/purespring-therapeutics-granted-european-medicines-agency-ema-orphan-drug-designation-for-ps-002-for-the-treatment-of-patients-with-primary-iga-nephropathy-igan/ 2025-07-28T17:49:31+00:00 https://forbion.com/fr/news-insights/news/prilenia-enters-into-a-collaboration-and-license-agreement-with-ferrer-for-the-commercialization-and-co-development-of-pridopidine-in-europe-and-other-select-markets/ 2025-07-28T17:40:06+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-100-million-series-b-financing-of-granite-bio/ 2025-09-10T11:53:40+00:00 https://forbion.com/fr/news-insights/news/boehringer-ingelheim-and-tessellate-bio-partner-to-develop-first-in-class-precision-treatments-for-people-with-hard-to-treat-cancers/ 2025-07-29T18:45:35+00:00 https://forbion.com/fr/news-insights/news/rycarma-therapeutics-appoints-elizabeth-tarka-md-as-chief-medical-officer/ 2025-07-29T18:51:08+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-oversubscribed-155-million-series-b-financing-in-airna-to-fund-phase-12-clinical-trial-for-alpha-1-antitrypsin-deficiency-and-future-pipeline/ 2025-09-10T11:54:35+00:00 https://forbion.com/fr/news-insights/news/vectory-therapeutics-appoints-olga-uspenskaya-cadoz-as-chief-medical-officer/ 2025-07-29T19:01:35+00:00 https://forbion.com/fr/news-insights/news/purespring-therapeutics-appoints-haseeb-ahmad-as-chief-executive-officer/ 2025-07-30T13:13:41+00:00 https://forbion.com/fr/news-insights/news/orbis-medicines-names-veteran-rd-leader-mikael-dolsten-board-chair/ 2025-07-30T10:12:28+00:00 https://forbion.com/fr/news-insights/news/forbion-expands-us-presence-with-the-appointment-of-regina-salvat-phd-as-principal-in-the-boston-office/ 2025-08-12T10:56:44+00:00 https://forbion.com/fr/news-insights/news/loqus23-therapeutics-appoints-cyrus-mozayeni-md-to-chair-of-the-board-of-directors/ 2025-07-30T10:16:48+00:00 https://forbion.com/fr/news-insights/news/navigator-medicines-appoints-tausif-tosh-butt-as-chief-executive-officer-and-khurem-farooq-as-chairman-of-the-board-of-directors/ 2025-07-30T10:20:34+00:00 https://forbion.com/fr/news-insights/news/forbion-bioeconomy-fund-i-surpasses-150-million-target-raising-1645-million-with-strong-institutional-lp-support/ 2025-07-18T15:35:50+00:00 https://forbion.com/fr/news-insights/news/forbion-promotes-dirk-kersten-to-managing-partner-and-strengthens-us-team/ 2025-07-18T15:36:12+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-over-410m-series-a-financing-to-launch-verdiva-bio-a-clinical-stage-cardiometabolic-company-advancing-next-generation-therapies/ 2025-07-30T13:28:27+00:00 https://forbion.com/fr/news-insights/news/catalym-appoints-scott-clarke-ceo-as-company-initiates-global-phase-2b-clinical-development-program-for-visugromab/ 2025-07-30T13:24:36+00:00 https://forbion.com/fr/news-insights/news/azafaros-granted-important-regulatory-designations-and-clearance-by-european-authorities-for-global-phase-3-studies-to-be-initiated-in-2025/ 2025-08-07T15:27:55+00:00 https://forbion.com/fr/news-insights/news/rycarma-therapeutics-announces-new-leadership-and-company-name-introduces-program-in-heart-failure/ 2025-08-07T15:34:09+00:00 https://forbion.com/fr/news-insights/news/orbis-medicines-raises-eur-90-million-series-a-funding-round-to-develop-pipeline-of-oral-macrocycles/ 2025-08-07T15:39:42+00:00 https://forbion.com/fr/news-insights/news/noema-pharma-appoints-volker-knappertz-md-as-executive-vicepresident-of-research-development/ 2025-08-07T15:49:34+00:00 https://forbion.com/fr/news-insights/news/kynexis-announces-positive-topline-results-from-phase-1-study-of-kyn-5356-a-potential-treatment-for-cognitive-impairment-associated-with-schizophrenia/ 2025-08-07T15:54:37+00:00 https://forbion.com/fr/news-insights/news/vectory-strengthens-leadership-team-with-appointment-of-jim-scibetta-as-new-ceo/ 2025-08-07T16:52:10+00:00 https://forbion.com/fr/news-insights/news/forbion-welcomes-gijs-van-den-brink-md-phd-as-operating-partner/ 2025-07-18T15:44:25+00:00 https://forbion.com/fr/news-insights/news/noema-pharma-extends-series-b-financing-round-closing-at-chf-130-million-147-million/ 2025-08-07T17:13:39+00:00 https://forbion.com/fr/news-insights/news/catalym-s-visugromab-phase-12a-data-demonstrating-clinical-proof-of-concept-for-reversing-resistance-to-checkpoint-inhibitors-through-gdf-15-neutralization-published-in-nature/ 2025-08-07T17:00:05+00:00 https://forbion.com/fr/news-insights/news/citryll-raises-eur-85-million-series-b-to-advance-novel-net-targeting-therapy-for-immune-mediated-inflammatory-disorders/ 2025-08-07T17:19:38+00:00 https://forbion.com/fr/news-insights/news/mestag-therapeutics-announces-licensing-of-a-novel-inflammatory-disease-target-from-its-raft-platform/ 2025-08-08T11:03:03+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-bio-announces-fda-orphan-drug-designation-for-aavb-081-for-the-treatment-of-usher-syndrome-type-1b-retinitis-pigmentosa/ 2025-08-08T15:18:36+00:00 https://forbion.com/fr/news-insights/news/forbion-in-collaboration-with-members-of-the-eu-life-sciences-esg-knowledge-project-release-2025-questionnaire/ 2025-07-18T14:42:00+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-appoints-dr-muhammad-ali-memon-frcophth-as-chief-medical-officer/ 2025-08-08T15:24:29+00:00 https://forbion.com/fr/news-insights/news/numab-therapeutics-and-kaken-pharmaceutical-enter-collaboration-and-option-agreement-for-multi-specific-antibody-nd081-for-treatment-of-inflammatory-bowel-disease/ 2025-08-08T15:32:54+00:00 https://forbion.com/fr/news-insights/news/tessellate-bio-announces-appointment-of-lara-boyd-as-chief-business-officer/ 2025-08-08T15:41:07+00:00 https://forbion.com/fr/news-insights/news/noema-pharma-announces-first-patients-dosed-in-phase-2b-study-with-gemlapodect-noe-105-a-first-in-class-investigational-therapy-for-tourette-syndrome/ 2025-08-08T15:45:55+00:00 https://forbion.com/fr/news-insights/news/synox-therapeutics-adds-new-investor-and-capital-to-series-b-financing-raising-total-to-92-million-and-doses-first-patients-in-phase-3-trial/ 2025-08-08T15:58:52+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-founder-and-chief-scientific-officer-professor-alberto-auricchio-is-elected-as-president-of-the-european-society-of-gene-and-cell-therapy/ 2025-08-08T16:02:19+00:00 https://forbion.com/fr/news-insights/news/forbion-policy-for-responsible-investments-2024/ 2025-07-21T16:16:52+00:00 https://forbion.com/fr/news-insights/news/bioeconomy-policy-for-responsible-investments-2024/ 2025-07-21T16:18:19+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-appoints-ms-lauren-kaskiel-as-chief-business-officer/ 2025-08-08T16:38:15+00:00 https://forbion.com/fr/news-insights/news/noema-pharma-announces-noe-105-gemlapodect-phase-2a-study-in-tourette-syndrome-met-primary-and-all-key-secondary-endpoints/ 2025-08-18T14:17:30+00:00 https://forbion.com/fr/news-insights/news/forbion-raises-in-excess-of-2-billion-for-two-new-funds/ 2025-07-23T10:15:35+00:00 https://forbion.com/fr/news-insights/news/purespring-therapeutics-raises-80-105-million-in-series-b-financing-to-transform-the-treatment-of-kidney-diseases/ 2025-08-18T14:29:48+00:00 https://forbion.com/fr/news-insights/news/calluna-pharma-appoints-mark-gaffney-as-chief-executive-officer-and-mark-altmeyer-as-independent-chair-of-the-board/ 2025-08-18T14:23:37+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-announces-3-oral-presentations-at-the-european-society-of-gene-cell-therapy-31st-annual-meeting-in-rome/ 2025-08-18T14:33:31+00:00 https://forbion.com/fr/news-insights/news/mestag-therapeutics-announces-license-and-research-collaboration-with-msd-to-identify-novel-targets-for-inflammatory-diseases/ 2025-08-18T14:38:31+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-35-million-c-43-million-series-a-financing-in-loqus23-therapeutics-to-advance-its-small-molecule-somatic-expansion-inhibition-therapy-for-huntington-s-disease/ 2025-08-18T14:43:28+00:00 https://forbion.com/fr/news-insights/news/forbion-head-of-impact-esg-named-as-one-of-top-50-women-in-sustainable-finance-2024/ 2025-07-18T15:06:23+00:00 https://forbion.com/fr/news-insights/news/prilenia-appoints-rob-lauzen-as-chief-financial-officer-and-jason-marks-as-chief-legal-officer/ 2025-08-18T14:49:48+00:00 https://forbion.com/fr/news-insights/news/orbis-medicines-vivtex-form-research-exclusive-licensing-collaboration-to-support-orbis-development-of-next-generation-orally-dosable-ncycles/ 2025-08-18T14:56:10+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-announces-first-patient-dosed-in-first-in-human-phase-12-luce-1-study-evaluating-aavb-081-dual-aav-in-retinitis-pigmentosa-related-to-usher-syndrome-type-1b/ 2025-08-18T15:22:23+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-174m-oversubscribed-series-a-financing-of-novameat-to-accelerate-and-scale-production-capacity-of-plant-based-meat/ 2025-09-10T12:31:03+00:00 https://forbion.com/fr/news-insights/news/f2g-announces-100-million-financing-to-advance-late-stage-development-and-commercialization-of-novel-antifungal-drug-candidate-olorofim-in-the-us/ 2025-08-18T15:32:15+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-14m-series-a-in-solasta-bio-to-advance-development-and-commercialisation-of-first-in-class-sustainable-crop-protection-solutions/ 2025-09-10T12:30:22+00:00 https://forbion.com/fr/news-insights/news/positive-niemann-pick-disease-type-c-npc-and-gm2-gangliosidosis-data-from-nizubaglustat-phase-2-rainbow-study-conducted-by-azafaros-presented-at-major-metabolic-disease-conference/ 2025-08-18T15:54:55+00:00 https://forbion.com/fr/news-insights/news/forbion-impact-esg-report-2023/ 2025-07-21T16:15:19+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-appoints-antony-mattessich-as-chief-executive-officer/ 2025-08-18T16:01:12+00:00 https://forbion.com/fr/news-insights/news/prilenia-s-pridopidine-for-huntington-s-disease-accepted-for-european-marketing-authorisation-review/ 2025-08-18T16:16:14+00:00 https://forbion.com/fr/news-insights/news/mestag-therapeutics-awarded-significant-grant-from-innovate-uk-s-prestigious-cancer-therapeutics-program-to-accelerate-the-path-to-the-clinic-for-mst-0300/ 2025-08-18T16:31:38+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-100-million-series-a-funding-in-navigator-medicines-to-advance-development-of-best-in-class-antibody-therapeutics-for-autoimmune-diseases/ 2025-08-18T16:48:13+00:00 https://forbion.com/fr/news-insights/news/noema-pharma-announces-completion-of-enrollment-for-galene-phase-2b-trial-evaluating-noe-101-a-first-in-class-mglur5-nam-for-seizure-control-in-tuberous-sclerosis-complex/ 2025-08-18T17:00:12+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-oversubscribed-60-million-financing-in-airna-to-advance-new-class-of-rna-editing-medicines-and-progress-best-in-class-aatd-program-into-the-clinic/ 2025-08-18T17:16:23+00:00 https://forbion.com/fr/news-insights/news/engene-announces-appointment-of-ron-cooper-as-chief-executive-officer/ 2025-08-19T10:21:48+00:00 https://forbion.com/fr/news-insights/news/beacon-therapeutics-appoints-lance-baldo-md-as-chief-executive-officer-and-thomas-biancardi-as-chief-financial-officer/ 2025-08-18T17:36:13+00:00 https://forbion.com/fr/news-insights/news/enterprise-therapeutics-doses-first-person-with-cystic-fibrosis-in-phase-2-trial-for-novel-therapy-etd001/ 2025-08-19T10:27:25+00:00 https://forbion.com/fr/news-insights/news/forbion-growth-opportunities-fund-participates-in-150m-series-d-financing-of-catalym/ 2025-08-19T11:20:26+00:00 https://forbion.com/fr/news-insights/news/vectory-appoints-seasoned-biotech-leader-adam-rosenberg-as-chair-of-the-board/ 2025-08-19T11:26:31+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-170-million-series-b-funding-in-beacon-therapeutics-to-advance-development-of-ophthalmic-gene-therapies/ 2025-08-19T11:31:18+00:00 https://forbion.com/fr/news-insights/news/forbion-strengthens-us-presence-hiring-biotech-industry-leader-and-opening-boston-office/ 2025-07-18T15:51:38+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-and-acino-sign-exclusive-licensing-and-supply-agreement-for-allecra-s-novel-antibiotic-exblifep-in-gulf-cooperation-council-countries-and-south-africa/ 2025-08-19T11:37:10+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-first-close-of-its-new-bioeconomy-fund-i-backing-biotech-enabled-companies-aiming-to-impact-the-future-of-our-planet/ 2025-07-18T15:54:44+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-190-million-financing-of-marea-therapeutics/ 2025-08-19T11:45:40+00:00 https://forbion.com/fr/news-insights/news/catalym-reports-impressive-and-lasting-responses-including-multiple-complete-responses-in-heavily-pretreated-late-to-last-line-metastatic-nsclc-urothelial-and-hepatocellular-cancer-patients-treated-with-visugromabnivolumab-combination/ 2025-08-19T11:58:54+00:00 https://forbion.com/fr/news-insights/news/kynexis-appoints-esteemed-scientific-advisory-board-members-to-advance-precision-therapeutics-for-brain-diseases/ 2025-08-19T13:13:57+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-125-billion-sale-to-johnson-johnson-of-numab-therapeutics-subsidiary-including-rights-to-nm26-a-bi-specific-antibody-for-the-treatment-of-atopic-dermatitis-marking-its-sixth-consecutive-billion-dollarplus-exit/ 2025-08-19T13:36:50+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-announces-closing-of-public-offering-of-common-stock-full-exercise-by-underwriters-of-option-to-purchase-additional-shares/ 2025-08-19T13:25:01+00:00 https://forbion.com/fr/news-insights/news/bicycle-therapeutics-announces-555-million-private-placement-equity-financing/ 2025-08-19T13:43:46+00:00 https://forbion.com/fr/news-insights/news/noema-pharma-announces-first-patient-dosed-in-phase-2a-study-of-noe-115-a-first-in-class-investigational-therapy-for-the-treatment-of-vasomotor-symptoms-and-additional-symptoms-associated-with-menopause/ 2025-08-19T13:48:03+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-65-million-series-a-financing-of-progentos-therapeutics/ 2025-08-19T13:52:27+00:00 https://forbion.com/fr/news-insights/news/pheon-therapeutics-announces-120m-series-b-financing-to-fund-development-of-its-differentiated-adc-pipeline/ 2025-08-19T13:58:14+00:00 https://forbion.com/fr/news-insights/news/engene-announces-the-election-of-paul-hastings-and-wouter-joustra-to-its-board-of-directors/ 2025-08-19T14:54:36+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-presents-the-design-of-its-innovative-luce-1-trial-for-ush1b-at-the-9th-annual-retinal-cell-and-gene-therapy-innovation-summit/ 2025-08-19T15:01:30+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/ 2025-08-19T16:10:07+00:00 https://forbion.com/fr/news-insights/news/synox-therapeutics-secures-up-to-35m-debt-financing-with-hercules-capital-to-progress-development-and-commercialisation-of-emactuzumab/ 2025-08-19T15:09:07+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-presents-positive-preclinical-data-in-large-animal-models-from-its-stargardt-disease-program-in-an-oral-presentation-at-the-asgct-2024-annual-meeting/ 2025-08-19T15:13:06+00:00 https://forbion.com/fr/news-insights/news/seamless-therapeutics-announces-new-ceo-and-board-chairman-to-support-us-expansion-of-programmable-recombinase-gene-editing-technology-platform/ 2025-08-19T15:30:33+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-75m-series-b-financing-in-synox-therapeutics/ 2025-08-19T15:47:10+00:00 https://forbion.com/fr/news-insights/news/prilenia-to-present-latest-research-from-its-pridopidine-programs-for-huntington-disease-and-als-at-aan-2024/ 2025-08-19T15:53:33+00:00 https://forbion.com/fr/news-insights/news/prilenia-names-jina-swartz-md-phd-as-chief-medical-officer/ 2025-08-19T16:04:49+00:00 https://forbion.com/fr/news-insights/news/forbion-invests-in-capstan-therapeutics-with-participation-in-175m-oversubscribed-series-b-financing/ 2025-08-19T16:15:39+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-oversubscribed-157m-series-b-financing-round-in-engrail-therapeutics/ 2025-08-19T16:21:39+00:00 https://forbion.com/fr/news-insights/news/azafaros-announces-completion-of-12-week-phase-2-rainbow-study-evaluating-lead-asset-nizubaglustat-in-rare-disease-patients/ 2025-08-19T16:29:31+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-doses-first-patient-in-phase-3-tandem-clinical-trial-evaluating-fixed-dose-combination-of-obicetrapib-and-ezetimibe-in-patients-with-hefh-andor-ascvd/ 2025-08-19T16:36:13+00:00 https://forbion.com/fr/news-insights/news/prilenia-plans-to-submit-marketing-authorization-application-maa-in-the-eu-for-pridopidine-in-huntington-s-disease/ 2025-08-19T16:41:02+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-26-million-seed-financing-with-launch-of-orbis-medicines/ 2025-08-19T16:50:13+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-announces-us-fda-approval-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections/ 2025-08-19T17:00:19+00:00 https://forbion.com/fr/news-insights/news/northsea-therapeutics-initiates-phase-2a-trial-of-orziloben-nst-6179-in-intestinal-failure-associated-liver-disease-ifald/ 2025-08-19T17:08:24+00:00 https://forbion.com/fr/news-insights/news/mestag-therapeutics-enlists-leading-cancer-biology-and-immunology-advisors-to-support-clinical-development-of-its-lead-oncology-program/ 2025-08-19T17:19:19+00:00 https://forbion.com/fr/news-insights/news/engene-announces-oversubscribed-200-million-private-placement-financing/ 2025-08-19T17:45:43+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-announces-pricing-of-1753-million-public-offering-of-ordinary-shares-and-pre-funded-warrants/ 2025-08-20T09:41:28+00:00 https://forbion.com/fr/news-insights/news/enterprise-therapeutics-closes-26-million-331-million-series-b-follow-on-financing/ 2025-08-20T11:43:51+00:00 https://forbion.com/fr/news-insights/news/armgo-pharma-publishes-positive-phase-1b-trial-results-of-rycal-arm210-for-the-treatment-of-ryanodine-receptor-1-related-myopathies/ 2025-08-20T12:21:39+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-announces-new-data-demonstrating-in-vivo-efficacy-and-cns-activity-of-its-mechanistically-differentiated-targeted-protein-degraders/ 2025-08-22T14:03:36+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-75-million-eur-series-a-financing-in-calluna-pharma/ 2025-08-22T14:11:35+00:00 https://forbion.com/fr/news-insights/news/azafaros-to-present-data-from-pronto-study-in-patients-with-gm1-and-gm2-gangliosidoses-at-the-20th-annual-worldsymposium/ 2025-08-22T14:07:04+00:00 https://forbion.com/fr/news-insights/news/investing-in-vision-innovation-in-retinal-therapeutics-and-the-influence-on-venture-capital-investment/ 2025-07-21T16:14:10+00:00 https://forbion.com/fr/news-insights/news/vectory-appoints-khurem-farooq-to-board-of-directors/ 2025-08-22T14:16:14+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-announces-closing-of-public-offering-of-common-stock-and-full-exercise-by-underwriters-of-option-to-purchase-additional-shares/ 2025-08-22T14:20:36+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-aiolos-bio-inc-aiolos-to-be-acquired-by-gsk-for-up-to-14-billion/ 2025-08-22T14:48:27+00:00 https://forbion.com/fr/news-insights/news/catalym-appoints-drug-development-leader-roy-baynes-to-its-board-of-directors-and-strengthens-scientific-advisory-board-with-three-accomplished-lung-and-bladder-cancer-specialists/ 2025-08-22T14:53:46+00:00 https://forbion.com/fr/news-insights/news/kynexis-announces-initiation-of-first-in-human-phase-1-study-of-kyn-5356-a-potential-treatment-for-cognitive-impairment-associated-with-schizophrenia/ 2025-08-26T14:37:30+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-announces-pricing-of-300-million-public-offering-of-common-stock/ 2025-08-26T14:36:11+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-announces-the-establishment-of-medical-advisory-board/ 2025-08-26T14:39:47+00:00 https://forbion.com/fr/news-insights/news/aiolos-bio-strengthens-and-expands-leadership-team-with-key-appointments/ 2025-08-26T14:41:48+00:00 https://forbion.com/fr/news-insights/news/azafaros-phase-2-rainbow-study-evaluating-nizubaglustat-in-gm2-and-npc-patients-is-now-fully-enrolled/ 2025-08-26T14:44:57+00:00 https://forbion.com/fr/news-insights/news/catalym-presents-positive-phase-2a-outcome-for-visugromab-in-advanced-nsclc-and-urothelial-cancer-at-the-esmo-immuno-oncology-congress-2023/ 2025-08-26T14:47:13+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-appoints-dr-matthias-hebben-as-chief-technology-officer/ 2025-08-26T15:08:43+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-129-million-series-a-financing-of-vectory-one-of-the-largest-private-biotech-financings-in-europe-in-2023/ 2025-08-26T15:25:40+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-enrols-first-us-participant-in-the-non-interventional-i-gain-study-of-people-diagnosed-with-geographic-atrophy/ 2025-08-26T15:30:54+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-appoints-dr-peter-k-kaiser-to-the-board-of-directors/ 2025-08-26T15:37:35+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-57-million-series-a-financing-in-kynexis-a-new-precision-therapeutics-biotech-for-brain-diseases/ 2025-08-26T15:41:08+00:00 https://forbion.com/fr/news-insights/news/engene-nasdaq-engn-launched-as-publicly-traded-genetic-medicines-company/ 2025-08-26T15:49:48+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-appoints-michael-heffernan-as-chairman-of-its-board-of-directors/ 2025-08-26T15:53:35+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-245-million-series-a-financing-of-aiolos/ 2025-08-26T15:59:30+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-85m-series-a-financing-in-rampart-bioscience/ 2025-08-26T16:13:03+00:00 https://forbion.com/fr/news-insights/news/oxular-doses-first-patients-in-oxeye-phase-2-clinical-trial-of-suprachoroidal-oxu-001-as-a-long-acting-treatment-for-diabetic-macular-edema/ 2025-08-26T16:16:36+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-tessellate-bio-emerges-from-stealth/ 2025-08-27T12:46:06+00:00 https://forbion.com/fr/news-insights/news/northsea-therapeutics-receives-fda-rare-pediatric-disease-designation-for-sefa-6179-for-the-treatment-of-intestinal-failure-associated-liver-disease/ 2025-08-27T12:45:11+00:00 https://forbion.com/fr/news-insights/news/forbion-impact-report-2022/ 2025-09-15T11:31:14+00:00 https://forbion.com/fr/news-insights/news/forbion-policy-for-responsible-investments-2023/ 2025-07-21T16:09:28+00:00 https://forbion.com/fr/news-insights/news/am-pharma-announces-positive-clinical-data-from-phase-1b-study-evaluating-ilofotase-alfa-in-hypophosphatasia-patients/ 2025-08-27T12:49:57+00:00 https://forbion.com/fr/news-insights/news/fierce-biotech-the-fundamentals-are-really-strong-why-investors-are-staying-loyal-to-european-biotech-in-2023/ 2025-07-18T16:02:25+00:00 https://forbion.com/fr/news-insights/news/euvc-223-podcast-with-forbion-partner-juliette-audet/ 2025-07-18T15:59:28+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-announces-initial-data-from-phase-2a-clinical-trial-evaluating-obicetrapib-in-patients-with-early-alzheimer-s-disease-who-carry-an-apoe4-mutation/ 2025-08-27T12:53:14+00:00 https://forbion.com/fr/news-insights/news/pharma-deal-making-a-bright-spot-amid-the-gloom/ 2025-07-18T15:57:57+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-appoints-dr-doug-kerr-to-the-board-of-directors/ 2025-08-27T12:59:58+00:00 https://forbion.com/fr/news-insights/news/oxular-announces-appointment-of-mark-gaffney-as-chief-executive-officer/ 2025-08-27T13:10:10+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-175-million-series-b-financing-of-mariana-oncology-as-first-investment-of-forbion-ventures-fund-vi/ 2025-08-27T13:14:18+00:00 https://forbion.com/fr/news-insights/news/amg-completes-investment-in-forbion/ 2025-07-18T16:02:45+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-announces-appointment-of-william-bj-jones-as-chief-commercial-officer/ 2025-08-27T14:18:59+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-inversago-pharma-to-be-acquired-by-novo-nordisk/ 2025-08-27T14:26:35+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-completes-enrollment-in-pivotal-phase-3-broadway-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia-andor-established-atherosclerotic-cardiovascular-disease/ 2025-08-27T14:33:44+00:00 https://forbion.com/fr/news-insights/news/pheon-therapeutics-appoints-industry-veteran-cyrus-mozayeni-md-as-chief-executive-officer/ 2025-08-27T14:38:56+00:00 https://forbion.com/fr/news-insights/news/tumor-derived-gdf-15-blocks-lfa-1-dependent-t-cell-recruitment-and-suppresses-responses-to-anti-pd-1-treatment/ 2025-07-21T16:08:03+00:00 https://forbion.com/fr/news-insights/news/armgo-pharma-enrolls-first-patient-in-phase-2-trial-of-arm210-for-the-treatment-of-catecholaminergic-polymorphic-ventricular-tachycardia/ 2025-08-27T14:44:18+00:00 https://forbion.com/fr/news-insights/news/lilly-to-acquire-versanis-to-improve-patient-outcomes-in-cardiometabolic-diseases/ 2025-08-27T14:48:08+00:00 https://forbion.com/fr/news-insights/news/sifted-the-10-most-active-techbio-investors-in-europe/ 2025-07-18T15:53:05+00:00 https://forbion.com/fr/news-insights/news/pheon-therapeutics-enters-into-license-agreement-with-biocytogen-pharmaceuticals/ 2025-08-27T14:55:55+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-submits-new-drug-application-to-the-us-fda-for-exblifep-for-the-treatment-of-complicated-urinary-tract-infections/ 2025-08-27T14:59:52+00:00 https://forbion.com/fr/news-insights/news/amg-announces-partnership-with-forbion/ 2025-07-18T16:01:53+00:00 https://forbion.com/fr/news-insights/news/inversago-pharma-presents-data-from-phase-1b-trial-of-inv-202-a-peripheral-cb1r-blocker-for-metabolic-syndrome-at-the-83rd-american-diabetes-association-scientific-sessions/ 2025-08-27T15:04:58+00:00 https://forbion.com/fr/news-insights/news/noema-pharma-appoints-ilise-lombardo-md-as-chief-executive-officer/ 2025-08-27T15:07:14+00:00 https://forbion.com/fr/news-insights/news/omeicos-therapeutics-receives-25-million-euros-in-grant-funding-supporting-omt-28-s-development-in-mitochondrial-diseases-through-a-phase-2a-clinical-study/ 2025-08-27T15:13:13+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-unveils-state-of-the-art-laboratory-at-stevenage-bioscience-catalyst/ 2025-08-27T15:20:16+00:00 https://forbion.com/fr/news-insights/news/azafaros-announces-enrollment-of-first-patient-in-phase-2-rainbow-study-evaluating-az-3102-in-gm2-and-np-c-patients/ 2025-08-27T15:34:02+00:00 https://forbion.com/fr/news-insights/news/bioinvent-announces-additional-efficacy-data-from-intravenous-part-of-phase-12-trial-with-bi-1206-in-solid-tumors/ 2025-08-27T15:40:22+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-61-million-series-a-financing-in-aavantgarde-to-advance-two-therapeutic-programs-into-the-clinic/ 2025-08-27T15:44:57+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-announces-pricing-of-upsized-secondary-offering-of-ordinary-shares/ 2025-08-27T15:50:18+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-announces-positive-topline-results-from-phase-2b-dose-finding-trial-evaluating-obicetrapib-in-japanese-patients/ 2025-08-27T15:57:05+00:00 https://forbion.com/fr/news-insights/news/replimune-appoints-veleka-r-peeples-dyer-to-its-board-of-directors/ 2025-08-27T16:02:06+00:00 https://forbion.com/fr/news-insights/news/ironwood-enters-into-definitive-agreement-to-acquire-vectivbio-a-clinical-stage-biotech-company-pioneering-novel-treatments-for-severe-rare-gastrointestinal-diseases/ 2025-08-27T16:11:07+00:00 https://forbion.com/fr/news-insights/news/engene-inc-and-forbion-european-acquisition-corp-feac-nasdaq-frbn-announce-business-combination-agreement-to-create-nasdaq-listed-biotechnology-company-developing-next-generation-non-viral-locally-administered-gene-therapies/ 2025-08-27T16:16:21+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-40-million-series-a-in-dualyx/ 2025-08-27T16:23:44+00:00 https://forbion.com/fr/news-insights/news/forbion-appoints-silva-dezelan-phd-as-head-of-impact-and-esg/ 2025-07-18T16:11:07+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-completes-enrollment-in-pivotal-phase-3-brooklyn-clinical-trial-evaluating-obicetrapib-in-patients-with-heterozygous-familial-hypercholesterolemia/ 2025-08-27T16:31:30+00:00 https://forbion.com/fr/news-insights/news/forbion-raises-135-billion-across-two-funds/ 2025-07-18T16:21:01+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-72-million-series-a-financing-in-complement-therapeutics-to-advance-novel-therapies-targeting-complement-mediated-diseases/ 2025-08-28T10:29:22+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-appoints-janneke-van-der-kamp-to-its-board-of-directors/ 2025-08-28T10:32:12+00:00 https://forbion.com/fr/news-insights/news/precision-financing/ 2025-07-18T15:50:55+00:00 https://forbion.com/fr/news-insights/news/vectory-appoints-michael-wyzga-as-cfo-and-adds-jean-franchi-to-its-board-of-directors/ 2025-08-28T13:21:27+00:00 https://forbion.com/fr/news-insights/news/azafaros-appoints-chief-operating-officer-and-head-of-finance/ 2025-08-28T13:17:33+00:00 https://forbion.com/fr/news-insights/news/seamless-therapeutics-launches-with-125m-seed-financing-to-advance-transformative-gene-editing-platform-based-on-programmable-precision-designer-recombinases/ 2025-08-28T13:22:52+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-chf-103-million-investment-in-noema-pharma/ 2025-08-28T13:28:14+00:00 https://forbion.com/fr/news-insights/news/life-changing-treatments-for-rare-disease-a-beacon-of-hope/ 2025-07-18T15:46:57+00:00 https://forbion.com/fr/news-insights/news/prilenia-announces-topline-results-for-pridopidine-in-phase-2-als-study/ 2025-08-28T15:02:52+00:00 https://forbion.com/fr/news-insights/news/rectify-pharmaceuticals-expands-clinical-drug-development-expertise-with-board-and-sab-appointments/ 2025-08-28T15:28:35+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-enrols-first-patient-in-non-interventional-i-gain-study-of-people-diagnosed-with-geographic-atrophy/ 2025-08-28T15:33:51+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-appoints-john-w-smither-to-its-board-of-directors/ 2025-08-28T15:46:27+00:00 https://forbion.com/fr/news-insights/news/bia-finance-report-forbion-named-the-most-active-non-uk-investor/ 2025-07-18T15:43:58+00:00 https://forbion.com/fr/news-insights/news/oxular-limited-announces-acceptance-of-ind-for-suprachoroidal-oxu-001-for-the-treatment-of-diabetic-macular-edema/ 2025-08-28T15:50:46+00:00 https://forbion.com/fr/news-insights/news/vectory-and-annogen-announce-research-collaboration-for-the-development-of-cns-cell-specific-promoters/ 2025-08-28T15:57:41+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-announces-positive-results-from-rose2-phase-2-trial-evaluating-obicetrapib-in-combination-with-ezetimibe-as-an-adjunct-to-high-intensity-statin-therapy/ 2025-08-28T16:01:06+00:00 https://forbion.com/fr/news-insights/news/azafaros-strengthens-medical-and-scientific-management-team-reflecting-clinical-progress/ 2025-08-28T16:05:14+00:00 https://forbion.com/fr/news-insights/news/azafaros-receives-fda-s-ind-clearance-and-fast-track-designation/ 2025-08-28T16:19:05+00:00 https://forbion.com/fr/news-insights/news/northsea-therapeutics-appoints-morris-j-birnbaum-to-the-board/ 2025-08-29T13:47:58+00:00 https://forbion.com/fr/news-insights/news/mestag-therapeutics-appoints-prof-ton-logtenberg-as-chair/ 2025-08-29T13:51:37+00:00 https://forbion.com/fr/news-insights/news/f2g-announces-fda-filing-acceptance-of-new-drug-application-for-olorofim-for-the-treatment-of-invasive-fungal-infections/ 2025-08-29T13:52:37+00:00 https://forbion.com/fr/news-insights/news/catalym-expands-visugromab-development-based-on-positive-early-phase-2-data-in-two-indications-and-adds-confirmatory-response-predictive-biomarker-cohort/ 2025-08-29T13:55:12+00:00 https://forbion.com/fr/news-insights/news/rectify-pharmaceutical-announces-publication-of-trends-in-molecular-medicine-review-article-highlighting-the-therapeutic-potential-of-the-abc-transporter-superfamily/ 2025-08-29T13:56:48+00:00 https://forbion.com/fr/news-insights/news/omeicos-therapeutics-announces-expansion-of-omt-28-clinical-development-program-into-primary-mitochondrial-diseases/ 2025-08-29T13:58:03+00:00 https://forbion.com/fr/news-insights/news/replimune-announces-pricing-of-public-offering/ 2025-08-29T14:07:03+00:00 https://forbion.com/fr/news-insights/news/replimune-enters-into-clinical-collaboration-agreement-with-roche-for-the-development-of-rp3-in-colorectal-cancer-and-hepatocellular-carcinoma/ 2025-08-29T14:07:30+00:00 https://forbion.com/fr/news-insights/news/inversago-pharma-doses-first-patient-in-phase-2-trial-of-inv-202-an-oral-peripherally-acting-cb1-inverse-agonist-in-patients-with-diabetic-kidney-disease/ 2025-08-29T14:07:48+00:00 https://forbion.com/fr/news-insights/news/oxitope-appoints-leading-interventional-cardiologist-gregg-stone-to-advisory-board-for-myocardial-reperfusion-injury/ 2025-08-29T14:13:58+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-debuts-as-publicly-traded-company/ 2025-08-29T14:16:06+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-catalym-closes-eur-50-million-series-c-financing/ 2025-08-29T14:19:16+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-inversago-named-in-labiotech-list-of-the-hottest-private-biotech-companies-in-canada/ 2025-07-18T15:41:56+00:00 https://forbion.com/fr/news-insights/news/angelika-amon-young-scientist-award-for-forbion-fellow-melanie-de-almeida-phd/ 2025-07-18T16:26:30+00:00 https://forbion.com/fr/news-insights/news/vectory-appoints-sander-van-deventer-as-ceo-and-makes-key-appointments-to-its-leadership-team/ 2025-08-29T14:20:49+00:00 https://forbion.com/fr/news-insights/news/vectivbio-announces-completion-of-enrollment-for-colon-in-continuity-cic-cohort-of-stars-pivotal-phase-3-study-investigating-apraglutide-in-short-bowel-syndrome-with-intestinal-failure-sbs-if/ 2025-08-29T14:22:50+00:00 https://forbion.com/fr/news-insights/news/mhra-awards-complement-therapeutics-innovation-passport-for-ctx001-to-accelerate-gene-therapy-for-geographic-atrophy/ 2025-08-29T14:23:42+00:00 https://forbion.com/fr/news-insights/news/f2g-announces-data-from-phase-2b-study-at-id-week-2022-showing-positive-therapeutic-response-in-patients-with-invasive-fungal-infections-treated-with-olorofim/ 2025-08-29T14:24:56+00:00 https://forbion.com/fr/news-insights/news/am-pharma-provides-business-update-and-outcome-of-pre-planned-interim-futility-analysis-of-phase-3-revival-study/ 2025-08-29T14:26:57+00:00 https://forbion.com/fr/news-insights/news/inversago-pharma-raises-95-million-cad-in-series-c-financing/ 2025-08-29T14:28:41+00:00 https://forbion.com/fr/news-insights/news/vectivbio-reports-positive-interim-clinical-data-from-stars-nutrition-a-phase-2-study-investigating-apraglutide-in-short-bowel-syndrome-with-intestinal-failure-patients-sbs-if-with-colon-in-continuity-cic/ 2025-08-29T15:40:00+00:00 https://forbion.com/fr/news-insights/news/vectivbio-announces-pricing-of-125-million-underwritten-offering-of-ordinary-shares/ 2025-08-29T14:46:29+00:00 https://forbion.com/fr/news-insights/news/forbion-policy-for-responsible-investments-2022/ 2025-07-21T16:05:48+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-publishes-final-phase-3-allium-data-in-jama-cefepimeenmetazobactam-met-criteria-for-superiority/ 2025-08-29T15:43:27+00:00 https://forbion.com/fr/news-insights/news/bloomberg-europe-edition-nordic-vc-firms-expand-to-listed-biotechs-in-hunt-for-bargains/ 2025-07-18T15:38:08+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-68m-investment-in-newly-launched-antibody-drug-conjugate-specialist-pheon-therapeutics/ 2025-08-29T15:44:40+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-announces-the-establishment-of-its-clinical-scientific-advisory-board/ 2025-08-29T15:48:16+00:00 https://forbion.com/fr/news-insights/news/catalym-receives-fda-ind-clearance-to-expand-development-of-visugromab-in-advanced-cancer-patients-into-the-us/ 2025-09-01T10:02:46+00:00 https://forbion.com/fr/news-insights/news/european-investor-sentiment-rebounds-on-cell-and-gene-therapy/ 2025-07-18T14:20:29+00:00 https://forbion.com/fr/news-insights/news/inversago-pharma-receives-ind-clearance-for-phase-2-trial-of-inv-202-in-diabetic-kidney-disease/ 2025-09-01T10:29:54+00:00 https://forbion.com/fr/news-insights/news/fierce-biotech-names-amphista-therapeutics-as-one-of-its-fierce-15-biotech-companies-of-2022/ 2025-09-01T10:32:12+00:00 https://forbion.com/fr/news-insights/news/catalym-demonstrates-clinical-efficacy-and-tolerability-in-first-in-human-phase-1-trial-for-visugromab-and-nivolumab-combination/ 2025-09-01T10:34:29+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-announces-initiation-of-phase-12-achieve-clinical-trial-of-dyne-101-for-the-treatment-of-myotonic-dystrophy-type-1/ 2025-09-01T10:36:56+00:00 https://forbion.com/fr/news-insights/news/the-2022-pharmavoice-100-legacy-leaders-dr-michael-hayden-the-ceo-at-prilenia-has-an-unwavering-dedication-to-address-the-needs-of-hd-patients-and-their-families/ 2025-07-18T15:34:05+00:00 https://forbion.com/fr/news-insights/news/catalym-to-present-complete-phase-1-safety-and-efficacy-data-on-gdf-15-neutralizing-antibody-visugromab-clt-002-at-the-2022-esmo-congress/ 2025-09-01T10:39:54+00:00 https://forbion.com/fr/news-insights/news/vectory-to-present-poster-on-huntington-s-preclinical-data-at-the-hereditary-disease-foundation-august-24-27-in-cambridge-ma/ 2025-09-01T10:41:45+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-announces-publication-in-nature-medicine-discussing-clinical-potential-of-obicetrapib/ 2025-09-01T10:44:36+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-ltd-announces-appointment-of-dr-dennis-keefe-as-chief-scientific-officer/ 2025-09-01T10:48:38+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-70-million-financing-of-f2g-to-advance-development-and-commercialization-of-new-antifungal-agent-olorofim/ 2025-09-01T10:51:37+00:00 https://forbion.com/fr/news-insights/news/precirix-and-eckert-ziegler-sign-agreement-on-actinium-225-supply/ 2025-09-01T10:53:39+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-holding-bv-and-frazier-lifesciences-acquisition-corporation-announce-merger-agreement-to-create-publicly-listed-company-focused-on-transformative-oral-therapies-for-major-cardiometabolic-diseases/ 2025-09-01T10:55:44+00:00 https://forbion.com/fr/news-insights/news/forbion-appoints-dr-peter-hoengaard-andersen-as-operating-partner-and-dr-matt-cooper-as-venture-partner/ 2025-07-18T16:42:02+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-ltd-announces-appointment-of-steve-axon-to-its-board-of-directors/ 2025-09-01T11:10:23+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-announces-clearance-of-clinical-trial-application-for-dyne-101-for-the-treatment-of-myotonic-dystrophy-type-1/ 2025-09-01T11:11:40+00:00 https://forbion.com/fr/news-insights/news/venture-capital-journal-european-vcs-may-be-better-prepared-for-a-downturn-than-their-us-peers/ 2025-07-18T15:33:16+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-and-the-menarini-group-sign-licensing-deal-to-commercialize-obicetrapib-in-europe/ 2025-09-01T13:20:21+00:00 https://forbion.com/fr/news-insights/news/spotting-biotech-opportunities-in-a-changing-market-commentary-by-forbion-general-partner-jasper-bos/ 2025-07-18T15:31:56+00:00 https://forbion.com/fr/news-insights/news/beyond-biotech-the-podcast-from-labiotech/ 2025-07-18T15:31:10+00:00 https://forbion.com/fr/news-insights/news/forbion-general-partner-nanna-lueneborg-phd-mba-proposed-as-new-board-member-of-bioinvent/ 2025-09-01T13:22:53+00:00 https://forbion.com/fr/news-insights/news/forbion-growth-opportunities-fund-ii-leads-usd-50-million-placement-of-vectivbio/ 2025-09-01T13:32:38+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-first-close-of-forbion-growth-opportunities-fund-ii-at-470-million/ 2025-07-21T15:46:22+00:00 https://forbion.com/fr/news-insights/news/endpoints-amidst-a-struggling-ipo-market-forbion-drums-up-half-a-billion-in-private-cash-for-second-late-stage-fund/ 2025-07-18T15:30:34+00:00 https://forbion.com/fr/news-insights/news/prilenia-announces-publication-of-data-elucidating-a-mechanism-for-neuroprotective-potential-of-pridopidine/ 2025-09-01T13:45:59+00:00 https://forbion.com/fr/news-insights/news/replimune-reports-fiscal-fourth-quarter-and-year-ended-2022-financial-results-and-provides-corporate-update/ 2025-09-01T13:52:00+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-to-present-at-upcoming-medical-conferences-new-post-hoc-analyses-from-phase-2-rose-trial-of-obicetrapib-in-patients-with-dyslipidemia/ 2025-09-01T13:48:16+00:00 https://forbion.com/fr/news-insights/news/dr-michael-hayden-mbchb-phd-interview-with-the-huntingtons-disease-youth-organisation-hdyo/ 2025-07-18T14:29:57+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-enters-strategic-collaboration-with-bristol-myers-squibb-for-discovery-and-development-of-targeted-protein-degradation-therapeutics/ 2025-09-01T13:59:24+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-enters-strategic-collaboration-with-merck-for-discovery-and-development-of-targeted-protein-degradation-therapeutics/ 2025-09-01T14:00:22+00:00 https://forbion.com/fr/news-insights/news/400-patients-have-been-enrolled-in-am-pharma-s-pivotal-phase-3-study-of-ilofotase-alfa-for-the-treatment-of-sepsis-associated-acute-kidney-injury/ 2025-09-01T14:18:13+00:00 https://forbion.com/fr/news-insights/news/sv-health-investors-joins-prilenia-series-b-as-the-company-prepares-for-als-and-hd-data-readouts-in-the-next-12-months/ 2025-09-01T14:28:54+00:00 https://forbion.com/fr/news-insights/news/wie-die-krise-life-sciences-investoren-beeinflusst-und-den-ma-markt-befluegelt/ 2025-07-18T14:28:37+00:00 https://forbion.com/fr/news-insights/news/forbion-appoints-both-dr-ton-logtenberg-and-dr-michael-hayden-as-venture-partners/ 2025-07-21T15:54:09+00:00 https://forbion.com/fr/news-insights/news/numab-therapeutics-and-ono-pharmaceutical-enter-development-and-license-agreement-for-multispecific-antibody-candidate-involving-novel-immuno-oncology-target/ 2025-09-01T14:33:34+00:00 https://forbion.com/fr/news-insights/news/azafaros-announces-fda-grant-of-orphan-drug-designation-for-az-3102-in-the-treatment-of-niemann-pick-disease/ 2025-09-01T14:41:51+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-eur-80m-series-b-investment-in-precirix-to-advance-its-pipeline-of-precision-radiopharmaceuticals/ 2025-09-01T14:43:43+00:00 https://forbion.com/fr/news-insights/news/biotech-stocks-in-total-eclipse-as-financial-pressures-mount/ 2025-07-18T14:27:30+00:00 https://forbion.com/fr/news-insights/news/forbion-strengthens-its-team-with-the-appointments-of-mathias-vinther-and-vanessa-carle/ 2025-07-21T15:58:57+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-appoints-carlo-incerti-md-to-its-board-of-directors/ 2025-09-01T14:46:03+00:00 https://forbion.com/fr/news-insights/news/catalym-commences-phase-2-development-of-gdf-15-targeting-antibody-ctl-002-following-successful-phase-1-completion/ 2025-09-01T14:47:45+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-doses-first-patient-in-prevail-the-cardiovascular-outcomes-trial-of-obicetrapib-in-adults-with-atherosclerotic-cardiovascular-disease-ascvd/ 2025-09-01T14:49:17+00:00 https://forbion.com/fr/news-insights/news/bioworld-complement-therapeutics-emerges-from-stealth-with-plan-to-take-on-untreatable-eye-disease/ 2025-07-18T14:26:42+00:00 https://forbion.com/fr/news-insights/news/forbion-and-bgv-announce-eur-5-million-seed-investment-in-complement-therapeutics-and-appointment-of-dr-rafiq-hasan-as-ceo/ 2025-09-01T14:52:45+00:00 https://forbion.com/fr/news-insights/news/late-stage-investors-see-opportunity-in-the-bear-market/ 2025-07-18T14:24:16+00:00 https://forbion.com/fr/news-insights/news/azafaros-presents-positive-clinical-and-preclinical-data-supporting-development-of-lead-compound-az-3102-in-lysosomal-storage-disorders-at-the-18th-annual-worldsymposium-conference/ 2025-09-01T14:57:44+00:00 https://forbion.com/fr/news-insights/news/engene-announces-positive-preliminary-phase-12-data-with-eg-70-in-bcg-unresponsive-non-muscle-invasive-bladder-cancer/ 2025-09-01T15:15:48+00:00 https://forbion.com/fr/news-insights/news/northsea-therapeutics-initiates-phase-1-trial-of-sefa-6179-targeting-the-orphan-indication-intestinal-failure-associated-liver-disease/ 2025-09-01T15:18:13+00:00 https://forbion.com/fr/news-insights/news/azafaros-receives-fda-orphan-drug-designation-for-az-3102-in-gm2-gangliosidosis/ 2025-09-01T15:20:59+00:00 https://forbion.com/fr/news-insights/news/vectory-and-wageningen-university-sign-strategic-collaboration-for-the-development-of-novel-baculovirus-based-aav-production-technologies/ 2025-09-01T15:24:36+00:00 https://forbion.com/fr/news-insights/news/lonza-forbion-and-biogeneration-ventures-extend-collaboration-to-add-development-and-manufacturing-services-of-small-molecules/ 2025-07-21T16:06:47+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-and-advanz-pharma-sign-exclusive-license-and-supply-agreement-for-allecra-s-antibiotic-cefepimeenmetazobactam-in-europe/ 2025-09-01T15:30:46+00:00 https://forbion.com/fr/news-insights/news/prilenia-announces-completion-of-patient-enrollment-ahead-of-schedule-in-the-pridopidine-arm-of-the-healey-als-platform-trial/ 2025-09-01T15:59:37+00:00 https://forbion.com/fr/news-insights/news/gyroscope-therapeutics-to-be-acquired-for-up-to-15-billion/ 2025-09-01T16:00:36+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-35m-series-b-for-armgo-pharma/ 2025-09-01T16:03:19+00:00 https://forbion.com/fr/news-insights/news/northsea-therapeutics-completes-us-80-million-series-c-fundraising-to-advance-clinical-programs-in-metabolic-disorders/ 2025-09-01T16:05:47+00:00 https://forbion.com/fr/news-insights/news/forbion-to-lead-oversubscribed-chf-110m-series-b-for-swiss-immune-oncology-company-anaveon/ 2025-09-01T16:07:51+00:00 https://forbion.com/fr/news-insights/news/forbion-closes-the-initial-public-offering-of-110-million-units-of-forbion-european-acquisition-corporation-feac-on-the-nasdaq-global-market/ 2025-09-10T12:37:09+00:00 https://forbion.com/fr/news-insights/news/forbion-european-acquisition-corp-announces-pricing-of-110-million-initial-public-offering/ 2025-09-01T16:18:21+00:00 https://forbion.com/fr/news-insights/news/uniqure-and-csl-behring-announce-primary-endpoint-achieved-in-hope-b-pivotal-trial-of-etranacogene-dezaparvovec-gene-therapy-in-patients-with-hemophilia-b/ 2025-09-01T16:25:03+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-appoints-dr-martin-pass-as-cdo/ 2025-09-01T16:28:55+00:00 https://forbion.com/fr/news-insights/news/prilenia-closes-oversubscribed-43-million-in-series-b-financing-round/ 2025-09-01T16:30:33+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-announces-submission-of-ind-application-to-initiate-clinical-trial-of-dyne-251-for-duchenne-muscular-dystrophy/ 2025-09-01T16:49:44+00:00 https://forbion.com/fr/news-insights/news/vifor-pharma-to-acquire-sanifit-to-further-strengthen-late-stage-pipeline-in-nephrology/ 2025-09-01T16:55:49+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-prilenia-receives-fast-track-designation-for-treatment-of-huntington-s-disease/ 2025-09-01T16:58:59+00:00 https://forbion.com/fr/news-insights/news/icosabutate-latest-phase-2b-interim-data-show-significant-decreases-in-nash-and-fibrosis-biomarkers-independent-of-fibrosis-stage-and-disease-severity/ 2025-09-02T14:11:27+00:00 https://forbion.com/fr/news-insights/news/catalym-presents-expanded-clinical-and-new-preclinical-data-from-gdf-15-targeting-program-ctl-002-at-sitc-conference/ 2025-09-02T14:13:38+00:00 https://forbion.com/fr/news-insights/news/interview-with-sander-slootweg-ma-magazine-in-dutch/ 2025-07-18T14:23:43+00:00 https://forbion.com/fr/news-insights/news/gyroscope-therapeutics-announces-sanofi-investment-of-up-to-60-million/ 2025-09-02T14:15:39+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-appoints-cbo-beverley-carr/ 2025-09-02T14:17:17+00:00 https://forbion.com/fr/news-insights/news/oxitope-led-consortium-awarded-prestigious-eurostars-grant-to-develop-new-drugs-for-cardiovascular-diseases/ 2025-09-02T14:19:52+00:00 https://forbion.com/fr/news-insights/news/prilenia-and-huntington-study-group-announce-completion-of-patient-enrollment-ahead-of-schedule-in-global-phase-3-proof-hd-huntington-s-disease-clinical-trial/ 2025-09-02T14:22:36+00:00 https://forbion.com/fr/news-insights/news/forbion-policy-for-responsible-investments-2021/ 2025-07-21T16:04:26+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-new-investment-in-rectify-pharmaceuticals-which-launches-with-100m-series-a-financing/ 2025-09-02T14:23:51+00:00 https://forbion.com/fr/news-insights/news/hmi-meets-sander-slootweg/ 2025-07-18T14:22:57+00:00 https://forbion.com/fr/news-insights/news/jj-webinar-with-general-partner-dirk-kersten/ 2025-07-18T14:21:35+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-covicept-therapeutics-initiates-a-phase-2-clinical-trial-of-pjs-539-for-the-treatment-of-patients-with-covid-19/ 2025-09-02T14:25:36+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-presents-new-in-vivo-data-for-its-duchenne-muscular-dystrophy-program-during-muscle-study-group-annual-scientific-meeting-demonstrating-robust-and-durable-exon-skipping-and-dystrophin-expression/ 2025-09-02T14:28:04+00:00 https://forbion.com/fr/news-insights/news/catalym-to-present-update-from-gdf-15-targeting-first-in-human-io-clinical-trial-in-plenary-session-at-aacr-nci-eortc-conference-on-molecular-targets-and-cancer-therapeutics/ 2025-09-02T14:27:10+00:00 https://forbion.com/fr/news-insights/news/sustained-release-steroid-options-for-dme-therapy/ 2025-07-21T16:03:04+00:00 https://forbion.com/fr/news-insights/news/fierce-biotech-names-forbion-portfolio-company-mestag-therapeutics-as-one-of-its-fierce-15-biotech-companies-2021/ 2025-09-02T14:34:47+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-appoints-new-chairman-joshua-t-brumm/ 2025-09-02T14:36:12+00:00 https://forbion.com/fr/news-insights/news/forbion-launches-portfolio-company-oxitope-pharma-focused-on-inflammatory-cardiovascular-and-fibrotic-diseases/ 2025-09-02T14:38:10+00:00 https://forbion.com/fr/news-insights/news/forbion-appoints-nanna-lueneborg-as-a-general-partner/ 2025-09-10T12:37:44+00:00 https://forbion.com/fr/news-insights/news/achilles-therapeutics-announces-grant-of-us-and-european-patents/ 2025-09-02T14:40:08+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-286million-seed-extension-financing-for-mestag-therapeutics/ 2025-09-02T14:42:06+00:00 https://forbion.com/fr/news-insights/news/synox-therapeutics-further-strengthens-team-with-appointments-of-chief-medical-officer-and-chief-technology-officer/ 2025-09-02T14:43:54+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-reports-positive-results-from-phase-2-study-of-oral-obicetrapib-demonstrating-over-50-ldl-c-lowering-as-an-adjunct-to-high-intensity-statins/ 2025-09-02T14:45:05+00:00 https://forbion.com/fr/news-insights/news/synox-therapeutics-strengthens-team-with-appointment-of-ton-logtenberg-as-chairman-and-ray-barlow-as-chief-executive-officer/ 2025-09-02T15:32:46+00:00 https://forbion.com/fr/news-insights/news/fda-grants-orphan-drug-designation-for-pridopidine-for-the-treatment-of-amyotrophic-lateral-sclerosis-als/ 2025-09-02T14:48:53+00:00 https://forbion.com/fr/news-insights/news/nerre-therapeutics-raises-20-million-in-a-series-b2-financing-round/ 2025-09-02T14:50:11+00:00 https://forbion.com/fr/news-insights/news/am-pharma-appoints-mark-altmeyer-as-chairman-of-its-supervisory-board/ 2025-09-02T14:52:23+00:00 https://forbion.com/fr/news-insights/news/am-pharma-enrolls-first-patient-in-japan-for-ongoing-phase-iii-sa-aki-pivotal-revival-trial/ 2025-09-02T15:31:38+00:00 https://forbion.com/fr/news-insights/news/azafaros-appoints-stefano-portolano-md-as-chief-executive-officer/ 2025-09-02T15:33:41+00:00 https://forbion.com/fr/news-insights/news/uniqure-to-acquire-corlieve-therapeutics-and-advance-its-gene-therapy-program-to-treat-temporal-lobe-epilepsy-tle/ 2025-09-02T15:35:11+00:00 https://forbion.com/fr/news-insights/news/gyroscope-therapeutics-announces-research-collaboration-agreement-with-children-s-medical-research-institute-to-develop-novel-gene-therapy-capsids/ 2025-09-02T15:38:04+00:00 https://forbion.com/fr/news-insights/news/enterprise-therapeutics-doses-first-subjects-in-phase-i-trial-for-novel-cystic-fibrosis-therapy-etd001/ 2025-09-02T15:39:29+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-vectory-eur-31-million-seed-financing/ 2025-09-02T15:42:21+00:00 https://forbion.com/fr/news-insights/news/engene-announces-first-in-human-dosing-of-eg-70-for-the-treatment-of-non-muscle-invasive-bladder-cancer-in-phase-12-clinical-trial/ 2025-09-02T15:59:03+00:00 https://forbion.com/fr/news-insights/news/forbion-s-growth-opportunities-fund-completes-eur-91-million-oversubscribed-series-c-financing-for-numab-therapeutics/ 2025-09-02T16:03:16+00:00 https://forbion.com/fr/news-insights/news/forbion-expands-team-with-new-general-partner/ 2025-07-21T16:45:54+00:00 https://forbion.com/fr/news-insights/news/prilenia-achieves-25-enrollment-in-its-phase-3-hd-trial-and-appoints-dr-goldberg-as-cso/ 2025-09-02T16:09:53+00:00 https://forbion.com/fr/news-insights/news/replimune-appoints-tanya-lewis-as-chief-development-operations-officer/ 2025-09-03T11:12:35+00:00 https://forbion.com/fr/news-insights/news/catalym-appoints-industry-leader-dr-phil-l-huillier-as-chief-executive-officer/ 2025-09-03T11:14:59+00:00 https://forbion.com/fr/news-insights/news/replimune-appoints-genentech-global-oncology-franchise-head-sushil-patel-phd-as-chief-commercial-officer/ 2025-09-03T11:17:53+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-final-close-of-forbion-growth-opportunities-fund-i-at-eur-360-million-usd-428-million/ 2025-07-21T16:52:12+00:00 https://forbion.com/fr/news-insights/news/forbion-appoints-head-of-communications/ 2025-07-21T16:56:50+00:00 https://forbion.com/fr/news-insights/news/azafaros-enters-clinical-stage-with-az-3102-an-oral-small-molecule-being-developed-for-rare-neurogenetic-disorders/ 2025-09-03T11:18:45+00:00 https://forbion.com/fr/news-insights/news/achilles-therapeutics-announces-pricing-of-initial-public-offering/ 2025-09-03T11:20:05+00:00 https://forbion.com/fr/news-insights/news/forbion-s-growth-opportunities-fund-leads-148m-series-c-financing-for-gyroscope-therapeutics/ 2025-09-03T11:21:32+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-raises-53m-in-oversubscribed-series-b-round-to-advance-next-generation-targeted-protein-degradation-assets/ 2025-09-03T11:24:33+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-appoints-wildon-farwell-md-mph-as-chief-medical-officer/ 2025-09-03T11:27:00+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-37m-financing-for-oxular/ 2025-09-03T11:30:45+00:00 https://forbion.com/fr/news-insights/news/launch-of-novel-gene-therapy-company-vectory-to-develop-innovative-vectorized-antibodies/ 2025-09-03T11:32:25+00:00 https://forbion.com/fr/news-insights/news/sanifit-granted-orphan-drug-designation-by-the-fda-for-snf472-for-the-treatment-of-peripheral-arterial-disease-in-patients-with-end-stage-kidney-disease/ 2025-09-03T12:39:04+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-appoints-ashish-dugar-phd-mba-senior-vice-president-global-head-of-medical-affairs/ 2025-09-03T12:43:32+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-positive-recommendation-from-data-safety-monitoring-board-of-phase-iii-clinical-trial-of-amt-130-for-the-treatment-of-huntington-s-disease/ 2025-09-03T12:48:08+00:00 https://forbion.com/fr/news-insights/news/catalym-starts-first-in-human-phase-i-clinical-trial-with-gdf-15-neutralizing-antibody-ctl-002-to-treat-patients-with-checkpoint-inhibitor-refractory-cancer/ 2025-09-03T12:49:57+00:00 https://forbion.com/fr/news-insights/news/prilenia-enrolls-first-subject-in-europe-in-its-proof-hd-phase-3-clinical-trial-for-huntington-s-disease/ 2025-09-03T12:52:14+00:00 https://forbion.com/fr/news-insights/news/forbion-invests-usd-23m-in-seed-financing-of-covicept-therapeutics-inc/ 2025-07-21T17:04:09+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-newamsterdam-pharma-completes-160m-series-a-funding-for-phase-3-development-program/ 2025-09-03T12:54:17+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-myotonic-dystrophy-type-1-program-achieves-robust-rna-knock-down-of-toxic-human-nuclear-dmpk-in-preclinical-study/ 2025-09-03T12:55:37+00:00 https://forbion.com/fr/news-insights/news/prilenia-announces-first-patient-enrolled-for-pridopidine-phase-23-platform-trial-for-als/ 2025-09-03T12:58:12+00:00 https://forbion.com/fr/news-insights/news/nst-positive-phase-2b-icona-interim-results-for-icosabutate-in-nash-patients/ 2025-09-03T12:57:00+00:00 https://forbion.com/fr/news-insights/news/biogeneration-ventures-bgv-iv-fund-closes-at-140-million/ 2025-07-21T17:08:10+00:00 https://forbion.com/fr/news-insights/news/am-pharma-announces-enrollment-and-financing-of-covid-19-cohort-in-phase-iii-revival-trial/ 2025-09-03T12:59:48+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-and-shanghai-haini-pharmaceutical-announce-exclusive-licensing-agreement-for-cefepimeenmetazobactam-for-greater-china/ 2025-09-03T13:03:13+00:00 https://forbion.com/fr/news-insights/news/uniqure-nv-uniqure-announces-clinical-update-on-hemophilia-b-gene-therapy-program/ 2025-09-03T13:06:04+00:00 https://forbion.com/fr/news-insights/news/lonza-forbion-and-biogeneration-ventures-announce-collaboration-for-development-and-manufacture-of-biologics-for-portfolio-companies/ 2025-09-03T13:07:42+00:00 https://forbion.com/fr/news-insights/news/forbion-secures-eur-460-million-for-oversubscribed-fifth-fund/ 2025-07-21T17:11:50+00:00 https://forbion.com/fr/news-insights/news/uniqure-presents-late-breaking-data-from-the-hope-b-pivotal-trial-of-etranacogene-dezaparvovec-gene-therapy-in-patients-with-hemophilia-b-at-the-62nd-annual-meeting-of-the-american-society-of-hematology/ 2025-09-03T13:09:29+00:00 https://forbion.com/fr/news-insights/news/uniqure-nv-uniqure-announces-two-year-follow-up-data-from-the-phase-iib-study-of-etranacogene-dezaparvovec-and-long-term-follow-up-data-for-amt-060-in-patients-with-hemophilia-b/ 2025-09-03T13:10:46+00:00 https://forbion.com/fr/news-insights/news/achilles-therapeutics-raises-527-million-in-an-oversubscribed-series-c-financing-to-further-advance-the-development-of-personalised-t-cell-therapies-to-treat-solid-tumours/ 2025-09-03T13:18:10+00:00 https://forbion.com/fr/news-insights/news/forbion-invests-in-eur-37m-series-a-financing-of-synox-therapeutics/ 2025-07-21T17:22:02+00:00 https://forbion.com/fr/news-insights/news/northsea-therapeutics-doses-first-patient-in-phase-1-trial-of-sefa-1024-in-dyslipidemia-and-further-expands-its-clinical-pipeline/ 2025-09-03T13:32:53+00:00 https://forbion.com/fr/news-insights/news/am-pharma-announces-enrollment-of-the-first-patient-in-revival-phase-iii-pivotal-trial-in-patients-with-sepsis-associated-acute-kidney-injury/ 2025-09-03T13:34:13+00:00 https://forbion.com/fr/news-insights/news/catalym-raises-eur50-million-to-advance-gdf-15-antibody-into-clinical-trials-for-checkpoint-inhibitor-refractory-patients/ 2025-09-03T13:35:29+00:00 https://forbion.com/fr/news-insights/news/replimune-announces-poster-presentations-at-the-sitc-2020-annual-meeting-and-a-presentation-at-the-sitc-2020-annual-meeting-virtual-press-conference/ 2025-09-03T13:39:54+00:00 https://forbion.com/fr/news-insights/news/replimune-reports-fiscal-second-quarter-financial-results-and-provides-corporate-update/ 2025-09-03T13:41:25+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-clinical-data-presentations-at-the-62nd-american-society-of-hematology-ash-annual-meeting/ 2025-09-03T13:42:32+00:00 https://forbion.com/fr/news-insights/news/uniqure-inc-uniqure-announces-third-quarter-2020-financial-results-and-highlights-recent-company-progress/ 2025-09-03T14:09:25+00:00 https://forbion.com/fr/news-insights/news/prilenia-enrolls-first-patients-into-its-proof-hd-phase-3-clinical-trial-for-huntington-s-disease-in-the-united-states/ 2025-09-03T14:08:09+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-announces-late-breaker-presentation-of-phase-3-allium-trial-with-cefepime-enmetazobactam-in-cutis-at-idweek-2020/ 2025-09-03T14:10:51+00:00 https://forbion.com/fr/news-insights/news/am-pharma-appoints-chief-medical-officer-and-vp-manufacturing-to-support-global-pivotal-trial-in-sepsis-associated-acute-kidney-injury/ 2025-09-03T14:16:32+00:00 https://forbion.com/fr/news-insights/news/replimune-releases-updated-corporate-presentation/ 2025-09-03T14:25:23+00:00 https://forbion.com/fr/news-insights/news/replimune-appoints-tanya-lewis-to-the-board-of-directors/ 2025-09-03T14:27:08+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-enterprise-therapeutics-first-in-class-tmem16a-potentiator-program-for-treatment-of-cystic-fibrosis-and-other-respiratory-diseases-acquired-by-roche/ 2025-09-03T14:33:42+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-inflazome-acquired-by-roche/ 2025-09-03T14:36:30+00:00 https://forbion.com/fr/news-insights/news/henk-schuring-joins-prilenia-as-chief-regulatory-and-commercialization-officer/ 2025-09-03T14:50:09+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-us-35m-series-b-financing-round-for-inversago-pharma/ 2025-09-03T14:53:00+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-acquires-obicetrapib-from-amgen/ 2025-09-03T14:54:43+00:00 https://forbion.com/fr/news-insights/news/enterprise-therapeutics-doses-first-subjects-in-phase-1-trial-for-first-in-class-cystic-fibrosis-therapy-etd002/ 2025-09-03T14:59:12+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-kandy-therapeutics-to-be-acquired-by-bayer/ 2025-09-03T15:02:06+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-announces-115-million-financing-to-advance-pipeline-of-modern-oligonucleotide-therapeutics-for-serious-muscle-diseases/ 2025-09-03T15:05:19+00:00 https://forbion.com/fr/news-insights/news/replimune-reports-fiscal-first-quarter-financial-results-and-provides-corporate-update/ 2025-09-04T14:23:15+00:00 https://forbion.com/fr/news-insights/news/replimune-appoints-andrea-pirzkall-md-as-chief-medical-officer/ 2025-09-04T14:29:09+00:00 https://forbion.com/fr/news-insights/news/sanifit-to-start-new-clinical-development-program-of-snf472-in-end-stage-kidney-disease-patients-with-peripheral-artery-disease/ 2025-09-04T14:30:38+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-first-close-of-forbion-growth-opportunities-fund-at-eur-185-million-usd-208-million/ 2025-07-21T17:26:52+00:00 https://forbion.com/fr/news-insights/news/snf472-mechanism-of-action-data-published-in-british-journal-of-pharmacology/ 2025-09-04T14:32:37+00:00 https://forbion.com/fr/news-insights/news/achilles-therapeutics-doses-first-patient-in-phase-iii-study-in-advanced-non-small-cell-lung-cancer/ 2025-09-04T14:45:43+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-first-two-patients-treated-in-phase-iii-clinical-trial-of-amt-130-for-the-treatment-of-huntington-s-disease/ 2025-09-04T14:54:25+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-625m-series-a-fund-raising-for-prilenia-therapeutics/ 2025-09-04T14:56:17+00:00 https://forbion.com/fr/news-insights/news/achilles-therapeutics-doses-first-patient-in-phase-iii-study-in-recurrent-or-metastatic-malignant-melanoma-with-first-til-therapy-to-specifically-target-clonal-neoantigens/ 2025-09-04T14:58:10+00:00 https://forbion.com/fr/news-insights/news/sanifit-enhances-leadership-team-with-new-executive-appointments/ 2025-09-04T14:59:06+00:00 https://forbion.com/fr/news-insights/news/hookipa-pharma-announces-publication-of-hb-101-phase-1-results-in-the-journal-of-infectious-diseases/ 2025-09-04T15:03:55+00:00 https://forbion.com/fr/news-insights/news/replimune-appoints-dieter-weinand-as-chairman-and-paolo-pucci-to-the-board-of-directors/ 2025-09-04T15:05:29+00:00 https://forbion.com/fr/news-insights/news/am-pharma-increases-funding-to-163m-for-phase-iii-trial-of-recap-in-sa-aki/ 2025-09-04T15:06:36+00:00 https://forbion.com/fr/news-insights/news/inzomelid-completes-phase-i-studies-and-shows-positive-results-in-the-treatment-of-cryopyrin-associated-periodic-syndrome-caps/ 2025-09-04T15:16:55+00:00 https://forbion.com/fr/news-insights/news/uniqure-and-gen-x-enter-into-research-collaboration-and-license-agreement-for-the-development-of-novel-synthetic-promoters/ 2025-09-04T15:18:34+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-announces-positive-top-line-results-for-phase-3-allium-clinical-trial-of-exblifep-for-complicated-urinary-tract-infections/ 2025-09-04T15:19:35+00:00 https://forbion.com/fr/news-insights/news/inflazome-s-somalix-demonstrates-positive-safety-tolerability-and-pharmacodynamic-profile-in-its-phase-i-study/ 2025-09-04T15:23:08+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-completion-of-acquisition-by-roche/ 2025-09-04T15:24:43+00:00 https://forbion.com/fr/news-insights/news/first-patient-dosed-in-pivotal-phase-3-trial-of-snf472-in-calciphylaxis/ 2025-09-04T15:26:12+00:00 https://forbion.com/fr/news-insights/news/replimune-reports-third-fiscal-quarter-financial-results-and-provides-corporate-update/ 2025-09-04T15:31:54+00:00 https://forbion.com/fr/news-insights/news/forbion-appoints-dr-john-montana-as-operating-partner/ 2025-07-22T11:33:38+00:00 https://forbion.com/fr/news-insights/news/kandy-therapeutics-announces-positive-phase-2b-data-in-post-menopausal-women-with-its-lead-non-hormonal-product-nt-814/ 2025-09-04T15:35:25+00:00 https://forbion.com/fr/news-insights/news/replimune-announces-the-evolution-of-its-management-team-as-it-advances-through-later-stage-clinical-development-and-prepares-for-commercialization/ 2025-09-04T15:36:12+00:00 https://forbion.com/fr/news-insights/news/northsea-therapeutics-announces-us-40-million-series-b-financing-to-complete-phase-iib-icona-study-in-nash-and-to-advance-two-additional-sefas-into-the-clinic/ 2025-09-05T12:10:55+00:00 https://forbion.com/fr/news-insights/news/enterprise-therapeutics-publishes-paper-on-novel-therapeutic-approach-for-treatment-of-all-cystic-fibrosis-patients/ 2025-09-05T10:48:29+00:00 https://forbion.com/fr/news-insights/news/forbion-wins-vc-firm-of-the-year-at-the-lsx-s-lifestars-awards/ 2025-07-22T11:37:01+00:00 https://forbion.com/fr/news-insights/news/promedior-enters-into-definitive-merger-agreement-to-be-acquired-by-roche/ 2025-09-05T12:12:54+00:00 https://forbion.com/fr/news-insights/news/positive-data-from-sanifit-s-phase-2b-calipso-trial-of-snf472-published-in-circulation/ 2025-09-05T12:14:20+00:00 https://forbion.com/fr/news-insights/news/replimune-presents-initial-clinical-data-with-rp1-that-strongly-supports-expansion-of-clinical-programs-in-melanoma-and-cutaneous-squamous-cell-carcinoma-cscc/ 2025-09-05T12:20:36+00:00 https://forbion.com/fr/news-insights/news/inflazome-progresses-two-drugs-into-clinical-trials/ 2025-09-05T12:17:12+00:00 https://forbion.com/fr/news-insights/news/sanifit-announces-that-the-phase-2b-calipso-trial-of-snf472-met-its-primary-endpoint-in-slowing-the-progression-of-cardiovascular-calcification-in-patients-on-hemodialysis/ 2025-09-05T12:26:39+00:00 https://forbion.com/fr/news-insights/news/replimune-announces-first-patient-enrolled-in-phase-1-clinical-trial-of-rp2-alone-and-in-combination-with-opdivo-in-advanced-cancer-patients/ 2025-09-05T12:27:34+00:00 https://forbion.com/fr/news-insights/news/replimune-provides-update-on-rp1-clinical-development-program-in-cutaneous-squamous-cell-carcinoma/ 2025-09-05T12:31:35+00:00 https://forbion.com/fr/news-insights/news/milestone-pharmaceuticals-announces-first-patient-enrolled-in-node-303-open-label-safety-study-of-etripamil-in-psvt/ 2025-09-05T12:32:45+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-announces-appointment-of-joshua-brumm-as-president-and-chief-executive-office/ 2025-09-05T12:34:17+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-and-astrazeneca-present-multiple-ascending-dose-phase-1b-data-for-inhaled-il4-rα-antagonist-azd1402prs-060-at-the-2019-european-respiratory-society-international-congress/ 2025-09-05T12:37:24+00:00 https://forbion.com/fr/news-insights/news/nst-doses-first-patient-in-phase-2b-clinical-study-of-icosabutate-in-nash-icona/ 2025-09-05T12:38:20+00:00 https://forbion.com/fr/news-insights/news/sanifit-named-as-one-of-2019-s-fierce-15-biotechnology-companies-by-fiercebiotech/ 2025-09-05T12:41:58+00:00 https://forbion.com/fr/news-insights/news/milestone-pharmaceuticals-announces-appointment-of-amit-hasija-as-chief-financial-officer-and-executive-vice-president-of-corporate-development/ 2025-09-05T12:43:45+00:00 https://forbion.com/fr/news-insights/news/forbion-participates-in-100m-series-b-financing-of-achilles-therapeutics/ 2025-07-22T11:44:00+00:00 https://forbion.com/fr/news-insights/news/omeicos-therapeutics-appoints-dr-simon-russell-as-chief-business-officer/ 2025-09-05T14:17:41+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-achievement-of-planned-enrollment-in-hope-b-pivotal-trial-of-amt-061-etranacogene-dezaparvovec-in-patients-with-hemophilia-b/ 2025-09-05T14:19:19+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-am-pharma-raises-116m-to-conduct-pivotal-phase-iii-trial-of-recap-in-acute-kidney-injury/ 2025-09-05T14:23:09+00:00 https://forbion.com/fr/news-insights/news/sanifit-announces-722m-809m-financing-in-spains-largest-private-biotech-fundraise/ 2025-09-05T14:29:28+00:00 https://forbion.com/fr/news-insights/news/replimune-announces-initiation-of-the-phase-2-portion-of-its-ongoing-phase-12-clinical-trial-of-rp1-as-monotherapy-and-in-combination-with-nivolumab/ 2025-09-05T14:38:26+00:00 https://forbion.com/fr/news-insights/news/issued-patents-in-the-us-and-eu-cover-rna-construct-specifically-designed-to-target-highly-toxic-exon1-protein/ 2025-09-05T14:41:32+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-positive-long-term-safety-and-efficacy-data-from-open-label-extension-study-of-prm-151-in-idiopathic-pulmonary-fibrosis/ 2025-09-05T14:42:57+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-companies-milestone-and-hookipa-successfully-list-on-the-nasdaq-stock-exchange/ 2025-09-10T12:39:24+00:00 https://forbion.com/fr/news-insights/news/milestone-pharmaceuticals-announces-pricing-of-upsized-initial-public-offering/ 2025-09-05T14:44:15+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-featured-presentations-of-new-data-on-spinocerebellar-ataxia-type-3-at-the-2019-american-academy-of-neurology-annual-meeting/ 2025-09-05T14:45:16+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-new-preclinical-data-in-hemophilia-a-and-fabry-disease-in-oral-presentations-at-the-22nd-asgct-annual-meeting/ 2025-09-05T14:45:59+00:00 https://forbion.com/fr/news-insights/news/omeicos-therapeutics-announces-first-dosing-in-phase-2-clinical-study-evaluating-its-lead-program-omt-28-in-patients-with-persistent-atrial-fibrillation/ 2025-09-05T14:47:30+00:00 https://forbion.com/fr/news-insights/news/whale-watching-what-a-decade-of-change-at-big-pharma-taught-us-about-corporate-phenotypes/ 2025-07-21T16:01:49+00:00 https://forbion.com/fr/news-insights/news/hookipa-pharma-announces-pricing-of-initial-public-offering/ 2025-09-05T14:49:06+00:00 https://forbion.com/fr/news-insights/news/uniqure-receives-fda-fast-track-designation-for-amt-130-gene-therapy-for-the-treatment-of-huntington-s-disease/ 2025-09-05T14:51:09+00:00 https://forbion.com/fr/news-insights/news/forbion-analysis-on-european-biotech-landscape-published-in-nature-biotechnology/ 2025-07-22T15:49:31+00:00 https://forbion.com/fr/news-insights/news/dyne-therapeutics-launches-with-50-million-series-a-to-develop-targeted-therapies-for-muscle-diseases/ 2025-09-05T14:52:11+00:00 https://forbion.com/fr/news-insights/news/mapping-the-european-startup-landscape/ 2025-07-21T16:00:01+00:00 https://forbion.com/fr/news-insights/news/curetis-and-menarini-diagnostics-enter-into-strategic-pan-european-exclusive-partnership-for-the-distribution-of-curetis-unyvero/ 2025-09-05T14:53:49+00:00 https://forbion.com/fr/news-insights/news/enterprise-therapeutics-strengthens-leadership-team-appoints-amit-d-munshi-as-non-executive-chairman/ 2025-09-05T14:54:37+00:00 https://forbion.com/fr/news-insights/news/data-from-snf472-phase-1b-clinical-trial-published-in-british-journal-of-clinical-pharmacology/ 2025-09-05T14:58:05+00:00 https://forbion.com/fr/news-insights/news/uniqure-to-participate-in-multiple-upcoming-industry-conferences/ 2025-09-05T15:00:12+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-2018-financial-results-and-highlights-recent-company-progress/ 2025-09-05T15:07:42+00:00 https://forbion.com/fr/news-insights/news/uniqure-presents-new-preclinical-data-on-amt-130-at-the-chdi-s-14th-annual-huntington-s-disease-therapeutics-conference/ 2025-09-05T15:08:40+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-publications-on-aav-gene-therapy-approach-to-treating-amyotrophic-lateral-sclerosis-als-and-frontotemporal-dementia-ftd-in-the-journal-molecular-therapy-nucleic-acids/ 2025-09-05T15:12:31+00:00 https://forbion.com/fr/news-insights/news/gotham-therapeutics-strengthens-board-of-directors-and-scientific-advisory-board/ 2025-09-05T15:21:02+00:00 https://forbion.com/fr/news-insights/news/omeicos-therapeutics-strengthens-board-of-directors-with-the-appointment-of-christian-schetter/ 2025-09-05T15:22:01+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-updated-clinical-data-from-phase-iib-study-of-amt-061-in-patients-with-hemophilia-b/ 2025-09-05T15:23:39+00:00 https://forbion.com/fr/news-insights/news/cellnovo-announces-its-q4-and-full-year-2018-sales/ 2025-09-05T15:25:58+00:00 https://forbion.com/fr/news-insights/news/curetis-subsidiary-ares-genetics-advances-ai-powered-infectious-disease-and-antibiotic-resistance-test/ 2025-09-05T15:27:21+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-pivotal-path-for-prm-151-in-idiopathic-pulmonary-fibrosis-following-positive-end-of-phase-2-meeting-with-fda/ 2025-09-05T15:28:11+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-staten-biotechnology-enters-into-a-collaboration-with-novo-nordisk-to-develop-novel-treatment-for-dyslipidaemia/ 2025-09-05T15:43:25+00:00 https://forbion.com/fr/news-insights/news/kandy-therapeutics-announces-initiation-of-phase-2b-trial-of-nt-814-for-the-treatment-of-troublesome-post-menopausal-symptoms/ 2025-09-05T15:46:42+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-long-term-clinical-data-from-ongoing-phase-iii-trial-of-amt-060-and-confirms-dose-for-amt-061-pivotal-study-in-hemophilia-b/ 2025-09-05T15:47:33+00:00 https://forbion.com/fr/news-insights/news/forbion-appoints-dr-carlo-incerti-as-operating-partner/ 2025-07-22T15:53:27+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-40m-series-b-financing-in-inflazome-to-develop-nlrp3-inflammasome-inhibitors-to-clinical-proof-of-concept/ 2025-07-22T16:44:15+00:00 https://forbion.com/fr/news-insights/news/uniqure-highlights-pipeline-expansion-and-advancements-in-technology-at-research-development-day/ 2025-09-05T15:48:58+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-initial-topline-data-from-dose-confirmation-study-of-amt-061-in-patients-with-hemophilia-b/ 2025-09-05T15:50:50+00:00 https://forbion.com/fr/news-insights/news/press-release-icosabutate-latest-data-shows-direct-and-potent-anti-fibrotic-effect-in-both-differentiated-rodent-nash-models-and-human-stellate-cells/ 2025-09-05T15:51:36+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-third-quarter-2018-financial-results-and-highlights-company-progress/ 2025-09-05T15:52:47+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-17m-series-c-financing-of-omeicos-therapeutics/ 2025-09-05T16:06:58+00:00 https://forbion.com/fr/news-insights/news/milestone-pharmaceuticals-announces-80-million-private-financing/ 2025-09-05T16:07:51+00:00 https://forbion.com/fr/news-insights/news/jama-publishes-phase-ii-recap-data-for-sepsis-associated-acute-kidney-injury/ 2025-09-08T14:30:32+00:00 https://forbion.com/fr/news-insights/news/data-from-first-in-human-clinical-trial-of-snf472-in-haemodialysis-patients-published-in-british-journal-of-clinical-pharmacology/ 2025-09-08T14:31:37+00:00 https://forbion.com/fr/news-insights/news/new-data-presented-at-the-european-society-of-gene-and-cell-therapy-annual-meeting-demonstrates-up-to-40-times-higher-liver-expression-with-optimized-promoter/ 2025-09-08T14:34:38+00:00 https://forbion.com/fr/news-insights/news/uniqure-inc-uniqure-presents-new-data-demonstrating-its-large-scale-manufacturing-capabilities-at-the-european-society-of-gene-and-cell-therapy-esgct-annual-meeting/ 2025-09-08T14:42:42+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-54m-series-a-financing-in-newly-formed-gotham-therapeutics/ 2025-09-08T15:04:54+00:00 https://forbion.com/fr/news-insights/news/forbion-closes-oversubscribed-fourth-life-sciences-vc-fund-at-eur-360-million/ 2025-07-22T16:54:35+00:00 https://forbion.com/fr/news-insights/news/uniqure-provides-update-on-dose-confirmation-study-of-amt-061-in-patients-with-hemophilia-b/ 2025-09-08T15:09:09+00:00 https://forbion.com/fr/news-insights/news/replimune-announces-fda-acceptance-of-investigational-new-drug-application-for-its-lead-oncolytic-immunotherapy-candidate-rp1/ 2025-09-08T15:15:15+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-announces-dosing-of-first-patient-in-phase-i-combination-trial-for-prs-343-plus-anti-pd-l1-immunotherapy/ 2025-09-08T15:19:02+00:00 https://forbion.com/fr/news-insights/news/kandy-therapeutics-successfully-raises-25-million-in-a-series-c-financing/ 2025-09-08T15:22:06+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-first-patient-treated-in-dose-confirmation-study-of-amt-061-in-patients-with-hemophilia-b/ 2025-09-08T15:25:17+00:00 https://forbion.com/fr/news-insights/news/escalier-doses-first-patient-with-esr-114-and-announces-clinical-advisory-board/ 2025-09-08T15:26:19+00:00 https://forbion.com/fr/news-insights/news/milestone-pharmaceuticals-announces-first-patient-randomized-in-the-phase-3-node-301-clinical-trial-evaluating-etripamil-for-termination-of-paroxysmal-supraventricular-tachycardia-psvt-episodes/ 2025-09-08T15:31:28+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-second-quarter-2018-financial-results-and-highlights-company-progress/ 2025-09-08T15:32:46+00:00 https://forbion.com/fr/news-insights/news/sanifit-announces-completion-of-enrollment-in-calipso-its-phase-2b-study-for-the-treatment-of-cardiovascular-calcification-in-end-stage-renal-disease-patients-on-haemodialsis/ 2025-09-08T15:34:08+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-replimune-successfully-completes-ipo-on-nasdaq/ 2025-09-08T15:34:51+00:00 https://forbion.com/fr/news-insights/news/engene-appoints-veteran-life-sciences-executive-jason-d-hanson-as-chief-executive-officer-and-president/ 2025-09-08T15:36:05+00:00 https://forbion.com/fr/news-insights/news/forbion-exceeds-target-with-eur-270-million-first-close-of-its-fourth-life-sciences-vc-fund/ 2025-07-22T16:56:17+00:00 https://forbion.com/fr/news-insights/news/hookipa-appoints-dr-christoph-lengauer-as-a-non-executive-director/ 2025-09-08T15:37:47+00:00 https://forbion.com/fr/news-insights/news/uniqure-inc-uniqure-enrolls-first-patient-in-phase-iii-hope-b-pivotal-study-of-amt-061-in-patients-with-hemophilia-b/ 2025-09-09T10:37:28+00:00 https://forbion.com/fr/news-insights/news/bio-techne-to-acquire-exosome-diagnostics-inc/ 2025-09-09T10:39:01+00:00 https://forbion.com/fr/news-insights/news/dirk-kersten-joins-forbion-as-general-partner/ 2025-09-10T12:40:18+00:00 https://forbion.com/fr/news-insights/news/cellnovo-announces-the-commercialisation-of-insulin-cartridges-following-the-successful-start-of-large-scale-manufacturing-at-the-flex-facility-in-althofen-austria/ 2025-09-09T10:40:32+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-new-appointments-to-its-board-of-directors/ 2025-09-09T10:41:35+00:00 https://forbion.com/fr/news-insights/news/replimune-appoints-dr-hyam-i-levitsky-to-board-of-directors/ 2025-09-09T10:42:16+00:00 https://forbion.com/fr/news-insights/news/kandy-therapeutics-announces-positive-clinical-data-with-lead-candidate-nt-814-for-the-treatment-of-symptoms-of-the-menopause/ 2025-09-09T10:43:40+00:00 https://forbion.com/fr/news-insights/news/curetis-launches-unyvero-system-and-lrt-cartridge-for-lower-respiratory-tract-infections-in-the-us/ 2025-09-09T10:43:02+00:00 https://forbion.com/fr/news-insights/news/hookipa-and-gilead-enter-into-a-collaboration-and-license-agreement-to-develop-immunotherapies-against-hiv-and-hepatitis-b/ 2025-09-09T11:02:07+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-the-issuance-of-new-patents-providing-broad-protection-of-the-padua-variant-of-factor-ix-in-gene-therapy/ 2025-09-09T12:35:21+00:00 https://forbion.com/fr/news-insights/news/uniqure-presents-new-data-demonstrating-clinical-benefit-in-hemophilia-b-patients-with-pre-existing-anti-aav5-neutralizing-antibodies/ 2025-09-09T12:24:57+00:00 https://forbion.com/fr/news-insights/news/curetis-publishes-business-and-financial-update-for-the-first-quarter-2018/ 2025-09-09T12:26:59+00:00 https://forbion.com/fr/news-insights/news/uniqure-presents-preclinical-data-demonstrating-advances-in-the-distribution-of-gene-therapy/ 2025-09-09T12:33:00+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares/ 2025-09-09T12:36:10+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-pricing-of-its-public-offering-2018/ 2025-09-09T12:37:31+00:00 https://forbion.com/fr/news-insights/news/curetis-announces-change-of-the-composition-of-its-supervisory-board/ 2025-09-09T12:55:16+00:00 https://forbion.com/fr/news-insights/news/curetis-publishes-full-year-2017-financial-results-and-updated-guidance-for-2018/ 2025-09-09T12:58:02+00:00 https://forbion.com/fr/news-insights/news/curetis-to-publish-its-2017-annual-results-on-april-30-2018/ 2025-09-09T13:01:33+00:00 https://forbion.com/fr/news-insights/news/curetis-launches-ce-ivd-marked-unyvero-urinary-tract-infection-uti-cartridge-at-eccmid-2018/ 2025-09-09T13:02:52+00:00 https://forbion.com/fr/news-insights/news/curetis-novel-products-and-study-data-to-be-presented-at-eccmid-2018/ 2025-09-09T13:04:35+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-to-present-data-at-28th-european-congress-of-clinical-microbiology-and-infectious-diseases/ 2025-09-09T13:06:30+00:00 https://forbion.com/fr/news-insights/news/forbion-participates-in-29m-series-b-financing-of-enterprise-therapeutics-to-advance-its-ion-channel-modulators-for-the-treatment-of-cystic-fibrosis-copd-and-severe-asthma/ 2025-07-22T17:01:44+00:00 https://forbion.com/fr/news-insights/news/curetis-establishes-us-scientific-advisory-board/ 2025-09-09T13:07:52+00:00 https://forbion.com/fr/news-insights/news/curetis-receives-us-fda-de-novo-clearance-of-unyvero-system-and-unyvero-lrt-lower-respiratory-tract-infection-cartridge/ 2025-09-09T13:09:15+00:00 https://forbion.com/fr/news-insights/news/curetis-unyvero-bcu-blood-culture-application-receives-approval-from-singapore-health-sciences-authority/ 2025-09-09T13:10:36+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-announces-participation-at-the-hc-wainwright-annual-global-life-sciences-conference-in-monte-carlo-monaco-on-april-8-10-2018/ 2025-09-09T13:13:27+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-announces-positive-top-line-results-from-phase-2-cactus-study-of-its-lead-candidate-aai101-in-combination-with-cefepime-to-treat-complicated-urinary-tract-infections-cuti/ 2025-09-09T13:15:27+00:00 https://forbion.com/fr/news-insights/news/curetis-to-attend-key-investor-and-scientific-conferences-in-the-second-quarter-2018/ 2025-09-09T13:17:02+00:00 https://forbion.com/fr/news-insights/news/forbion-s-portfolio-company-prexton-therapeutics-acquired-by-lundbeck-for-up-to-eur-905-million-usd-11-billion/ 2025-09-09T13:18:05+00:00 https://forbion.com/fr/news-insights/news/curetis-receives-uspto-notice-of-allowance-for-key-patent-covering-unyvero-technology/ 2025-09-09T13:19:59+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-19-million-series-b-financing-of-escalier-biosciences-to-advance-its-topical-and-systemic-rorγt-therapies-for-psoriasis-and-other-autoimmune-diseases/ 2025-07-22T17:15:29+00:00 https://forbion.com/fr/news-insights/news/am-pharma-announces-phase-ii-study-results-of-recap-in-sepsis-associated-acute-kidney-injury/ 2025-09-09T13:20:54+00:00 https://forbion.com/fr/news-insights/news/sanifit-announces-results-of-the-phase-ii-clinical-trial-of-snf472-in-patients-with-calciphylaxis/ 2025-09-09T13:24:21+00:00 https://forbion.com/fr/news-insights/news/curetis-subsidiary-ares-genetics-wins-incubator-stay-in-silicon-valley/ 2025-09-09T13:22:12+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-announces-fast-track-designation-for-lead-antibiotic-in-resistant-infections/ 2025-09-09T13:26:30+00:00 https://forbion.com/fr/news-insights/news/curetis-group-ares-genetics-receives-funding-commitment-for-eur-16-mio-project-curetis-announces-non-audited-financial-results-for-2017/ 2025-09-09T13:27:36+00:00 https://forbion.com/fr/news-insights/news/curetis-unyvero-hpn-application-receives-singapore-health-sciences-authority-approval-updates-on-sepsis-host-response-test/ 2025-09-09T13:29:33+00:00 https://forbion.com/fr/news-insights/news/curetis-and-mgi-advance-strategic-partnership-in-ngs-based-molecular-microbiology/ 2025-09-09T13:30:52+00:00 https://forbion.com/fr/news-insights/news/sanifit-announces-the-appointment-of-cris-calsada-as-chief-financial-officer/ 2025-09-09T13:34:19+00:00 https://forbion.com/fr/news-insights/news/curetis-expects-near-term-fda-decision-on-de-novo-request/ 2025-09-09T13:32:38+00:00 https://forbion.com/fr/news-insights/news/sanifit-announces-last-patient-last-visit-completed-in-clinical-trial-of-snf472-in-patients-with-calciphylaxis/ 2025-09-09T13:37:48+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-publication-in-the-journal-blood-of-clinical-data-from-phase-iii-trial-of-amt-060-in-patients-with-severe-hemophilia-b/ 2025-09-09T13:39:05+00:00 https://forbion.com/fr/news-insights/news/uniqure-added-to-nasdaq-biotechnology-index/ 2025-09-09T13:40:36+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-25-million-series-a-fundraising-in-northsea-therapeutics-and-its-promising-nash-drug-programme/ 2025-07-22T17:18:28+00:00 https://forbion.com/fr/news-insights/news/hookipa-biotech-raises-60-million-50-million-in-an-oversubscribed-round-c-financing/ 2025-09-09T13:42:12+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-updated-long-term-clinical-data-from-ongoing-phase-iii-trial-of-amt-060-in-patients-with-severe-hemophilia-b/ 2025-09-09T13:42:50+00:00 https://forbion.com/fr/news-insights/news/allecra-therapeutics-announces-new-staged-financing-deal-to-take-the-company-through-to-end-of-phase-3/ 2025-09-09T13:43:50+00:00 https://forbion.com/fr/news-insights/news/curetis-publishes-business-and-financial-update-for-the-first-nine-months-of-2017/ 2025-09-09T13:44:59+00:00 https://forbion.com/fr/news-insights/news/engene-named-company-of-the-year-by-biotecanada/ 2025-09-09T13:46:00+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-pricing-of-its-public-offering/ 2025-09-09T13:47:20+00:00 https://forbion.com/fr/news-insights/news/curetis-initiates-us-fda-study-for-unyvero-invasive-joint-infections-cartridge/ 2025-09-09T13:48:53+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-hemophilia-b-gene-therapy-program-to-enter-pivotal-study-with-fix-padua-variant-in-2018/ 2025-09-09T13:50:02+00:00 https://forbion.com/fr/news-insights/news/uniqure-strengthens-intellectual-property-portfolio-with-acquisition-of-patent-family/ 2025-09-09T13:51:31+00:00 https://forbion.com/fr/news-insights/news/dr-jan-van-de-winkel-joins-hookipa-as-chairman-of-its-board-of-directors/ 2025-09-09T13:52:20+00:00 https://forbion.com/fr/news-insights/news/uniqure-presents-new-preclinical-data-on-amt-130-in-huntington-s-disease/ 2025-09-09T13:53:31+00:00 https://forbion.com/fr/news-insights/news/nerre-therapeutics-appoints-andrew-kay-as-chairman-of-the-board/ 2025-09-09T13:57:13+00:00 https://forbion.com/fr/news-insights/news/kandy-therapeutics-launched-to-advance-a-breakthrough-treatment-in-womens-health/ 2025-09-09T13:54:58+00:00 https://forbion.com/fr/news-insights/news/mgi-and-curetis-to-collaborate-on-ngs-based-infectious-disease-diagnostics/ 2025-09-09T13:59:17+00:00 https://forbion.com/fr/news-insights/news/replimune-raises-55-million-to-advance-its-oncolytic-immunotherapy-programs/ 2025-09-09T14:00:29+00:00 https://forbion.com/fr/news-insights/news/msd-to-acquire-rigontec/ 2025-09-09T14:03:03+00:00 https://forbion.com/fr/news-insights/news/allecra-announces-initiation-of-a-phase-2-clinical-trial-for-its-novel-antibiotic-to-treat-resistant-bacterial-infections/ 2025-09-09T14:01:28+00:00 https://forbion.com/fr/news-insights/news/insmed-announces-positive-top-line-results-from-phase-3-convert-study-of-alis/ 2025-09-09T14:04:39+00:00 https://forbion.com/fr/news-insights/news/carefirst-bluecross-blueshield-and-exosome-diagnostics-announce-evidence-development-collaboration-for-molecular-diagnostic-tests/ 2025-09-09T14:06:29+00:00 https://forbion.com/fr/news-insights/news/exosome-launches-the-medoncalyzer-pan-cancer-panel/ 2025-09-09T14:07:26+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-achieves-iso-13485-certification/ 2025-09-09T14:08:05+00:00 https://forbion.com/fr/news-insights/news/milestone-pharmaceuticals-closes-55-million-series-c-financing/ 2025-09-09T14:11:33+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-completes-30-million-series-c-financing/ 2025-09-09T14:13:16+00:00 https://forbion.com/fr/news-insights/news/cellnovo-2017-first-half-sales/ 2025-09-09T14:14:44+00:00 https://forbion.com/fr/news-insights/news/cellnovo-concludes-a-loan-agreement-for-up-to-20-million-from-the-european-investment-bank/ 2025-09-09T14:15:27+00:00 https://forbion.com/fr/news-insights/news/prexton-announces-initiation-of-phase-ii-clinical-testing-in-parkinson-s-disease/ 2025-09-09T14:16:28+00:00 https://forbion.com/fr/news-insights/news/argenx-presents-full-data-from-argx-111-phase-ib-study-in-patients-with-advanced-cancers-over-expressing-the-met-protein-at-best-of-asco-asia-2017-singapore/ 2025-09-09T14:17:16+00:00 https://forbion.com/fr/news-insights/news/curetis-to-attend-key-investor-and-scientific-conferences-in-the-third-quarter-2017/ 2025-09-09T14:19:27+00:00 https://forbion.com/fr/news-insights/news/cellnovo-successfully-raises-175-million-from-healthcare-investors/ 2025-09-09T14:18:33+00:00 https://forbion.com/fr/news-insights/news/cellnovo-expands-international-distribution-network/ 2025-09-09T14:21:06+00:00 https://forbion.com/fr/news-insights/news/cellnovo-signs-expanded-agreement-to-build-second-production-line-with-flex/ 2025-09-09T14:22:44+00:00 https://forbion.com/fr/news-insights/news/curetis-provides-update-on-unyvero-lrt-fda-510-k-submission/ 2025-09-10T10:45:41+00:00 https://forbion.com/fr/news-insights/news/curetis-provides-business-and-financial-update-for-the-first-quarter-2017/ 2025-09-09T14:24:35+00:00 https://forbion.com/fr/news-insights/news/am-pharma-completes-patient-recruitment-of-recombinant-human-alkaline-phosphatase-recap-phase-ii-trial-in-acute-kidney-injury/ 2025-09-10T10:46:49+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-successful-dual-listing-of-portfolio-company-argenx-argx-on-nasdaq/ 2025-07-22T17:20:40+00:00 https://forbion.com/fr/news-insights/news/curetis-to-hold-annual-general-shareholders-meeting-on-june-23-2017/ 2025-09-10T10:47:42+00:00 https://forbion.com/fr/news-insights/news/rigontec-starts-first-in-human-phase-iii-trial-of-rig-i-agonist/ 2025-09-10T10:49:03+00:00 https://forbion.com/fr/news-insights/news/recent-data-on-curetis-unyvero-iti-application-demonstrate-its-clinical-and-health-economic-benefits/ 2025-09-10T11:06:41+00:00 https://forbion.com/fr/news-insights/news/cellnovo-announces-its-full-year-2016-results-and-q1-2017-sales/ 2025-09-10T10:54:25+00:00 https://forbion.com/fr/news-insights/news/american-medical-association-ama-grants-exosome-diagnostics-a-cpt-pla-specific-to-its-exodx-prostate-intelliscore-test/ 2025-09-10T10:53:34+00:00 https://forbion.com/fr/news-insights/news/engene-announces-appointment-of-theresa-podrebarac-md-as-chief-medical-officer/ 2025-09-10T10:55:44+00:00 https://forbion.com/fr/news-insights/news/engene-s-mucosal-gene-delivery-platform-is-successful-in-targeting-pd-l1-expression-in-the-gut-demonstrating-effective-treatment-of-colitis-and-g-v-hd-in-preclinical-models/ 2025-09-10T11:09:05+00:00 https://forbion.com/fr/news-insights/news/cellnovo-delivers-first-commercial-batch-of-insulin-cartridges-with-manufacturing-partner-flex/ 2025-09-10T11:10:17+00:00 https://forbion.com/fr/news-insights/news/cellnovo-announces-that-diabeloop-is-launching-a-ce-marking-registration-study-on-artificial-pancreas-with-cellnovo-pump/ 2025-09-10T11:16:49+00:00 https://forbion.com/fr/news-insights/news/curetis-unyvero-intra-abdominal-infection-iai-cartridge-receives-ce-marking/ 2025-09-10T11:28:57+00:00 https://forbion.com/fr/news-insights/news/cellnovo-acquires-commercial-license-for-artificial-pancreas-technology-from-type-zero-technologies/ 2025-09-10T11:33:52+00:00 https://forbion.com/fr/news-insights/news/curetis-expands-supervisory-and-medical-advisory-boards/ 2025-09-10T11:34:46+00:00 https://forbion.com/fr/news-insights/news/monthly-information-regarding-the-total-number-of-voting-rights-and-total-number-of-shares-of-the-company/ 2025-09-10T11:35:38+00:00 https://forbion.com/fr/news-insights/news/curetis-starts-subsidiary-ares-genetics-to-advance-genetic-antibiotic-resistance-testing/ 2025-09-10T11:37:58+00:00 https://forbion.com/fr/news-insights/news/curetis-to-publish-its-annual-results-2016-on-april-12-2017/ 2025-09-10T11:40:35+00:00 https://forbion.com/fr/news-insights/news/curetis-announces-participation-in-major-investor-and-scientific-conferences-in-the-second-quarter-2017/ 2025-09-10T11:42:08+00:00 https://forbion.com/fr/news-insights/news/cellnovo-announces-arrangement-of-an-equity-line-to-support-its-development/ 2025-09-10T11:44:28+00:00 https://forbion.com/fr/news-insights/news/curetis-cebit-2017-computational-biologists-predict-antibiotic-resistances-using-biotech/ 2025-09-10T10:41:26+00:00 https://forbion.com/fr/news-insights/news/uniqure-receives-2017-frost-sullivan-manufacturing-leadership-award/ 2025-09-10T10:40:05+00:00 https://forbion.com/fr/news-insights/news/forbion-invests-in-prexton-therapeutics-eur-29-million-usd-31-million-series-b-financing/ 2025-07-22T17:26:27+00:00 https://forbion.com/fr/news-insights/news/curetis-global-installed-base-expanding-to-over-150-unyvero-analyzers/ 2025-09-10T10:38:18+00:00 https://forbion.com/fr/news-insights/news/cellnovo-2016-full-year-sales/ 2025-09-10T10:39:04+00:00 https://forbion.com/fr/news-insights/news/sanifit-announces-enrollment-of-first-patient-in-calipso/ 2025-09-10T10:35:07+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-nerre-therapeutics-raises-23-million-in-oversubscribed-series-b-financing-round/ 2025-07-22T17:32:06+00:00 https://forbion.com/fr/news-insights/news/curetis-files-for-us-fda-clearance-for-unyvero-platform-and-lrt-application-cartridge/ 2025-09-10T10:34:16+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-to-host-investor-call-today-to-discuss-servier-collaboration/ 2025-09-09T15:53:12+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-and-servier-forge-strategic-immuno-oncology-co-development-alliance/ 2025-09-09T15:52:00+00:00 https://forbion.com/fr/news-insights/news/curetis-to-present-at-key-investor-and-scientific-conferences-in-the-first-quarter-2017/ 2025-09-09T15:49:56+00:00 https://forbion.com/fr/news-insights/news/curetis-completes-development-of-unyvero-cartridge-for-intra-abdominal-infections/ 2025-09-09T15:51:01+00:00 https://forbion.com/fr/news-insights/news/exodxtm-prostate-intelliscore-a-more-precise-genetically-informed-prostate-cancer-test/ 2025-09-09T15:47:15+00:00 https://forbion.com/fr/news-insights/news/mitralign-news-piedmont-hospital-testimonial-with-trialign/ 2025-09-09T15:45:30+00:00 https://forbion.com/fr/news-insights/news/cellnovo-update-on-progress-towards-full-scale-manufacturing-of-insulin-cartridges-by-flex/ 2025-09-09T15:44:13+00:00 https://forbion.com/fr/news-insights/news/positive-phase-ii-in-eosinophilic-asthma-for-pulmagenteijin/ 2025-09-09T15:42:24+00:00 https://forbion.com/fr/news-insights/news/curetis-acquires-real-time-qpcr-platform-from-carpegen-and-systec/ 2025-09-09T15:40:51+00:00 https://forbion.com/fr/news-insights/news/curetis-obtains-eib-debt-financing-totaling-up-to-eur-25-million-to-further-expand-its-diagnostic-platform/ 2025-09-09T15:39:33+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-the-first-instrument-for-point-of-care-liquid-biopsy/ 2025-09-09T15:38:05+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-first-clinical-data-from-second-dose-cohort-of-amt-060-in-ongoing-phase-iii-trial-in-patients/ 2025-09-09T15:36:45+00:00 https://forbion.com/fr/news-insights/news/curetis-publishes-business-and-financial-update-for-the-first-nine-months-2016/ 2025-09-09T15:32:08+00:00 https://forbion.com/fr/news-insights/news/cellnovo-files-for-510-k-approval-with-the-fda-for-its-mobile-connected-all-in-one-diabetes-management-system/ 2025-09-09T14:17:04+00:00 https://forbion.com/fr/news-insights/news/rigontec-appoints-dr-joerg-vollmer-as-chief-scientific-officer/ 2025-09-09T14:16:04+00:00 https://forbion.com/fr/news-insights/news/curetis-announces-positive-top-line-data-from-us-fda-trial/ 2025-09-09T14:14:46+00:00 https://forbion.com/fr/news-insights/news/sanifit-announces-initiation-of-first-clinical-trial-of-snf472-in-patients-with-calciphylaxis/ 2025-09-09T13:47:37+00:00 https://forbion.com/fr/news-insights/news/curetis-to-present-at-several-investor-and-scientific-conferences-in-the-fourth-quarter-2016/ 2025-09-09T13:45:59+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-enters-agreement-with-amgen/ 2025-09-09T10:41:46+00:00 https://forbion.com/fr/news-insights/news/venturing-across-the-atlantic/ 2025-07-21T15:57:23+00:00 https://forbion.com/fr/news-insights/news/cellnovo-strengthens-board-by-appointing-remi-soula-as-a-non-executive-director/ 2025-09-09T10:40:53+00:00 https://forbion.com/fr/news-insights/news/uniqure-nv-nasdaq-qure-a-leader-in-human-gene-therapy-today-announced-that-its-board-of-directors-has-accepted-the-resignation-of-daniel-soland-as-chief-executive-officer-ceo-and-an-executive-member-of-the-board-effective-immediately/ 2025-09-09T10:40:01+00:00 https://forbion.com/fr/news-insights/news/forbion-s-portfolio-company-akarna-therapeutics-ltd-acquired-by-allergan-plc/ 2025-09-09T09:20:33+00:00 https://forbion.com/fr/news-insights/news/cellnovo-raises-circa-eur-54m-in-capital-increase-without-preferential-subscription-rights/ 2025-09-09T09:19:40+00:00 https://forbion.com/fr/news-insights/news/cellnovo-announces-its-half-year-2016-results/ 2025-09-09T08:48:28+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-launch-of-exodx-prostate-intelliscore-a-completely-non-invasive-liquid-biopsy-test-to-help-rule-out-high-grade-prostate-cancer/ 2025-09-09T08:47:32+00:00 https://forbion.com/fr/news-insights/news/curetis-acquires-patents-and-rights-to-genetic-antibiotic-resistance-and-susceptibility-gear-database-and-know-how-from-siemens/ 2025-09-09T15:48:04+00:00 https://forbion.com/fr/news-insights/news/first-batch-of-cellnovo-insulin-cartridges-produced-by-flex/ 2025-09-09T08:13:32+00:00 https://forbion.com/fr/news-insights/news/rigontec-raises-additional-15m-in-extended-series-a-to-advance-novel-rig-i-targeted-immuno-oncology-therapeutics/ 2025-09-08T15:51:34+00:00 https://forbion.com/fr/news-insights/news/curetis-to-launch-next-generation-ce-ivd-unyvero-implant-and-tissue-infection-application-cartridge/ 2025-09-09T08:14:48+00:00 https://forbion.com/fr/news-insights/news/uniqure-nv-nasdaqqure-a-leader-in-human-gene-therapy-today-announced-updated-clinical-data-from-its-ongoing-phase-iii-trial-of-amt-060-its-proprietary-investigational-gene-therapy-in-patients-with-severe-hemophilia-b/ 2025-09-08T15:49:59+00:00 https://forbion.com/fr/news-insights/news/uniqure-nv-nasdaqqure-a-leader-in-human-gene-therapy-today-announced-that-updated-data-from-its-ongoing-phase-iii-clinical-study-of-amt-060-in-hemophilia-b-patients-will-be-presented-at-the-world-federation-of-hemophilia-2016-world-congress/ 2025-09-08T15:47:43+00:00 https://forbion.com/fr/news-insights/news/curetis-appoints-christopher-m-bernard-as-chief-executive-officer-of-newly-formed-us-subsidiary/ 2025-09-08T15:43:28+00:00 https://forbion.com/fr/news-insights/news/curetis-announces-participation-in-clinical-scientific-and-investor-meetings-in-the-third-quarter-2016/ 2025-09-08T15:06:02+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-enters-partnership-with-takeda/ 2025-09-08T15:04:39+00:00 https://forbion.com/fr/news-insights/news/curetis-completes-sample-enrollment-in-unyvero-us-fda-trial-in-lower-respiratory-tract-infections/ 2025-09-08T13:37:23+00:00 https://forbion.com/fr/news-insights/news/cellnovo-new-study-highlights-superior-accuracy-of-cellnovo-diabetes-management-system-compared-to-other-leading-patch-pumps/ 2025-09-08T13:36:16+00:00 https://forbion.com/fr/news-insights/news/fcf-ii-co-invest-i-supports-eur-22m-series-b-of-allecra-therapeutics/ 2025-07-23T14:29:28+00:00 https://forbion.com/fr/news-insights/news/curetis-announces-excellent-study-data-and-multi-region-launch-of-unyvero-bcu-blood-culture-application-cartridge/ 2025-09-08T12:58:17+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-appoints-john-healy-as-vice-president-of-informatics/ 2025-09-08T12:13:52+00:00 https://forbion.com/fr/news-insights/news/curetis-publishes-first-quarter-2016-business-and-financial-update/ 2025-09-08T12:56:54+00:00 https://forbion.com/fr/news-insights/news/sanifit-expands-board-with-senior-hire/ 2025-09-08T12:12:50+00:00 https://forbion.com/fr/news-insights/news/am-pharma-receives-fda-fast-track-designation-for-recap-in-acute-kidney-injury-and-reports-completion-of-first-stage-in-phase-ii-trial/ 2025-09-08T11:47:41+00:00 https://forbion.com/fr/news-insights/news/clinical-data-for-world-s-first-truly-non-invasive-prostate-cancer-test-published-in-jama-oncology/ 2025-09-08T11:46:25+00:00 https://forbion.com/fr/news-insights/news/forbion-closes-third-life-sciences-fund-fcf-iii-raising-over-200m/ 2025-07-23T14:38:17+00:00 https://forbion.com/fr/news-insights/news/curetis-publishes-full-year-2015-financial-results-and-introduces-2016-guidance/ 2025-09-08T10:36:38+00:00 https://forbion.com/fr/news-insights/news/akarna-therapeutics-announces-formation-of-clinical-advisory-board/ 2025-09-08T10:35:16+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-reports-fourth-quarter-and-full-year-2015-financial-results-and-operational-highlights/ 2025-09-08T10:17:43+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-announces-initiation-of-a-phase-2-clinical-trial/ 2025-09-08T10:15:16+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-reports-full-year-2015-financial-results-and-corporate-update/ 2025-09-08T10:01:40+00:00 https://forbion.com/fr/news-insights/news/curetis-to-launch-ce-ivd-unyvero-blood-culture-application-cartridge-at-eccmid-2016/ 2025-09-08T10:03:12+00:00 https://forbion.com/fr/news-insights/news/cellnovo-and-roche-sign-commercial-blood-glucose-monitor-agreement/ 2025-09-08T09:00:31+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-announces-financing-of-up-to-60-million/ 2025-09-08T08:59:23+00:00 https://forbion.com/fr/news-insights/news/cellnovo-reaches-first-insulin-cartridge-industrialisation-milestone/ 2025-09-08T08:58:30+00:00 https://forbion.com/fr/news-insights/news/mitralign-percutaneous-annuloplasty-system-earns-ce-mark-approval-for-functional-mitral-regurgitation/ 2025-09-08T08:12:19+00:00 https://forbion.com/fr/news-insights/news/curetis-starts-final-validation-study-for-new-unyvero-blood-culture-application-cartridge/ 2025-09-08T08:11:13+00:00 https://forbion.com/fr/news-insights/news/cellnovo-appoints-thierry-moulin-as-chief-financial-officer/ 2025-09-08T08:00:00+00:00 https://forbion.com/fr/news-insights/news/forbion-invests-in-akarna-therapeutics-15-million-series-b-financing-to-develop-novel-fxr-agonist-based-therapies-for-the-treatment-of-nash-and-other-fibrotic-diseases/ 2025-09-08T07:59:00+00:00 https://forbion.com/fr/news-insights/news/cellnovo-partners-with-us-company-typezero-on-artificial-pancreas-programme/ 2025-09-08T07:56:00+00:00 https://forbion.com/fr/news-insights/news/curetis-expands-commercial-team/ 2025-09-08T07:54:49+00:00 https://forbion.com/fr/news-insights/news/exodxtm-prostate-intelliscore-a-more-precise-genetically-informed-prostate-cancer-test-from-a-simple-urine-sample/ 2025-09-05T16:11:22+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-launches-world-s-first-exosomal-rna-based-liquid-biopsy-exodx-lung-alk/ 2025-09-05T16:09:49+00:00 https://forbion.com/fr/news-insights/news/cellnovo-2015-full-year-sales/ 2025-09-05T14:41:38+00:00 https://forbion.com/fr/news-insights/news/takeda-and-engene-establish-strategic-alliance-to-develop-novel-therapeutics/ 2025-09-05T14:40:41+00:00 https://forbion.com/fr/news-insights/news/uniqure-appoints-dan-soland-as-chief-executive-officer/ 2025-09-05T14:19:46+00:00 https://forbion.com/fr/news-insights/news/acerta-pharma-announces-strategic-transaction-with-astrazeneca/ 2025-07-23T14:40:08+00:00 https://forbion.com/fr/news-insights/news/independent-data-monitoring-committee-recommends-continuation-of-adapt-phase-3-clinical-trial/ 2025-09-05T14:18:56+00:00 https://forbion.com/fr/news-insights/news/cellnovo-s-diabetes-management-system-featured-in-nhs-alliance-programme-communities-of-care/ 2025-09-05T14:12:38+00:00 https://forbion.com/fr/news-insights/news/engene-inc-announces-the-appointment-of-dr-dennis-h-langer-to-the-companys-board-of-directors/ 2025-09-05T14:10:30+00:00 https://forbion.com/fr/news-insights/news/rspr-pharma-initiates-phase-ii-clinical-trial-of-oral-mast-cell-inhibitor-crd007-in-uncontrolled-asthma/ 2025-09-05T14:13:42+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-announces-first-cancer-immunotherapy-collaboration/ 2025-09-05T12:20:23+00:00 https://forbion.com/fr/news-insights/news/appointment-of-javaid-masoud-as-chief-technology-officer/ 2025-09-05T12:19:28+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-launches-clinical-commercialization-program-for-the-research-market/ 2025-09-05T10:48:08+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-exosomal-rna-exorna-plus-cell-free-dna-cfdna-liquid-biopsy-panel/ 2025-09-05T10:46:44+00:00 https://forbion.com/fr/news-insights/news/curetis-ipo-priced-at-eur-1000-per-share-raises-eur-40-million/ 2025-09-05T10:38:44+00:00 https://forbion.com/fr/news-insights/news/leading-liquid-biopsy-company-exosome-diagnostics-appoints-john-boyce-as-chief-executive-officer/ 2025-09-05T10:37:46+00:00 https://forbion.com/fr/news-insights/news/cellnovo-records-strong-sales-growth-over-the-first-9-months-of-2015/ 2025-09-05T10:19:31+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-engene-announces-collaboration-with-johnson-and-johnson-innovation/ 2025-09-05T10:18:30+00:00 https://forbion.com/fr/news-insights/news/curetis-and-acumen-to-collaborate-on-unyvero-sepsis-test-and-asean-distribution/ 2025-09-05T10:16:14+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-presents-new-data-demonstrating-exosomal-rna-based-platform-s-ability-to-serially-and-longitudinally-monitor-response-to-immunotherapy-treatment-in-patients-with-malignant-melanoma/ 2025-09-05T09:40:39+00:00 https://forbion.com/fr/news-insights/news/curetis-enters-into-distribution-agreement-to-expand-commercial-activities-into-greater-china/ 2025-09-05T09:38:34+00:00 https://forbion.com/fr/news-insights/news/replimune-ltd-raises-30-million-series-a-financing/ 2025-09-05T09:12:57+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-publication-of-exointelliscore-prostate-initial-clinical-study-positive-results/ 2025-09-05T09:11:56+00:00 https://forbion.com/fr/news-insights/news/positive-topline-results-announced-from-phase-iii-trial-in-sanfilippo-b-syndrome-patients-using-uniqure-s-novel-aav5-based-gene-therapy/ 2025-09-05T07:36:30+00:00 https://forbion.com/fr/news-insights/news/amgen-acquires-forbion-portfolio-company-dezima-pharma/ 2025-07-23T14:43:14+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-the-closing-of-fcf-ii-co-invest-fund-i-at-eur-75m/ 2025-07-23T14:46:07+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-presents-clinical-performance-data-for-exodx-lung-alk-liquid-biopsy-test-and-new-data-on-detection-of-egfr-activating-mutations-and-t790m-resistance-mutation/ 2025-09-05T07:33:23+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-initiation-of-a-phase-2-clinical-study-of-prm-151-in-idiopathic-pulmonary-fibrosis-ipf/ 2025-09-04T16:45:05+00:00 https://forbion.com/fr/news-insights/news/forbion-invests-in-sanifit-s-366m-41m-series-c-financing-round/ 2025-07-23T14:49:36+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-new-data-demonstrating-superior-ability-to-isolate-and-extract-highly-pure-rna-from-serum-and-plasma-for-research-applications/ 2025-09-04T16:43:32+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-raises-176-million-in-second-round-series-b-financing/ 2025-09-04T16:34:18+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-strenghtens-senior-management-team-and-establishes-us-headquarters-in-boston/ 2025-09-04T16:33:13+00:00 https://forbion.com/fr/news-insights/news/mitralign-receives-fda-approval-for-percutaneous-tricuspid-repair-early-feasibility-study/ 2025-09-04T16:22:13+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-bristol-myers-squibb-enters-agreement-providing-exclusive-right-to-acquire-promedior-inc-and-its-novel-prm-151-in-development-for-fibrotic-diseases/ 2025-07-23T14:56:13+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-financial-results-for-second-quarter-2015/ 2025-09-04T16:21:03+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-two-successful-initial-public-offerings-of-portfolio-companies-pieris-pharmaceutical-inc-and-cellnovo-group-sa/ 2025-07-23T14:58:28+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-announces-closing-of-over-allotment-option-in-public-offering-of-common-stock/ 2025-09-04T15:45:36+00:00 https://forbion.com/fr/news-insights/news/cellnovo-full-exercise-of-the-overallotment-option/ 2025-09-04T15:44:22+00:00 https://forbion.com/fr/news-insights/news/rigontec-gmbh-appoints-donald-j-debethizy-as-chairman-of-the-board/ 2025-09-04T15:10:21+00:00 https://forbion.com/fr/news-insights/news/success-of-cellnovo-s-ipo-with-316-million-raised-on-euronext-in-paris/ 2025-09-04T15:09:28+00:00 https://forbion.com/fr/news-insights/news/pieris-to-receive-seventh-milestone-payment-from-daiichi-sankyo-collaboration-to-develop-anticalin-therapeutics/ 2025-09-04T14:56:57+00:00 https://forbion.com/fr/news-insights/news/curetis-initiates-next-phase-of-unyvero-us-fda-trial-in-lower-respiratory-tract-infections/ 2025-09-04T14:55:39+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-closes-public-offering-of-common-stock/ 2025-09-04T14:30:20+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-prices-public-offering-of-common-stock/ 2025-09-04T14:29:35+00:00 https://forbion.com/fr/news-insights/news/cellnovo-launches-its-ipo-on-the-euronext-regulated-market-in-paris/ 2025-09-04T14:07:30+00:00 https://forbion.com/fr/news-insights/news/curetis-unyvero-system-selected-for-global-phase-iii-antibiotics-trial/ 2025-09-04T14:06:30+00:00 https://forbion.com/fr/news-insights/news/cellnovo-starts-the-expansion-of-its-distribution-network/ 2025-09-04T13:30:15+00:00 https://forbion.com/fr/news-insights/news/promedior-presents-additional-positive-phase-2-data-for-prm-151-in-myelofibrosis-at-eha-annual-meeting/ 2025-09-04T13:29:06+00:00 https://forbion.com/fr/news-insights/news/dezima-pharma-s-cetp-inhibitor-ta-8995-phase-2b-tulip-study-results-published-in-the-lancet/ 2025-09-04T13:10:14+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-presents-data-on-plasma-based-solid-tumor-mutation-panel-liquid-biopsy-test/ 2025-09-04T13:09:07+00:00 https://forbion.com/fr/news-insights/news/pieris-pharmaceuticals-to-present-data-on-novel-anti-cd137-and-her2-bispecific-immuno-oncology-program-at-ubs-global-healthcare-conference/ 2025-09-04T12:15:01+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-positive-results-from-large-clinical-validation-study-of-prostate-cancer-liquid-biopsy/ 2025-09-04T12:44:55+00:00 https://forbion.com/fr/news-insights/news/forbion-invests-in-autonomic-technologies-europe-gmbh/ 2025-07-23T15:04:34+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-that-pfizer-acquires-minority-interest-in-its-portfolio-company-am-pharma-secures-option-to-acquire-company/ 2025-09-04T12:13:37+00:00 https://forbion.com/fr/news-insights/news/curetis-strengthens-executive-team-appoints-dr-achim-plum-as-chief-commercial-officer/ 2025-09-04T09:25:45+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-presents-data-demonstrating-ability-to-detect-eml4-alk-fusion-transcripts-on-exosomal-rna-in-patients-with-non-small-cell-lung-cancer/ 2025-09-04T09:25:00+00:00 https://forbion.com/fr/news-insights/news/curetis-expands-commercial-organization/ 2025-09-04T08:15:49+00:00 https://forbion.com/fr/news-insights/news/curetis-to-launch-next-generation-pneumonia-application-at-eccmid-2015/ 2025-09-04T08:14:54+00:00 https://forbion.com/fr/news-insights/news/bristol-myers-squibb-and-uniqure-enter-into-exclusive-strategic-collaboration-to-develop-gene-therapies-for-cardiovascular-diseases/ 2025-09-03T16:05:00+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-invests-eur-24-million-in-2nd-closing-of-series-a-financing-round-for-rigontec-gmbh/ 2025-07-23T15:07:23+00:00 https://forbion.com/fr/news-insights/news/curetis-initiates-clinical-ce-performance-evaluation-of-unyvero-p55-pneumonia-application/ 2025-09-03T16:03:03+00:00 https://forbion.com/fr/news-insights/news/cellnovo-announces-the-registration-of-its-document-de-base-in-the-context-of-its-planned-ipo-on-the-regulated-market-of-euronext-in-paris/ 2025-09-03T15:50:30+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-positive-results-from-initial-clinical-study-of-novel-prostate-cancer-liquid-biopsy/ 2025-09-03T15:49:02+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-leads-cad-135-million-eur-96-million-series-b-financing-round-for-engene-inc/ 2025-09-03T15:30:35+00:00 https://forbion.com/fr/news-insights/news/am-pharma-starts-adaptive-phase-ii-trial-of-recap-in-acute-kidney-injury/ 2025-09-03T15:11:01+00:00 https://forbion.com/fr/news-insights/news/argen-x-launches-innovative-access-program/ 2025-09-03T15:09:55+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-and-the-addario-lung-cancer-medical-institute-alcmi-announce-collaboration-to-accelerate-development-of-plasma-based-lung-cancer-diagnostics/ 2025-09-03T14:32:02+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-pieris-pharmaceuticals-inc-goes-public-raises-122-million/ 2025-09-03T14:30:02+00:00 https://forbion.com/fr/news-insights/news/pieris-initiates-phase-i-clinical-trial-for-anticalin-to-treat-anemia/ 2025-09-03T14:08:38+00:00 https://forbion.com/fr/news-insights/news/argen-x-announces-advancement-of-therapeutic-antibody-alliance-with-shire/ 2025-09-03T14:10:04+00:00 https://forbion.com/fr/news-insights/news/promedior-presents-positive-phase-2-data-for-prm-151-in-myelofibrosis-at-ash-annual-meeting/ 2025-09-03T13:21:11+00:00 https://forbion.com/fr/news-insights/news/pieris-achieves-glp-tox-milestone-payment-in-daiichi-sankyo-collaboration-to-develop-anticalin-therapeutics/ 2025-09-03T13:19:59+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-sale-of-portfolio-company-pneumrx-to-btg-for-up-to-usd-475m-eur-385m/ 2025-07-23T15:09:48+00:00 https://forbion.com/fr/news-insights/news/preclinical-data-published-on-am-pharma-s-recap-to-treat-ultra-rare-disease-hypophosphatasia/ 2025-09-03T13:08:54+00:00 https://forbion.com/fr/news-insights/news/pieris-achieves-second-preclinical-milestone-payment-in-sanofi-collaboration/ 2025-09-03T13:07:39+00:00 https://forbion.com/fr/news-insights/news/curetis-closes-eur-145-million-extension-to-series-b-financing/ 2025-09-03T12:56:47+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-demonstrates-superior-mutation-detection-utilizing-combined-exosomal-rna-exorna-and-cell-free-dna-cfdna-isolation-and-analysis/ 2025-09-03T12:55:51+00:00 https://forbion.com/fr/news-insights/news/argen-x-third-quarter-business-update/ 2025-09-03T12:48:37+00:00 https://forbion.com/fr/news-insights/news/am-pharma-presents-preclinical-data-on-mode-of-action-for-recap-in-acute-kidney-injury-at-asn-meeting/ 2025-09-03T12:47:39+00:00 https://forbion.com/fr/news-insights/news/dezima-pharma-announces-complete-enrolment-of-cetp-inhibitor-ta-8995-study/ 2025-09-03T12:42:44+00:00 https://forbion.com/fr/news-insights/news/pieris-appoints-michael-richman-as-supervisory-board-member/ 2025-09-03T12:41:25+00:00 https://forbion.com/fr/news-insights/news/argen-x-initiates-clinical-efficacy-evaluation-of-argx-110-in-patients-with-relapsedrefractory-cd70-positive-t-cell-lymphomas/ 2025-09-03T12:15:12+00:00 https://forbion.com/fr/news-insights/news/invetech-and-argos-therapeutics-announce-agreement-to-support-global-production/ 2025-09-03T10:48:26+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-breaks-ground-on-state-of-the-art-biomanufacturing-facility/ 2025-09-03T12:14:05+00:00 https://forbion.com/fr/news-insights/news/promedior-receives-fast-track-designation-for-prm-151-for-the-treatment-of-myelofibrosis/ 2025-09-03T10:47:21+00:00 https://forbion.com/fr/news-insights/news/argen-x-submits-investigational-new-drug-application-to-evaluate-argx-110-in-waldenstroem-s-macroglobulinemia/ 2025-09-03T10:45:54+00:00 https://forbion.com/fr/news-insights/news/argen-x-completes-recruitment-of-first-cohort-of-15-patients-with-cd70-positive-hematological-malignancies-into-its-phase-1b-expansion-trial-with-argx-110/ 2025-09-03T09:28:31+00:00 https://forbion.com/fr/news-insights/news/mitralign-confirms-first-in-man-percutaneous-tricuspid-repair/ 2025-09-03T08:38:52+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-announces-first-close-of-fcf-iii/ 2025-07-23T15:16:00+00:00 https://forbion.com/fr/news-insights/news/curetis-presents-new-unyvero-pneumonia-data-at-major-clinical-microbiology-meetings/ 2025-09-03T08:37:49+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-presentation-of-retrospective-quantitative-imaging-analysis-of-phase-1b-data-in-idiopathic-pulmonary-fibrosis/ 2025-09-03T08:36:48+00:00 https://forbion.com/fr/news-insights/news/argen-x-completes-recruitment-of-first-cohort-of-15-patients-with-cd70-positive-solid-tumors-into-its-phase-1b-expansion-trial-with-argx-110/ 2025-09-03T08:15:55+00:00 https://forbion.com/fr/news-insights/news/enrollment-in-argos-therapeutics-pivotal-phase-iii-adapt-trial-of-ags-003-for-metastatic-renal-cell-carcinoma-surpasses-fifty-percent/ 2025-09-03T08:13:57+00:00 https://forbion.com/fr/news-insights/news/argen-x-core-patents-protecting-lead-clinical-candidates-argx-110-and-argx-111-receive-accelerated-grant-in-the-united-states/ 2025-09-02T16:21:32+00:00 https://forbion.com/fr/news-insights/news/pulmologix-raises-96-million-to-develop-a-new-oral-non-steroidal-anti-asthmatic-drug/ 2025-09-02T16:20:16+00:00 https://forbion.com/fr/news-insights/news/am-pharma-closes-122m-financing-round/ 2025-09-02T16:18:56+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-results-for-the-second-quarter-and-first-half-of-2014-and-provides-update-on-gene-therapy-programs/ 2025-09-02T16:17:58+00:00 https://forbion.com/fr/news-insights/news/dezima-reports-positive-results-in-its-phase-2b-tulip-trial-with-cetp-inhibitor-ta-8995-in-dyslipidemia/ 2025-09-02T16:14:04+00:00 https://forbion.com/fr/news-insights/news/argen-x-announces-positive-preclinical-results-for-argx-113/ 2025-09-02T16:11:25+00:00 https://forbion.com/fr/news-insights/news/skyepharma-acquires-a-novel-inhaled-therapy-platform/ 2025-09-02T16:03:14+00:00 https://forbion.com/fr/news-insights/news/uniqure-acquires-cardiology-gene-therapy-company-inocard/ 2025-09-02T16:01:23+00:00 https://forbion.com/fr/news-insights/news/chiesi-and-uniqure-provide-update-on-glybera-launch/ 2025-09-02T15:56:15+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-sale-of-portfolio-company-santaris-pharma-to-roche-for-up-to-450m/ 2025-07-23T15:19:29+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-appointment-of-thomas-mclain-as-chief-executive-officer/ 2025-09-02T15:55:28+00:00 https://forbion.com/fr/news-insights/news/xention-awarded-14m-from-technology-strategy-board-to-develop-new-medicines-for-atrial-fibrillation/ 2025-09-02T15:53:30+00:00 https://forbion.com/fr/news-insights/news/bluebird-bio-announces-pricing-of-public-offering-of-common-stock/ 2025-09-02T15:52:12+00:00 https://forbion.com/fr/news-insights/news/dezima-pharma-extends-clinical-development-program-for-its-cetp-inhibitor-ta-8995/ 2025-09-02T15:50:16+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-closing-of-initial-public-offering-of-portfolio-company-argen-x/ 2025-07-23T15:22:28+00:00 https://forbion.com/fr/news-insights/news/uniqure-secures-additional-10m-venture-loan-from-hercules-capital/ 2025-09-02T15:48:54+00:00 https://forbion.com/fr/news-insights/news/pieris-achieves-milestone-payment-in-daiichi-sankyo-collaboration-to-develop-anticalin-therapeutics/ 2025-09-02T15:37:24+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-will-lewis-as-new-board-member/ 2025-09-02T15:36:15+00:00 https://forbion.com/fr/news-insights/news/argen-x-and-the-leukemia-lymphoma-society-partner-on-the-development-of-argx-110-for-the-treatment-of-waldenstroem-s-macroglobulinemia/ 2025-09-02T15:31:03+00:00 https://forbion.com/fr/news-insights/news/argen-x-enters-long-term-strategic-alliance-with-shire-pharmaceuticals-in-therapeutic-antibodies/ 2025-09-02T15:29:45+00:00 https://forbion.com/fr/news-insights/news/treatment-with-ags-003-and-sunitinib-associated-with-doubling-of-expected-survival-in-patients-with-unfavorable-risk-metastatic-renal-cell-carcinoma-mrcc/ 2025-09-02T15:28:32+00:00 https://forbion.com/fr/news-insights/news/uniqure-and-medison-sign-glybera-distribution-agreement-for-israel/ 2025-09-02T15:14:06+00:00 https://forbion.com/fr/news-insights/news/promedior-to-present-positive-preliminary-phase-2-data-for-prm-151-in-myelofibrosis-at-asco-annual-meeting/ 2025-09-02T15:15:42+00:00 https://forbion.com/fr/news-insights/news/argen-x-to-present-results-of-phase-1-study-of-argx-110-in-patients-with-advanced-cancer-at-asco/ 2025-09-02T15:12:07+00:00 https://forbion.com/fr/news-insights/news/forbion-advisor-awarded-prestigious-anitschkow-price/ 2025-07-23T15:25:16+00:00 https://forbion.com/fr/news-insights/news/argen-x-announces-collaboration-with-bayer-to-discover-and-develop-therapeutic-antibody-candidates/ 2025-09-02T14:50:35+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-named-as-a-red-herring-top-100-north-america-winner/ 2025-09-02T14:49:38+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-successful-transfection-of-liver-cells-with-aav5-and-strong-safety-data-from-acute-intermittent-porphyria-clinical-trial/ 2025-09-02T14:30:59+00:00 https://forbion.com/fr/news-insights/news/ario-pharma-strengthens-scientific-advisory-board-with-two-key-appointments/ 2025-09-02T14:15:00+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-presentation-of-interim-phase-2-data-on-prm-151-in-myelofibrosis-at-asco/ 2025-09-02T14:14:05+00:00 https://forbion.com/fr/news-insights/news/mayo-clinic-s-dr-robin-patel-named-principal-investigator-for-curetis-unyvero-lrt-trial/ 2025-09-02T13:30:46+00:00 https://forbion.com/fr/news-insights/news/curetis-launches-unyvero-i60-implant-and-tissue-infection-cartridge-in-europe/ 2025-09-02T13:29:45+00:00 https://forbion.com/fr/news-insights/news/new-favorable-clinical-evaluation-data-for-unyvero-p50-pneumonia-application/ 2025-09-02T13:12:00+00:00 https://forbion.com/fr/news-insights/news/argen-x-appoints-dr-werner-lanthaler-to-its-supervisory-board/ 2025-09-02T13:10:53+00:00 https://forbion.com/fr/news-insights/news/uniqure-announces-changes-in-management-team/ 2025-09-02T13:05:32+00:00 https://forbion.com/fr/news-insights/news/argen-x-uses-its-simple-antibody-platform-to-identify-four-hotspots/ 2025-09-02T13:04:35+00:00 https://forbion.com/fr/news-insights/news/forbions-portfolio-company-hookipa-biotech-winner-of-the-best-financing-deal-award-in-the-vaccine-industry-excellence-awards-2014/ 2025-09-02T12:48:58+00:00 https://forbion.com/fr/news-insights/news/am-pharma-announces-positive-phase-i-data-on-recap-for-acute-kidney-injury/ 2025-09-02T12:46:26+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-raises-27-million-in-series-b-financing/ 2025-09-02T11:01:19+00:00 https://forbion.com/fr/news-insights/news/amakem-appoints-dr-james-tsai-of-the-yale-school-of-medicine-to-its-clinical-advisory-board/ 2025-09-02T11:00:27+00:00 https://forbion.com/fr/news-insights/news/curetis-prepares-launch-of-second-unyvero-application/ 2025-09-02T09:29:20+00:00 https://forbion.com/fr/news-insights/news/acquiring-orphans-rogier-rooswinkel-geert-jan-mulder-sander-van-deventer/ 2025-07-21T09:49:28+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-closing-of-public-offering-of-portfolio-company-argos-therapeutics/ 2025-07-23T15:28:32+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-closing-of-initial-public-offering-of-portfolio-company-uniqure/ 2025-07-23T15:32:47+00:00 https://forbion.com/fr/news-insights/news/pieris-achieves-preclinical-milestone-payment-in-sanofi-collaboration/ 2025-09-02T09:28:23+00:00 https://forbion.com/fr/news-insights/news/dezima-pharma-completes-patient-enrolment-for-tulip-phase-2b-study-with-cetp-inhibitor-ta-8995/ 2025-09-02T09:15:35+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-and-qiagen-expand-collaboration-to-develop-non-invasive-biofluid-diagnostic-for-lung-cancer/ 2025-09-02T09:16:47+00:00 https://forbion.com/fr/news-insights/news/argen-x-starts-phase-ib-expansion-cohorts-with-argx-110-a-novel-anti-cd70-antibody-in-cancer-patients/ 2025-09-02T08:18:28+00:00 https://forbion.com/fr/news-insights/news/argen-x-receives-two-preclinical-milestone-payments-under-collaboration-with-shire/ 2025-09-02T08:17:15+00:00 https://forbion.com/fr/news-insights/news/pieris-achieves-fourth-milestone-payment-in-daiichi-sankyo-collaboration-to-develop-anticalin-therapeutics/ 2025-09-02T08:08:49+00:00 https://forbion.com/fr/news-insights/news/curetis-and-laboratorios-leti-sign-exclusive-distribution-agreement-for-unyverotm-in-spain-and-portugal/ 2025-09-02T08:07:16+00:00 https://forbion.com/fr/news-insights/news/promedior-attains-patient-enrollment-milestone-in-phase-2-clinical-study-of-prm-151-in-myelofibrosis/ 2025-09-02T07:56:04+00:00 https://forbion.com/fr/news-insights/news/promedior-appoints-william-hodder-as-vice-president-of-business-development/ 2025-09-02T07:57:00+00:00 https://forbion.com/fr/news-insights/news/stelis-biopharma-and-pieris-forge-alliance-for-novel-anticalin-therapeutics-in-ophthalmology/ 2025-09-01T17:01:20+00:00 https://forbion.com/fr/news-insights/news/argx-110-meets-translational-development-goals-in-dose-escalation-part-of-phase-ib-cancer-study/ 2025-09-01T17:00:01+00:00 https://forbion.com/fr/news-insights/news/clinical-trial-launched-to-treat-sanfilippo-b-syndrome-using-gene-therapy/ 2025-09-01T16:58:50+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-announces-additional-175-million-of-series-e-financing-bringing-total-commitment-to-60-million/ 2025-09-01T16:57:45+00:00 https://forbion.com/fr/news-insights/news/amakem-presents-positive-top-line-clinical-results-for-ama0076-for-glaucoma-at-ophthalmology-innovation-summit/ 2025-09-01T16:56:12+00:00 https://forbion.com/fr/news-insights/news/pieris-receives-third-milestone-payment-in-daiichi-sankyo-collaboration-to-develop-anticalin-therapeutics/ 2025-09-01T16:54:43+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-presents-data-showing-memory-t-cell-expansion/ 2025-09-01T16:53:00+00:00 https://forbion.com/fr/news-insights/news/am-pharma-presents-positive-data-from-recap-preclinical-study-at-asn-meeting/ 2025-09-01T16:29:08+00:00 https://forbion.com/fr/news-insights/news/hookipa-biotech-closes-20-million-275-million-in-series-b-financing/ 2025-09-01T16:22:41+00:00 https://forbion.com/fr/news-insights/news/argen-x-and-de-duve-instituteucl-to-collaborate-on-novel-immunomodulation-therapy-in-cancer/ 2025-09-01T16:28:09+00:00 https://forbion.com/fr/news-insights/news/argen-x-raises-eur-5-million-from-pmv-in-extension-of-eur-325-million-series-b/ 2025-09-01T16:27:11+00:00 https://forbion.com/fr/news-insights/news/curetis-receives-clearance-for-unyvero-system-and-pneumonia-application-in-russia-and-serbia/ 2025-09-01T16:21:28+00:00 https://forbion.com/fr/news-insights/news/pneumrx-incs-repneu-coil-becoming-therapy-of-choice-for-patients-with-severe-emphysema/ 2025-09-01T16:20:02+00:00 https://forbion.com/fr/news-insights/news/curetis-presents-first-data-on-novel-unyvero-i60-iti-application-for-implant-and-tissue-infections/ 2025-09-01T16:18:58+00:00 https://forbion.com/fr/news-insights/news/zydus-and-pieris-sign-broad-co-development-alliance-for-novel-anticalin-therapeutics/ 2025-09-01T16:17:56+00:00 https://forbion.com/fr/news-insights/news/promedior-initiates-phase-2-clinical-study-of-prm-151-in-myelofibrosis/ 2025-09-01T16:16:57+00:00 https://forbion.com/fr/news-insights/news/curetis-presents-new-clinical-validation-data-on-its-unyvero-p50-pneumonia-lrt-application/ 2025-09-01T16:15:59+00:00 https://forbion.com/fr/news-insights/news/christian-meyer-joins-uniqure-as-chief-medical-officer/ 2025-09-01T16:14:43+00:00 https://forbion.com/fr/news-insights/news/uniqure-selected-as-fierce-15-company-by-fiercebiotech/ 2025-09-01T16:13:50+00:00 https://forbion.com/fr/news-insights/news/xention-and-servier-announce-a-cardiovascular-collaboration-to-further-develop-modulator-for-the-treatment-of-atrial-fibrillation/ 2025-09-01T16:12:50+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-enters-collaboration-agreement-with-lilly-for-exosome-blood-based-biomarker-discovery/ 2025-09-01T16:10:32+00:00 https://forbion.com/fr/news-insights/news/argen-x-reaches-milestone-in-simple-antibody-research-and-product-development-collaboration-with-shire/ 2025-09-01T16:11:50+00:00 https://forbion.com/fr/news-insights/news/argen-x-initiates-phase-ib-study-of-argx-111-in-cancer/ 2025-09-01T16:07:58+00:00 https://forbion.com/fr/news-insights/news/jaids-study-by-argos-therapeutics-evaluates-impact-of-personalized-immunotherapy-in-hiv-infected-patients/ 2025-09-01T16:09:06+00:00 https://forbion.com/fr/news-insights/news/argen-x-identifies-potent-antibody-antagonist-against-complex-chronic-pain/ 2025-09-01T16:06:40+00:00 https://forbion.com/fr/news-insights/news/santaris-pharma-as-completes-enrollment-in-phase-2-clinical-trial-of-miravirsen/ 2025-09-01T16:03:03+00:00 https://forbion.com/fr/news-insights/news/shire-and-santaris-extend-their-strategic-alliance-to-discover-and-develop-lna-drugs-in-the-rare-genetic-disease-field/ 2025-09-01T16:04:25+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-secures-425-million-financing-funds-pivotal-phase-3-adapt-trial-for-personalized-immunotherapy/ 2025-09-01T16:01:28+00:00 https://forbion.com/fr/news-insights/news/mount-sinai-and-exosome-diagnostics-partner-to-accelerate-translation-of-body-fluid-molecular-diagnostics-to-overcome-limitations-of-tissue-biopsy-in-areas-of-critical-unmet-medical-needs/ 2025-09-01T15:59:36+00:00 https://forbion.com/fr/news-insights/news/gicare-pharma-initiates-phase-2a-study-of-its-lead-product-gic-1001-in-sedation-free-analgesia-for-colorectal-cancer-screening/ 2025-09-01T15:58:05+00:00 https://forbion.com/fr/news-insights/news/uniqure-to-build-55-000-square-foot-state-of-the-art-gene-therapy-production-plant-in-us-to-leverage-aav-manufacturing-strength/ 2025-09-01T15:56:04+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-and-qiagen-partner-to-launch-comprehensive-line-of-biofluid-nucleic-acid-kits-to-address-limitations-of-tissue-biopsy-in-clinical-research-market/ 2025-09-01T15:50:46+00:00 https://forbion.com/fr/news-insights/news/uniqure-signs-eu-commercialization-agreement-with-chiesi-farmaceutici/ 2025-09-01T15:49:09+00:00 https://forbion.com/fr/news-insights/news/curetis-initiates-prospective-multicenter-unyvero-study-in-europe/ 2025-09-01T15:48:18+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-names-joseph-slattery-to-the-board-of-directors/ 2025-09-01T15:46:33+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-announces-plans-for-hiv-eradication-study/ 2025-09-01T15:47:22+00:00 https://forbion.com/fr/news-insights/news/bluebird-bio-announces-pricing-of-initial-public-offering/ 2025-09-01T15:45:43+00:00 https://forbion.com/fr/news-insights/news/leading-hiv-researchers-and-argos-therapeutics-highlight-importance-of-immunotherapy-in-hiv-eradication-efforts/ 2025-09-01T15:39:55+00:00 https://forbion.com/fr/news-insights/news/dezima-pharma-appoints-seasoned-new-ceo/ 2025-09-01T15:38:11+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-announces-us-and-global-expansion-for-ongoing-pivotal-phase-3-adapt-study-for-personalized-immunotherapy/ 2025-09-01T15:34:35+00:00 https://forbion.com/fr/news-insights/news/uniqure-and-consortium-to-receive-eur-25-million-eurostars-grant-to-develop-rnai-gene-therapy-for-huntington-s-disease/ 2025-09-01T15:32:28+00:00 https://forbion.com/fr/news-insights/news/circulite-receives-approval-to-begin-ce-mark-trial-for-synergy-ic-circulatory-support-system/ 2025-09-01T15:31:11+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-presents-data-demonstrating-utility-of-urine-exosome-technology-to-predict-prostate-biopsy-outcome-at-american-urological-association-annual-meeting/ 2025-09-01T15:17:46+00:00 https://forbion.com/fr/news-insights/news/argos-confirms-improved-rna-amplification-protocol-enhances-quality-of-antigen-specific-immune-response/ 2025-09-01T15:15:58+00:00 https://forbion.com/fr/news-insights/news/bluebird-bio-appoints-two-new-members-to-its-board-of-directors-wendy-dixon-phd-and-david-schenkein-md/ 2025-09-01T14:41:56+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-names-kapil-dhingra-chairman-of-the-board-of-directors/ 2025-09-01T14:40:33+00:00 https://forbion.com/fr/news-insights/news/argen-x-advances-argx-113-into-preclinical-development-for-autoimmune-disorders/ 2025-09-01T14:32:11+00:00 https://forbion.com/fr/news-insights/news/curetis-raises-eur-125-million-in-series-b-round/ 2025-09-01T14:31:05+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-co-leads-15-million-series-a-financing-for-allecra-therapeutics/ 2025-07-23T15:33:52+00:00 https://forbion.com/fr/news-insights/news/santaris-pharma-announces-a-worldwide-discovery-alliance-with-bristolmyers-squibb-for-rna-targeted-medicines/ 2025-09-01T14:14:52+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-presents-data-at-the-international-society-for-extracellular-vesicles-2013-annual-meeting/ 2025-09-01T14:04:30+00:00 https://forbion.com/fr/news-insights/news/pieris-and-sanofi-broaden-existing-collaboration/ 2025-09-01T14:02:29+00:00 https://forbion.com/fr/news-insights/news/exosome-presents-late-breaking-study-demonstrating-ability-to-profile-rna-from-archived-clinical-trial-blood-samples-at-2013-american-association-of-cancer-research-annual-meeting/ 2025-09-01T13:50:07+00:00 https://forbion.com/fr/news-insights/news/argen-x-announces-preclinical-development-of-argx-112-for-dermatology/ 2025-09-01T13:48:07+00:00 https://forbion.com/fr/news-insights/news/bluebird-bio-announces-global-strategic-collaboration-with-celgene-to-advance-gene-therapy-in-oncology/ 2025-09-01T13:20:51+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-welcomes-jean-lamarre-to-board-of-directors/ 2025-09-01T13:19:28+00:00 https://forbion.com/fr/news-insights/news/curetis-ag-strengthens-commercial-team-and-expands-distribution-network/ 2025-09-01T12:51:00+00:00 https://forbion.com/fr/news-insights/news/circulite-receives-conditional-ide-approval-for-synergy-circulatory-support-system-feasibility-trial/ 2025-09-01T12:49:59+00:00 https://forbion.com/fr/news-insights/news/dezima-pharma-raises-142m-186m-to-develop-its-cetp-inhibitor-program-dez-001/ 2025-09-01T10:34:38+00:00 https://forbion.com/fr/news-insights/news/uniqure-named-to-mit-technology-review-s-2013-50-disruptive-companies-list-recognizing-world-s-most-innovative-companies/ 2025-09-01T10:32:32+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-announces-updated-phase-2-data-for-ags-003-personalized-immunotherapy-for-metastatic-renal-cell-carcinoma/ 2025-09-01T09:23:42+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-to-present-on-automated-manufacturing-process-at-2013-cell-and-gene-therapy-forum/ 2025-09-01T09:22:27+00:00 https://forbion.com/fr/news-insights/news/uniqure-appoints-philip-astley-sparke-president-us/ 2025-09-01T09:12:53+00:00 https://forbion.com/fr/news-insights/news/dezima-pharma-in-licenses-cetp-inhibitor-program-from-mitsubishi-tanabe-pharma-corporation/ 2025-09-01T09:13:57+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-enrolls-initial-patients-in-pivotal-phase-3-adapt-study/ 2025-09-01T08:40:58+00:00 https://forbion.com/fr/news-insights/news/argen-x-expands-its-therapeutic-antibody-alliance-with-shire/ 2025-09-01T08:40:00+00:00 https://forbion.com/fr/news-insights/news/argen-x-initiaties-phase-ib-study-of-argx-110-in-cancer/ 2025-09-01T08:34:33+00:00 https://forbion.com/fr/news-insights/news/promedior-opens-new-office-and-laboratories-in-lexington-mass/ 2025-09-01T08:32:29+00:00 https://forbion.com/fr/news-insights/news/uniqure-licenses-rna-interference-technology-to-advance-huntington-s-disease-program/ 2025-09-01T08:21:26+00:00 https://forbion.com/fr/news-insights/news/uniqure-initiates-phase-i-in-acute-intermittent-porphyria/ 2025-09-01T08:22:24+00:00 https://forbion.com/fr/news-insights/news/uniqure-appoints-hans-christian-rohde-chief-commercial-officer/ 2025-09-01T08:23:11+00:00 https://forbion.com/fr/news-insights/news/argen-x-announces-grant-of-broad-us-patent-covering-its-simple-antibody-platform/ 2025-09-01T08:15:38+00:00 https://forbion.com/fr/news-insights/news/curetis-and-scholz-collaborate-to-industrialize-and-scaleup-production-of-unyvero-cartridge-plastics-parts/ 2025-09-01T08:14:00+00:00 https://forbion.com/fr/news-insights/news/pieris-presents-data-and-reveals-targets-for-anticalin-bispecific-prs-190-at-european-antibody-congress/ 2025-09-01T08:08:02+00:00 https://forbion.com/fr/news-insights/news/study-shows-innovative-ert-based-solution-has-the-potential-to-address-unmet-clinical-needs-across-a-range-of-lysosomal-storage-diseases/ 2025-09-01T08:06:50+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-appointment-of-two-leading-experts-in-oncology-and-metabolic-disease-as-scientific-advisors-to-its-various-funds/ 2025-07-23T15:37:09+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-study-confirms-optimal-quality-control-methods-for-production-of-its-rna-based-immunotherapies/ 2025-08-29T14:59:24+00:00 https://forbion.com/fr/news-insights/news/insmed-announces-clear-108-phase-3-clinical-study-has-completed-target-enrollment/ 2025-08-29T14:57:34+00:00 https://forbion.com/fr/news-insights/news/insmed-appoints-andrew-drechsler-as-chief-financial-officer/ 2025-08-29T14:52:21+00:00 https://forbion.com/fr/news-insights/news/southeast-bio-recognizes-argos-therapeutics-with-the-2012-southeast-bio-deal-of-the-year/ 2025-08-29T14:51:33+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-uniqure-receives-approval-for-glybera-first-gene-therapy-by-european-commission/ 2025-07-23T15:40:02+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-selects-promega-corp-for-cgmp-clinical-sample-concentrator-kit/ 2025-08-29T14:50:31+00:00 https://forbion.com/fr/news-insights/news/argen-x-appoints-dr-david-l-lacey-to-its-supervisory-board/ 2025-08-29T14:49:36+00:00 https://forbion.com/fr/news-insights/news/promedior-appoints-elizabeth-trehu-md-as-chief-medical-officer/ 2025-08-29T14:30:16+00:00 https://forbion.com/fr/news-insights/news/promedior-expands-series-d-round-of-financing/ 2025-08-29T14:29:19+00:00 https://forbion.com/fr/news-insights/news/eric-rose-md-named-chairman-of-the-circulite-board-of-directors/ 2025-08-29T14:28:25+00:00 https://forbion.com/fr/news-insights/news/pieris-achieves-first-milestone-payment-in-daiichi-sankyo-collaboration-to-develop-anticalin-therapeutics/ 2025-08-29T14:27:30+00:00 https://forbion.com/fr/news-insights/news/curetis-completes-enrollment-for-its-eu-trial/ 2025-08-29T14:25:58+00:00 https://forbion.com/fr/news-insights/news/ruiyi-formerly-anaphore-and-argen-x-announce-exclusive-worldwide-license-agreement-for-argx-109-a-novel-anti-il-6-antibody/ 2025-08-29T10:31:58+00:00 https://forbion.com/fr/news-insights/news/amakem-initiates-phase-2a-proof-of-concept-study-with-the-rho-kinase-rock-inhibitor-ama0076-in-patients-with-glaucoma-and-ocular-hypertension-under-a-us-ind/ 2025-08-29T10:30:54+00:00 https://forbion.com/fr/news-insights/news/teijin-pharma-and-pulmagen-therapeutics-sign-exclusive-agreement/ 2025-08-29T10:19:47+00:00 https://forbion.com/fr/news-insights/news/21st-century-health-and-business-highlighted-novogi/ 2025-08-29T10:18:38+00:00 https://forbion.com/fr/news-insights/news/curetis-ag-to-present-its-unyvero-solution-at-dghm-conference/ 2025-08-29T09:42:11+00:00 https://forbion.com/fr/news-insights/news/insmed-appoints-will-lewis-as-president-and-chief-executive-officer/ 2025-08-29T09:41:11+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-appointment-of-philip-astley-sparke-as-venture-partner/ 2025-07-23T15:43:26+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-circulite-receives-ce-marking-approval-for-synergy-circulatory-support-system/ 2025-07-23T15:46:03+00:00 https://forbion.com/fr/news-insights/news/bluebird-bio-secures-60-million-in-oversubscribed-financing/ 2025-08-29T09:31:24+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-uniqure-receives-positive-opinion-for-glybera-in-europe-from-chmp/ 2025-07-23T15:47:05+00:00 https://forbion.com/fr/news-insights/news/curetis-ag-signs-distribution-deal-in-middle-east-with-atc/ 2025-08-29T09:30:32+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-receives-fda-approval-of-special-protocol-assessment-for-ags-003-phase-3-trial/ 2025-08-29T09:28:24+00:00 https://forbion.com/fr/news-insights/news/uniqure-collaborates-with-ucsf-on-gdnf-gene-therapy-in-parkinson-s-disease/ 2025-08-29T09:26:14+00:00 https://forbion.com/fr/news-insights/news/novogi-announces-purchase-of-ip-and-collaboration-with-leading-gastroenterologist-dr-christopher-paul-swain/ 2025-08-29T09:19:57+00:00 https://forbion.com/fr/news-insights/news/cytheris-appoints-damian-marron-as-chief-executive-officer/ 2025-08-29T09:18:11+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-presents-positive-phase-1a-data-for-ags-009-in-patients-with-lupus-at-2012-eular-congress/ 2025-08-29T09:11:09+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-signs-agreement-with-life-technologies-to-use-real-time-pcr-platform-for-exosome-biofluid-in-vitro-oncology-diagnostics/ 2025-08-29T09:10:05+00:00 https://forbion.com/fr/news-insights/news/insmed-provides-corporate-update-company-sets-current-arikace-development-priorities-insmed-projects-cash-sufficient-to-generate-top-line-data-from-three-priority-studies/ 2025-08-29T09:03:24+00:00 https://forbion.com/fr/news-insights/news/pneumrx-inc-acquires-key-broncus-assets/ 2025-08-29T07:43:45+00:00 https://forbion.com/fr/news-insights/news/pneumrx-inc-receives-fda-approval-to-commence-pivotal-clinical-trial-of-repneu-lung-volume-reduction-coil-repneu-lvrc-system/ 2025-08-29T08:27:41+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-presents-data-at-american-urology-association-demonstrating-potential-utility-of-urine-exosomes-to-non-invasively-detect-and-manage-prostate-cancer/ 2025-08-29T08:29:19+00:00 https://forbion.com/fr/news-insights/news/promedior-appoints-suzanne-l-bruhn-phd-as-president-and-chief-executive-officer/ 2025-08-28T16:16:31+00:00 https://forbion.com/fr/news-insights/news/argen-x-granted-first-us-patent-covering-its-unique-nhance-technology/ 2025-08-28T15:48:40+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-secures-25-million-series-d-financing-to-commence-phase-3-adapt-study-in-patients-with-metastatic-renal-cell-carcinoma-mrcc-in-mid-2012/ 2025-08-28T15:50:15+00:00 https://forbion.com/fr/news-insights/news/pieris-presents-preclinical-data-for-prs-110-at-aacr-annual-meeting/ 2025-08-28T15:47:12+00:00 https://forbion.com/fr/news-insights/news/kapil-dhingra-former-head-of-roche-oncology-joins-exosome-diagnostics-board-of-directors/ 2025-08-28T15:45:11+00:00 https://forbion.com/fr/news-insights/news/argen-x-appoints-alain-thibault-as-chief-medical-officer-and-koos-rasser-as-ip-counsel/ 2025-08-28T15:43:03+00:00 https://forbion.com/fr/news-insights/news/argen-x-launches-nhance-technology-to-generate-better-human-antibody-therapies/ 2025-08-28T15:27:05+00:00 https://forbion.com/fr/news-insights/news/xention-reports-positive-phase-1-data-for-new-atrial-fibrillation-drug/ 2025-08-28T14:54:35+00:00 https://forbion.com/fr/news-insights/news/promedior-receives-us-orphan-drug-designation-for-prm-151-for-the-treatment-of-idiopathic-pulmonary-fibrosis-ipf/ 2025-08-28T13:27:12+00:00 https://forbion.com/fr/news-insights/news/promedior-secures-215-million-in-first-closing-of-series-d-financing-to-expand-and-advance-pipeline-of-pentraxin-2-therapeutics-for-fibrotic-diseases/ 2025-08-28T13:09:08+00:00 https://forbion.com/fr/news-insights/news/argen-x-enters-into-a-therapeutic-antibody-alliance-with-shire/ 2025-08-28T13:01:59+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-business-to-be-acquired-by-uniqure-bv/ 2025-08-28T12:33:52+00:00 https://forbion.com/fr/news-insights/news/curetis-ag-initiates-prospective-clinical-trial-for-rapid-pneumonia-diagnostics/ 2025-08-28T12:24:23+00:00 https://forbion.com/fr/news-insights/news/cellnovo-launches-worlds-first-mobile-connected-diabetes-management-system-with-largest-ever-usability-trial-of-insulin-pump-technology/ 2025-08-28T12:04:25+00:00 https://forbion.com/fr/news-insights/news/argen-x-advances-a-third-therapeutic-antibody-program-into-preclinical-development/ 2025-08-28T10:41:35+00:00 https://forbion.com/fr/news-insights/news/accelerate-brain-cancer-cure-and-exosome-diagnostics-collaborate-to-advance-clinical-studies-of-exosome-biofluid-molecular-diagnostics-technology-in-brain-cancer/ 2025-08-28T09:55:00+00:00 https://forbion.com/fr/news-insights/news/pieris-receives-bmbf-grant-to-fund-prs-110-c-met-antagonist-anticalin-program/ 2025-08-28T09:39:03+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-announces-new-data-demonstrating-prolonged-overall-survival-in-a-phase-2-study-of-its-arcelis-immunotherapy-ags-003-in-combination-with-sunitinib-in-patients-with-metastatic-renal-cell-carcinoma-mrcc/ 2025-08-28T09:36:32+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutic-arcelis-immunotherapy-ags-003-in-combination-with-sunitinib-shows-statistically-significant-correlation-of-immune-system-response-to-overall-survival-in-phase-2-study-in-patients-with-advanced-renal-cell-carcinoma-rcc/ 2025-08-28T09:32:18+00:00 https://forbion.com/fr/news-insights/news/eur-10-million-grant-awarded-to-exosome-diagnostics-and-ludwig-maximilian-university-from-german-federal-ministry-for-education-and-research-to-develop-biofluid-derived-exosome-diagnostics/ 2025-08-28T09:24:20+00:00 https://forbion.com/fr/news-insights/news/am-pharma-announces-appointment-of-russell-greig-as-chairman/ 2025-08-28T09:16:10+00:00 https://forbion.com/fr/news-insights/news/argen-x-is-awarded-13-million-iwt-grant-to-advance-proprietary-simple-antibody-platform-for-addressing-challenging-disease-targets/ 2025-08-28T09:14:53+00:00 https://forbion.com/fr/news-insights/news/pieris-presents-preclinical-data-for-prs-080-hepcidin-antagonist-anticalin-program-at-ash-annual-meeting/ 2025-08-28T08:22:43+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-closing-of-second-fcf-1-co-investment-fund/ 2025-07-23T15:47:36+00:00 https://forbion.com/fr/news-insights/news/cellnovos-mobile-health-approach-to-diabetes-care/ 2025-08-28T08:13:29+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-circulite-inc-raises-30m-in-series-d-round/ 2025-08-27T14:56:32+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-argen-x-raises-eur-275-million-usd-37-million-in-oversubscribed-series-b-round/ 2025-08-27T14:58:28+00:00 https://forbion.com/fr/news-insights/news/oxyrane-raises-265m-in-series-d-financing/ 2025-08-27T14:55:40+00:00 https://forbion.com/fr/news-insights/news/pieris-announces-results-and-successful-completion-of-its-prs-050-anticalin-phase-i-trial-at-aacr-eortc-nci-molecular-targets-and-cancer-therapeutics-conference/ 2025-08-27T14:54:40+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-leads-96-million-expansion-financing-of-curetis-ag/ 2025-07-23T15:48:13+00:00 https://forbion.com/fr/news-insights/news/pieris-outlines-strategic-impact-of-six-million-euro-eurocalin-grant-award-on-anticalin-pipeline-development/ 2025-08-27T14:53:26+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-and-sofinnova-participate-in-the-7-million-series-a-financing-of-hookipa-biotech/ 2025-07-23T15:55:32+00:00 https://forbion.com/fr/news-insights/news/the-prostate-cancer-foundation-and-exosome-diagnostics-collaborate-to-accelerate-clinical-validation-of-exosome-biofluid-molecular-diagnostics-in-prostate-cancer/ 2025-08-27T14:51:50+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-additions-to-management-and-scientific-advisory-board-as-company-expands-clinical-validation-studies-in-oncology/ 2025-08-27T13:13:11+00:00 https://forbion.com/fr/news-insights/news/cardoz-announces-the-successful-completion-of-enrollment-in-the-aorta-trial-investigating-crd007-in-patients-with-abdominal-aortic-aneurysm/ 2025-08-27T13:30:06+00:00 https://forbion.com/fr/news-insights/news/cellnovo-receives-2011-european-technology-innovation-award-in-diabetes-care/ 2025-08-27T11:26:21+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-late-scientific-co-founder-ralph-steinman-md-awarded-nobel-prize-in-medicine-for-discovery-of-dendritic-cells-as-critical-sentinels-of-immune-system/ 2025-08-27T11:37:34+00:00 https://forbion.com/fr/news-insights/news/am-pharma-raises-292m-in-series-d-financing/ 2025-07-23T15:54:29+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-acquisition-of-pathway-medical-technologies-by-bayer-healthcare/ 2025-07-23T15:57:19+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-leads-18-million-financing-of-amakem-nv/ 2025-07-23T15:59:42+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-leads-cad-7-million-series-a-financing-of-gicare-pharma-inc/ 2025-07-23T16:01:42+00:00 https://forbion.com/fr/news-insights/news/insmeds-arikace-demonstrates-sustained-benefit-through-six-cycles-of-treatment-for-cystic-fibrosis-patients-with-pseudomonas-lung-infections/ 2025-08-27T09:53:43+00:00 https://forbion.com/fr/news-insights/news/cardoz-announces-the-start-of-the-international-phase-ii-dose-finding-aorta-trial-investigating-a-new-oral-drug-treatment-for-abdominal-aortic-aneurysm/ 2025-08-26T14:29:50+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-arcelis-immunotherapy-for-the-treatment-of-renal-cell-carcinoma-rcc-in-combination-with-sunitinib-demonstrates-strong-immunologic-response-that-correlates-to-improved-clinical-outcomes/ 2025-08-26T13:56:38+00:00 https://forbion.com/fr/news-insights/news/exosome-diagnostics-announces-expansion-of-scientific-advisory-board/ 2025-08-26T13:54:32+00:00 https://forbion.com/fr/news-insights/news/pieris-announces-preclinical-in-vitro-and-in-vivo-data-for-its-anticalin-prs-080-hepcidin-antagonist-drug-program/ 2025-08-26T13:53:16+00:00 https://forbion.com/fr/news-insights/news/promedior-presents-clinical-data-for-prm-151-rhptx-2-in-idiopathic-pulmonary-fibrosis-at-american-thoracic-society-2011/ 2025-08-26T13:52:10+00:00 https://forbion.com/fr/news-insights/news/santaris-pharma-as-advances-a-second-drug-from-its-cardiometabolic-program-spc4955-inhibiting-apob-into-phase-1-clinical-trials-for-the-treatment-of-high-cholesterol/ 2025-08-20T13:24:26+00:00 https://forbion.com/fr/news-insights/news/promedior-to-present-clinical-data-for-prm-151-rhptx-2-in-idiopathic-pulmonary-fibrosis-at-ats-2011/ 2025-08-20T13:13:37+00:00 https://forbion.com/fr/news-insights/news/biogeneration-announces-closing-of-biogeneration-ventures-ii/ 2025-08-20T13:07:44+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-presentation-of-data-at-arvo-demonstrating-that-prm-151-rhptx-2-suppresses-choroidal-and-retinal-neovascularization/ 2025-08-20T12:34:01+00:00 https://forbion.com/fr/news-insights/news/bluebird-bio-secures-additional-30-million-in-financing/ 2025-08-20T12:28:13+00:00 https://forbion.com/fr/news-insights/news/pieris-and-daiichi-sankyo-sign-therapeutic-collaboration-to-develop-anticalin-therapeutics/ 2025-08-20T11:51:37+00:00 https://forbion.com/fr/news-insights/news/provesica-starts-phase-2-study-in-overactive-bladder/ 2025-08-20T11:42:18+00:00 https://forbion.com/fr/news-insights/news/pieris-to-present-interim-data-from-the-phase-i-clinical-trial-of-prs-050-at-molecular-medicine-tri-conference/ 2025-08-19T16:49:15+00:00 https://forbion.com/fr/news-insights/news/il-7-engages-multiple-mechanisms-to-overcome-chronic-viral-infection-and-limit-organ-pathology/ 2025-08-19T16:48:06+00:00 https://forbion.com/fr/news-insights/news/il-7-knocks-the-socs-off-chronic-viral-infection/ 2025-08-19T16:46:57+00:00 https://forbion.com/fr/news-insights/news/cytheris-announces-publication-of-preclinical-study-in-cell-showing-that-interleukin-7-engages-multiple-mechanisms-to-overcome-chronic-viral-infection-and-limit-organ-pathology/ 2025-08-19T17:06:08+00:00 https://forbion.com/fr/news-insights/news/xention-and-gruenenthal-enter-drug-discovery-collaboration-in-ion-channel-research/ 2025-08-19T16:45:53+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-publication-of-new-research-demonstrating-pentraxin-2sap-is-a-potent-inhibitor-of-pulmonary-fibrosis/ 2025-08-19T16:43:40+00:00 https://forbion.com/fr/news-insights/news/promedior-initiates-clinical-study-of-anti-fibrotic-therapeutic-prm-151-in-patients-with-idiopathic-pulmonary-fibrosis-ipf/ 2025-08-19T16:41:45+00:00 https://forbion.com/fr/news-insights/news/cellnovo-to-secure-30-million-in-series-b-financing/ 2025-08-19T16:40:26+00:00 https://forbion.com/fr/news-insights/news/key-genes-associated-with-cancer-found-in-circulating-blood-microvesicles/ 2025-08-19T16:39:28+00:00 https://forbion.com/fr/news-insights/news/amt-receives-11-million-funding-for-acute-intermittent-porphyria-gene-therapy-as-part-of-eu-consortium-grant/ 2025-08-19T16:38:16+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-amgen-agreement-to-acquire-portfolio-company-biovex-for-up-to-us-1-billion/ 2025-08-19T16:23:57+00:00 https://forbion.com/fr/news-insights/news/amt-to-supply-cgmp-manufacturing-to-consortium-led-by-institut-pasteur-for-clinical-development-of-gene-therapy-for-rare-genetic-disorder-in-children/ 2025-08-19T16:15:18+00:00 https://forbion.com/fr/news-insights/news/takeda-san-francisco-and-pieris-sign-anticalin-therapeutic-collaboration/ 2025-08-19T15:44:09+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-leads-33-million-series-c-financing-of-pneumrx-inc/ 2025-07-23T16:03:08+00:00 https://forbion.com/fr/news-insights/news/argen-x-signs-discovery-and-development-alliance-with-lilly/ 2025-08-19T15:00:21+00:00 https://forbion.com/fr/news-insights/news/santaris-pharma-as-announces-expanded-worldwide-strategic-alliance-with-pfizer-inc-directed-to-development-of-rna-targeted-medicines/ 2025-08-18T16:46:20+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-initiates-dosing-of-patients-in-phase-1-clinical-trial-of-monoclonal-antibody-based-therapy-for-treatment-of-systemic-lupus-erythematosus/ 2025-08-19T11:41:58+00:00 https://forbion.com/fr/news-insights/news/4m-financing-into-provesica-to-complete-phase-2-trial-for-overactive-bladder/ 2025-08-18T16:36:09+00:00 https://forbion.com/fr/news-insights/news/xention-spins-out-overactive-bladder-business/ 2025-08-18T16:35:07+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-announces-that-insmed-incorporated-and-transave-inc-combine-their-businesses/ 2025-08-18T14:24:34+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-initiates-dosing-of-patients-in-phase-2b-clinical-trial-of-arcelis-personalized-immunotherapy-for-treatment-of-hiv-patients/ 2025-08-18T14:19:43+00:00 https://forbion.com/fr/news-insights/news/cytheris-announces-publication-of-clinical-case-study-combining-recombinant-human-interleukin-7-cyt107-with-antiviral-agent-cmx001-as-potential-treatment-for-progressive-multifocal-leukoencephalopathy-pml/ 2025-08-18T14:10:17+00:00 https://forbion.com/fr/news-insights/news/amt-submits-responses-to-day-120-questions-to-ema-as-part-of-the-review-process-for-glybera/ 2025-08-18T13:45:19+00:00 https://forbion.com/fr/news-insights/news/xention-raises-8-million-in-private-equity-placement/ 2025-08-18T13:37:11+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-arcelis-immunotherapy-for-renal-cell-carcinoma-demonstrates-encouraging-results-in-phase-2-combination-study-with-sunitinib/ 2025-08-18T13:25:36+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-successfully-lowers-cholesterol-in-vivo-with-enhanced-novel-microrna-aav-gene-therapy/ 2025-08-18T13:31:40+00:00 https://forbion.com/fr/news-insights/news/arikace-demonstrates-sustained-benefit-in-multiple-studies-and-over-multiple-cycles-of-treatment-of-pseudomonas-lung-infections-in-cystic-fibrosis-patients/ 2025-08-18T13:16:15+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-successfully-raised-143m-through-an-equity-issue/ 2025-08-18T11:55:58+00:00 https://forbion.com/fr/news-insights/news/pieris-signs-broad-collaboration-with-sanofi-aventis-and-sanofi-pasteur-to-develop-anticalin-therapeutics/ 2025-08-18T10:49:14+00:00 https://forbion.com/fr/news-insights/news/argen-x-awarded-15-million-iwt-grant-to-accelerate-pre-clinical-antibody-development/ 2025-08-18T10:26:27+00:00 https://forbion.com/fr/news-insights/news/amt-receives-orphan-drug-designation-from-the-us-food-and-drug-administration-duchenne-muscular-dystrophy-gene-therapy/ 2025-08-18T10:18:54+00:00 https://forbion.com/fr/news-insights/news/cardoz-raises-sek-124-m-17-m-13-m-in-series-a-financing-to-develop-drug-for-aortic-aneurysm/ 2025-08-14T14:51:57+00:00 https://forbion.com/fr/news-insights/news/nature-publishes-promising-results-on-treatment-of-first-patient-in-bluebird-bio-s-phase-12-beta-thalassemia-study/ 2025-08-14T14:49:32+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-initiation-of-phase-2a-clinical-study-of-anti-fibrotic-therapeutic-prm-151-in-the-prevention-of-post-surgical-scarring-in-glaucoma-patients/ 2025-08-14T14:47:53+00:00 https://forbion.com/fr/news-insights/news/promedior-announces-publication-of-new-research-demonstrating-pentraxin-2sap-is-a-potent-inhibitor-of-asthma-and-asthma-induced-lung-fibrosis/ 2025-08-14T14:46:21+00:00 https://forbion.com/fr/news-insights/news/genetix-pharmaceuticals-renamed-bluebird-bio-announces-appointment-of-nick-leschly-as-chief-executive-officer/ 2025-08-14T14:45:05+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-raises-190m-for-new-investments/ 2025-07-23T16:04:03+00:00 https://forbion.com/fr/news-insights/news/amt-s-marketing-authorisation-application-for-glybera-progressing-on-schedule/ 2025-08-14T14:43:52+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-arcelis-hiv-immunotherapy-demonstrates-significant-reduction-in-viral-load-and-delay-in-viral-rebound-kinetics-in-interim-analysis-of-phase-2-study/ 2025-08-14T14:27:31+00:00 https://forbion.com/fr/news-insights/news/argen-x-granted-broad-patent-covering-its-unique-simple-antibody-platform/ 2025-08-14T14:25:17+00:00 https://forbion.com/fr/news-insights/news/pieris-initiates-phase-i-clinical-trial-for-lead-anticalin-compound/ 2025-08-14T14:23:09+00:00 https://forbion.com/fr/news-insights/news/pieris-ag-appoints-chief-scientific-officer/ 2025-08-14T14:21:06+00:00 https://forbion.com/fr/news-insights/news/cytheris-closes-12-million-15-million-series-d-financing/ 2025-08-14T14:22:04+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-reports-promising-data-from-cholesterol-lowering-gene-therapy-study/ 2025-08-14T14:20:07+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-co-leads-20-million-series-a-financing-of-exosome-diagnostics/ 2025-07-23T16:05:06+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-leads-10m-series-a-financing-in-cardoz-to-develop-drug-for-aortic-aneuryism/ 2025-07-23T16:06:30+00:00 https://forbion.com/fr/news-insights/news/pieris-announces-positive-preclinical-data-on-c-met-anticalin-drug-program/ 2025-08-14T14:18:44+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-presents-transplantation-data-for-soluble-cd83-demonstrating-its-ability-to-induce-immune-tolerance-and-suppress-anti-donor-antibody-responses/ 2025-08-14T14:17:30+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-publishes-positive-immune-response-safety-and-manufacturing-data-for-its-arcelis-hiv-program-in-clinical-immunology/ 2025-08-14T14:14:26+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-presents-positive-phase-2-data-of-its-arcelis-personalized-immunotherapy-platform-in-metastatic-rcc-at-asco-gu-symposium/ 2025-07-31T12:29:23+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-opens-german-office-and-expands-team/ 2025-07-23T16:10:32+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-leads-12-million-series-c-financing-of-promedior-inc/ 2025-07-23T16:12:14+00:00 https://forbion.com/fr/news-insights/news/genetix-pharmaceuticals-secures-35m-in-series-b-funding/ 2025-07-23T17:06:05+00:00 https://forbion.com/fr/news-insights/news/argen-x-simple-antibody-platform-set-to-transform-therapeutic-antibody-discovery-development/ 2025-07-23T17:04:24+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-amends-amgen-gdnf-gene-license-agreement/ 2025-07-31T12:27:36+00:00 https://forbion.com/fr/news-insights/news/amt-initiates-phase-iii-gene-therapy-clinical-trial-for-hemophilia-b/ 2025-07-31T12:11:22+00:00 https://forbion.com/fr/news-insights/news/genetix-pharmaceuticals-appoints-mitchell-finer-phd-as-chief-scientific-officer/ 2025-07-23T17:07:22+00:00 https://forbion.com/fr/news-insights/news/galapagos-acquires-argenta-discoverys-service-operations/ 2025-07-31T12:10:28+00:00 https://forbion.com/fr/news-insights/news/ema-starts-formal-review-of-glybera-dossier/ 2025-07-31T12:09:28+00:00 https://forbion.com/fr/news-insights/news/amt-submits-its-lead-product-glybera-application-for-marketing-authorisation-application-to-ema/ 2025-07-31T12:08:26+00:00 https://forbion.com/fr/news-insights/news/pieris-appoints-a-new-ceo/ 2025-07-23T17:09:00+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-amt-successfully-raises-eur-5-million-via-a-convertible-bond-issue-with-shareholder-forbion/ 2025-07-23T16:01:16+00:00 https://forbion.com/fr/news-insights/news/argen-x-concludes-eur-125-million-series-a-financing-round/ 2025-07-23T15:59:07+00:00 https://forbion.com/fr/news-insights/news/pangenetics-announces-acquisition-by-abbott-of-pg110-anti-ngf-antibody-to-treat-chronic-pain/ 2025-07-23T17:10:46+00:00 https://forbion.com/fr/news-insights/news/genetix-pharmaceuticals-announces-global-clinical-plans-to-treat-adrenoleukodystrophy-ald/ 2025-07-23T15:56:30+00:00 https://forbion.com/fr/news-insights/news/amt-successful-in-preclinical-treatment-of-duchenne-muscular-dystrophy/ 2025-07-23T15:57:38+00:00 https://forbion.com/fr/news-insights/news/biovex-announces-publication-of-phase-2-melanoma-results-with-oncovex-gm-csf-in-the-journal-of-clinical-oncology/ 2025-07-23T15:54:45+00:00 https://forbion.com/fr/news-insights/news/amt-starts-development-lplchiptm-with-progenika/ 2025-07-23T15:50:16+00:00 https://forbion.com/fr/news-insights/news/transave-completes-successful-phase-ii-clinical-program-for-arikace-in-the-treatment-of-pseudomonas-lung-infections/ 2025-07-23T15:49:05+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-presents-positive-phase-2-viral-load-and-immune-response-data-for-arcelis-hiv-program-at-the-aids-vaccine-2009-conference/ 2025-07-23T15:47:55+00:00 https://forbion.com/fr/news-insights/news/amt-receives-emea-orphan-drug-designation-for-duchenne-muscular-dystrophy/ 2025-07-23T15:46:00+00:00 https://forbion.com/fr/news-insights/news/pieris-reports-preclinical-development-progress-of-its-next-generation-vegf-antagonist/ 2025-07-23T15:45:02+00:00 https://forbion.com/fr/news-insights/news/sanofi-aventis-to-acquire-fovea-pharmaceuticals-a-french-biopharmaceutical-ophthalmology-company/ 2025-07-23T15:43:53+00:00 https://forbion.com/fr/news-insights/news/joern-aldag-appointed-as-amts-ceo/ 2025-07-23T14:53:30+00:00 https://forbion.com/fr/news-insights/news/cytheris-announces-interim-data-from-inspire-study-showing-interleukin-7-cyt107-induces-dose-dependent-and-sustained-increase-of-cd4-t-cells-in-chronic-hiv-infected-patients/ 2025-07-23T14:52:34+00:00 https://forbion.com/fr/news-insights/news/pieris-ag-enters-into-anticalin-collaboration-with-allergan-inc/ 2025-07-23T13:55:10+00:00 https://forbion.com/fr/news-insights/news/transave-announces-positive-phase-ii-results-for-once-daily-arikace-in-the-treatment-of-non-cf-bronchiectasis-patients-who-have-pseudomonas-lung-infections/ 2025-07-23T13:54:03+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-co-leads-eur-95-million-financing-of-argen-x-bv/ 2025-07-23T17:22:22+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-leads-185-million-financing-of-niti-surgical-solutions/ 2025-07-23T17:24:15+00:00 https://forbion.com/fr/news-insights/news/synergy-circulites-micro-blood-pump-shown-to-provide-sustained-improvements-in-cardiac-function-and-evidence-of-myocardial-recovery-in-patients-with-chronic-heart-failure/ 2025-07-23T13:40:52+00:00 https://forbion.com/fr/news-insights/news/pangenetics-receives-approval-for-clinical-evaluation-of-anti-ngf-antibody-in-patients-with-chronic-pain/ 2025-07-23T13:13:50+00:00 https://forbion.com/fr/news-insights/news/argenta-discovery-announces-two-year-extension-of-major-drug-discovery-collaboration-with-genentech/ 2025-07-23T13:10:37+00:00 https://forbion.com/fr/news-insights/news/argenta-discovery-announces-entry-into-phase-i-for-first-candidate-from-collaboration-with-astrazeneca-to-develop-improved-inhaled-bronchodilators-for-copd/ 2025-07-23T12:43:43+00:00 https://forbion.com/fr/news-insights/news/argenta-discovery-and-porsolt-join-forces-to-provide-fully-integrated-cns-and-pain-contract-drug-discovery-services/ 2025-07-23T12:40:00+00:00 https://forbion.com/fr/news-insights/news/amt-starts-preregistration-trial-for-glybera/ 2025-07-23T10:38:05+00:00 https://forbion.com/fr/news-insights/news/fovea-reports-positive-results-with-prednisporintm-in-persistent-allergic-conjunctivitis/ 2025-07-23T10:37:16+00:00 https://forbion.com/fr/news-insights/news/transave-completes-enrollment-in-arikacetm-phase-ii-bronchiectasis-study/ 2025-07-23T10:35:54+00:00 https://forbion.com/fr/news-insights/news/biovex-commences-oncovex-gm-csf-pivotal-trial-in-melanoma/ 2025-07-23T10:34:51+00:00 https://forbion.com/fr/news-insights/news/circulite-demonstrates-long-term-improvements-and-hemodynamic-benefits-with-synergy-partial-circulatory-support-in-chronic-heart-failure-patients/ 2025-07-23T10:14:38+00:00 https://forbion.com/fr/news-insights/news/circulite-completes-initial-close-on-33-million-series-c-financing-plan-and-appoints-chief-medical-officer/ 2025-07-21T18:36:06+00:00 https://forbion.com/fr/news-insights/news/xention-enters-drug-discovery-agreement-with-ono-pharmaceutical-co-ltd/ 2025-07-21T18:32:25+00:00 https://forbion.com/fr/news-insights/news/wyeth-pharmaceuticals-and-santaris-pharma-announce-strategic-alliance-to-develop-rna-based-medicines/ 2025-07-23T17:25:45+00:00 https://forbion.com/fr/news-insights/news/dsm-and-crucell-sign-agreement-with-bioceros-to-serve-as-pre-approved-cell-line-generation-partner-of-perc6-cell-line-proteins/ 2025-07-23T17:28:37+00:00 https://forbion.com/fr/news-insights/news/pieris-reports-development-progress-for-anticalin-prs-050-a-next-generation-vegf-antagonist/ 2025-07-21T18:30:48+00:00 https://forbion.com/fr/news-insights/news/amt-ceo-ronald-lorijn-steps-down-sander-van-deventer-interim-ceo/ 2025-07-21T18:29:28+00:00 https://forbion.com/fr/news-insights/news/mitralign-initiates-its-first-european-study/ 2025-07-23T17:30:34+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-completes-352-million-series-c-financing/ 2025-07-23T17:32:17+00:00 https://forbion.com/fr/news-insights/news/amt-intends-to-incorporate-additional-data-to-its-marketing-authorization-dossier-for-glybera/ 2025-07-21T18:27:41+00:00 https://forbion.com/fr/news-insights/news/amt-obtains-license-to-amgens-gdnf-gene-to-develop-treatment-for-parkinsons-disease-with-amts-proprietary-gene-therapy-platform/ 2025-07-21T18:25:44+00:00 https://forbion.com/fr/news-insights/news/pathway-medical-technologies-receives-fda-clearance-for-jetstream-pathway-pv-atherectomy-system/ 2025-07-23T17:33:19+00:00 https://forbion.com/fr/news-insights/news/amt-prepares-for-submission-of-marketing-authorization-dossier-for-amt-011-glybera/ 2025-07-21T18:22:27+00:00 https://forbion.com/fr/news-insights/news/amt-announces-positive-interim-clinical-data-on-its-lead-product-amt-011/ 2025-07-21T18:24:11+00:00 https://forbion.com/fr/news-insights/news/biovex-reports-positive-phase-ii-clinical-trial-results-of-oncovex-gm-csf-in-metastatic-melanoma-at-the-2008-american-society-of-clinical-oncology-meeting/ 2025-07-23T17:35:57+00:00 https://forbion.com/fr/news-insights/news/amts-cooperative-research-and-development-agreement-with-nih-to-boost-production-capacity/ 2025-07-21T18:20:46+00:00 https://forbion.com/fr/news-insights/news/amt-accesses-technology-for-treatment-of-duchenne-muscular-dystrophy/ 2025-07-23T17:38:33+00:00 https://forbion.com/fr/news-insights/news/pathway-medical-technologies-inc-secures-245-million-financing/ 2025-07-23T17:43:32+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-secures-352-million-series-c-financing/ 2025-07-21T18:18:57+00:00 https://forbion.com/fr/news-insights/news/forbion-s-portfolio-company-transave-inc-raises-35-million-through-series-d-convertible-preferred-stock-financing/ 2025-07-23T17:47:38+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-presents-positive-phase-1-safety-data-for-its-arcelis-platform-in-hiv-at-keystone-symposia/ 2025-07-23T17:49:36+00:00 https://forbion.com/fr/news-insights/news/forbion-s-portfolio-company-pieris-ag-raises-25-m-us-38m-in-series-b-financing-round/ 2025-07-23T17:52:41+00:00 https://forbion.com/fr/news-insights/news/pathway-medical-technologies-names-paul-buckman-chairman-of-the-board-of-directors/ 2025-07-23T18:00:10+00:00 https://forbion.com/fr/news-insights/news/circulite-announces-initiation-of-european-registration-study-for-synergy-circulatory-assist-device/ 2025-07-23T18:04:14+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-co-invests-in-23m-euro-series-c-financing-of-pangenetics/ 2025-07-24T14:39:57+00:00 https://forbion.com/fr/news-insights/news/argenta-discovery-announces-the-initiation-of-a-phase-ii-clinical-trial-with-adc4022/ 2025-07-24T14:43:52+00:00 https://forbion.com/fr/news-insights/news/circulite-reports-preliminary-results-of-first-in-man-pilot-study-for-synergy-circulatory-assist-device/ 2025-07-24T14:45:02+00:00 https://forbion.com/fr/news-insights/news/cytheris-announces-48-week-results-of-phase-iii-study-showing-administration-of-interleukin-7-il-77-significantly-improves-cd4-t-cell-counts-in-chronically-infected-hiv-1-patients/ 2025-07-24T14:53:07+00:00 https://forbion.com/fr/news-insights/news/mitralign-successfully-completes-first-human-case/ 2025-07-24T14:54:03+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-publishes-novel-approach-to-amplifying-hiv-genes-for-personalized-immunotherapy-treatments-for-hiv/ 2025-07-24T14:55:29+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-co-leads-24m-series-c-financing-of-mitralign/ 2025-07-24T15:00:04+00:00 https://forbion.com/fr/news-insights/news/amt-s-lead-product-poised-to-address-major-liver-disease-european-patent-office-grants-patent-for-treatment-of-non-alcoholic-steatotic-hepatitis/ 2025-07-24T14:58:09+00:00 https://forbion.com/fr/news-insights/news/mitralign-announces-the-closing-of-a-series-c-financing/ 2025-07-24T15:01:07+00:00 https://forbion.com/fr/news-insights/news/cytheris-releases-promising-clinical-data-on-its-interleukin-7-immune-enhancer-at-the-2007-croi-meeting-in-los-angeles/ 2025-07-24T15:17:22+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-initiates-program-for-late-stage-liver-cirrhosis-and-reports-strong-progress-in-amt-011-with-trial-fully-recruited-and-european-and-us-submission-on-track-for-first-half-of-2008/ 2025-07-24T15:19:13+00:00 https://forbion.com/fr/news-insights/news/flowmedica-announces-completion-of-the-benephit-system-renal-infusion-therapy-be-rite-registry/ 2025-07-24T15:20:55+00:00 https://forbion.com/fr/news-insights/news/pathway-medical-technologies-adds-joe-rafferty-as-vp-sales-and-moves-to-larger-facility-to-accommodate-rapid-growth/ 2025-07-24T15:27:53+00:00 https://forbion.com/fr/news-insights/news/amgen-to-acquire-alaska-pharmaceuticals/ 2025-07-24T15:32:27+00:00 https://forbion.com/fr/news-insights/news/revolutionary-miniature-blood-pump-from-circulite-successfully-implanted-in-first-chronic-heart-failure/ 2025-07-24T15:29:11+00:00 https://forbion.com/fr/news-insights/news/biovex-raises-22-million-in-first-close-of-series-e-financing/ 2025-07-24T15:33:30+00:00 https://forbion.com/fr/news-insights/news/bram-bout-joins-bioceros-as-ceo/ 2025-07-25T13:30:20+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-announces-pricing-of-initial-public-offering/ 2025-07-25T13:35:43+00:00 https://forbion.com/fr/news-insights/news/pieris-progresses-development-of-its-proprietary-biotherapeutics-platform-successful-demonstration-of-dual-targeting-with-duocalin-technology/ 2025-07-25T13:34:55+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-announces-launch-of-initial-public-offering-ipo-on-euronext-amsterdam/ 2025-07-25T13:37:55+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-successful-exit-from-alantos-pharmaceuticals/ 2025-07-25T13:41:53+00:00 https://forbion.com/fr/news-insights/news/amt-presents-positive-results-of-phase-iii-study-with-lead-product-at-annual-meeting-of-american-society-of-gene-therapy/ 2025-07-25T13:43:30+00:00 https://forbion.com/fr/news-insights/news/amt-appoints-ferdinand-verdonck-as-chairman-of-the-supervisory-board/ 2025-07-25T13:46:04+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-announces-intention-to-launch-an-initial-public-offering-ipo-on-euronext-amsterdam/ 2025-07-25T13:45:23+00:00 https://forbion.com/fr/news-insights/news/pieris-ag-a-biopharmaceutical-company-developing-anticalins-a-novel-class-of-targeted-human-protein-therapeutics/ 2025-07-25T13:51:19+00:00 https://forbion.com/fr/news-insights/news/forbion-capital-partners-adds-top-tier-investors-to-its-investor-base/ 2025-07-25T13:52:30+00:00 https://forbion.com/fr/news-insights/news/circulite-closes-an-additional-5m-in-series-b-private-placement-funding/ 2025-07-25T13:55:31+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-awarded-us-patent-for-cd83-protein-for-use-in-immunological-disorders/ 2025-07-25T16:48:26+00:00 https://forbion.com/fr/news-insights/news/pieris-demonstrates-potent-anti-tumor-activity-of-a-vegf-specific-anticalin-in-preclinical-studies/ 2025-07-25T16:51:18+00:00 https://forbion.com/fr/news-insights/news/acadia-announces-positive-results-from-acp-103-phase-ii-schizophrenia-co-therapy-trial/ 2025-07-25T16:47:12+00:00 https://forbion.com/fr/news-insights/news/circulite-closes-20m-series-b-private-placement-funding/ 2025-07-25T16:50:41+00:00 https://forbion.com/fr/news-insights/news/argos-therapeutics-initiates-personalized-immunotherapy-clinical-trial-in-hiv-patients/ 2025-07-25T17:00:00+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-bv-receives-global-rights-to-develop-and-commercialize-amt-020-for/ 2025-07-25T16:52:22+00:00 https://forbion.com/fr/news-insights/news/forbion-partner-sander-van-deventer-receives-award-for-development-of-new-therapies-for-crohns-disease/ 2025-07-25T16:55:22+00:00 https://forbion.com/fr/news-insights/news/am-pharma-announces-the-appointment-of-bart-wuurman-as-ceo/ 2025-07-25T16:58:35+00:00 https://forbion.com/fr/news-insights/news/pangenetics-bv-licenses-therapeutic-antibody-from-schering-plough-corporation/ 2025-07-25T17:01:10+00:00 https://forbion.com/fr/news-insights/news/jan-van-heek-joins-pangenetics-supervisory-board/ 2025-07-25T17:00:32+00:00 https://forbion.com/fr/news-insights/news/b-cell-chronic-lymphocytic-leukemia-clinical-trial-initiated-with-argos-therapeutics-ags-005-personalized-immunotherapy/ 2025-07-25T17:08:08+00:00 https://forbion.com/fr/news-insights/news/argenta-discovery-and-astrazeneca-sign-a-research-collaboration-and-licensing-agreement-to-discover-improved-bronchodilators-for-copd/ 2025-07-25T17:06:42+00:00 https://forbion.com/fr/news-insights/news/fda-approves-enzon-ind-for-santaris-pharmas-second-new-cancer-drug/ 2025-07-25T17:12:31+00:00 https://forbion.com/fr/news-insights/news/analysis-by-algonomics-reveals-that-anticalins-intrinsically-have-an-immunogenicity-level-comparable-to-the-wild-type-human-lipocalin/ 2025-07-25T17:15:31+00:00 https://forbion.com/fr/news-insights/news/amsterdam-molecular-therapeutics-bv-amt-acquires-license-to-aav-patents-from-targeted-genetics-corporation/ 2025-07-25T17:17:08+00:00 https://forbion.com/fr/news-insights/news/first-closing-of-biogeneration-ventures-fund/ 2025-07-28T15:44:21+00:00 https://forbion.com/fr/news-insights/news/pathway-medical-closes-25-million-series-b-funding-raising/ 2025-07-28T15:45:20+00:00 https://forbion.com/fr/news-insights/news/pieris-confirms-in-vivo-activity-of-potent-vegf-specific-anticalin/ 2025-07-28T15:47:55+00:00 https://forbion.com/fr/news-insights/news/cytheris-closes-eur-243m-usd-307m-series-b-financing-funds-to-progress-phase-ii-clinical-studies-of-il-7-to-treat-hiv/ 2025-07-28T15:47:01+00:00 https://forbion.com/fr/news-insights/news/alantos-pharmaceuticals-and-servier-form-collaboration/ 2025-07-28T15:48:40+00:00 https://forbion.com/fr/news-insights/news/claus-braestrup-ceo-of-lundbeck-appointed-to-santaris-pharma-board/ 2025-07-28T15:50:17+00:00 https://forbion.com/fr/news-insights/news/synox-therapeutics-completes-enrollment-in-registrational-phase-3-tangent-clinical-trial-significantly-ahead-of-timeline/ 2025-08-12T13:40:33+00:00 https://forbion.com/fr/news-insights/news/newamsterdam-pharma-presents-positive-data-from-broadway-trial-demonstrating-statistically-significant-reductions-in-key-alzheimer-s-disease-biomarkers-at-aaic-2025/ 2025-08-13T10:02:40+00:00 https://forbion.com/fr/news-insights/news/azafaros-announces-initiation-of-two-global-phase-3-studies-with-nizubaglustat-in-niemann-pick-disease-type-c-npc-and-gm1gm2-gangliosidoses-respectively/ 2025-08-12T14:05:52+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-3725-million-series-d-financing-in-maplight-therapeutics/ 2025-08-12T14:13:30+00:00 https://forbion.com/fr/news-insights/news/citryll-announces-formation-of-scientific-advisory-board/ 2025-08-12T14:18:03+00:00 https://forbion.com/fr/news-insights/news/prilenia-and-ferrer-provide-update-on-european-regulatory-process-for-pridopidine-in-huntington-s-disease/ 2025-08-12T15:36:11+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-receives-fda-clearance-to-progress-stargardt-disease-asset-aavb-039-into-celeste-a-phase-12-clinical-trial/ 2025-08-12T15:42:15+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-bio-announces-fda-fast-track-designation-for-aavb-039-for-the-treatment-of-stargardt-disease/ 2025-08-27T12:33:57+00:00 https://forbion.com/fr/news-insights/news/calluna-pharma-announces-initiation-of-phase-2-aurora-study-of-cal101-for-idiopathic-pulmonary-fibrosis/ 2025-08-27T09:48:44+00:00 https://forbion.com/fr/news-insights/news/inflazome-receives-funding-from-the-michael-j-fox-foundation-for-parkinson-s-research/ 2025-09-05T14:56:43+00:00 https://forbion.com/fr/news-insights/news/first-patient-dosed-in-citrylls-phase-iia-trial-evaluating-cit-013-i-rheumatoid-arthritis/ 2025-09-05T15:58:09+00:00 https://forbion.com/fr/news-insights/news/nature-medicine-publishes-phase-3-data-on-pridopidine-in-early-stage-huntington-s-disease-highlighting-impact-on-clinical-progression/ 2025-09-10T11:50:57+00:00 https://forbion.com/fr/news-insights/news/forbion-impact-esg-report-2024/ 2025-09-16T15:16:36+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-45m-series-a-in-genomines/ 2025-09-17T10:06:33+00:00 https://forbion.com/fr/news-insights/news/vectory-therapeutics-and-shape-therapeutics-announce-option-and-license-agreement/ 2025-09-18T11:27:15+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-95m-series-b-in-sparrow-pharmaceuticals/ 2025-09-24T12:33:10+00:00 https://forbion.com/fr/news-insights/news/forbion-portfolio-company-orbis-medicines-named-in-2025-endpoints-11/ 2025-09-19T21:11:03+00:00 https://forbion.com/fr/news-insights/news/catalym-announces-first-patient-dosed-in-phase-2b-trial-evaluating-visugromab-in-combination-with-chemoimmunotherapy-as-first-line-treatment-in-metastatic-non-squamous-nsclc/ 2025-09-30T15:27:56+00:00 https://forbion.com/fr/news-insights/news/kynexis-announces-first-patient-dosed-in-phase-2-clinical-trial-of-kyn-5356-for-cognitive-impairment-associated-with-schizophrenia/ 2025-10-01T07:48:57+00:00 https://forbion.com/fr/news-insights/news/jon-edwards-phd-appointed-partner/ 2025-10-01T12:02:14+00:00 https://forbion.com/fr/news-insights/news/am-pharma-completes-enrollment-in-phase-2-study-of-ilofotase-alfa-for-prevention-of-cardiac-surgery-associated-renal-damage/ 2025-10-02T10:49:38+00:00 https://forbion.com/fr/news-insights/news/maplight-therapeutics-announces-commencement-of-initial-public-offering/ 2025-10-07T12:50:14+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-receives-fda-ind-clearance-to-advance-ctx001-into-opti-gain-a-phase-iii-clinical-trial-in-geographic-atrophy-secondary-to-amd/ 2025-10-08T13:18:28+00:00 https://forbion.com/fr/news-insights/news/expedition-therapeutics-raises-165-million-in-oversubscribed-series-a-financing-to-advance-next-generation-dpp1-inhibitor-for-copd/ 2025-10-09T11:59:41+00:00 https://forbion.com/fr/news-insights/news/prilenia-and-ferrer-to-share-new-data-and-analyses-of-pridopidine-s-impact-on-huntington-s-disease-at-the-huntington-study-group-hsg-congress/ 2025-10-10T13:05:27+00:00 https://forbion.com/fr/news-insights/news/forbion-promotes-mathias-vinther-phd-to-partner-within-its-growth-strategy/ 2025-10-21T11:52:56+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-70-million-series-a-financing-for-elevara-medicines-to-advance-phase-2-rheumatoid-arthritis-trial-and-expand-pipeline/ 2025-10-22T06:35:43+00:00 https://forbion.com/fr/news-insights/news/plattform-life-sciences-interview/ 2025-10-22T11:31:03+00:00 https://forbion.com/fr/news-insights/news/europe-s-biotech-and-healthcare-future-depends-on-more-capital-faster-access-and-smarter-incentives/ 2025-10-27T09:47:22+00:00 https://forbion.com/fr/news-insights/news/maplight-therapeutics-announces-pricing-of-initial-public-offering/ 2025-10-27T10:07:07+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-20m-series-a-in-pact-to-scale-revolutionary-biomaterials/ 2025-10-30T07:52:03+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-141-million-series-b-of-aavantgarde-bio-to-accelerate-gene-therapies-for-stargardt-disease-and-usher-1b-syndrome/ 2025-11-03T08:36:58+00:00 https://forbion.com/fr/news-insights/news/forbion-appoints-joy-faucher-as-general-partner-to-support-continued-growth-in-its-bioeconomy-strategy/ 2025-11-03T19:03:12+00:00 https://forbion.com/fr/news-insights/news/forbion-closes-oversubscribed-bioeconomy-fund-i-at-200-million-hard-cap/ 2025-11-05T07:08:59+00:00 https://forbion.com/fr/news-insights/news/braveheart-bio-launches-with-185m-series-a-aiming-to-transform-care-of-hypertrophic-cardiomyopathy/ 2025-11-05T12:20:24+00:00 https://forbion.com/fr/news-insights/news/noema-pharma-announces-phase-2a-study-results-with-cendifensine-in-women-with-vasomotor-symptoms-hot-flashes-due-to-menopause/ 2025-11-06T15:39:07+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-65-million-series-b-financing-in-gate-bioscience-to-advance-first-in-class-oral-molecular-gate-medicines-into-the-clinic/ 2025-11-13T13:01:21+00:00 https://forbion.com/fr/news-insights/news/numab-therapeutics-and-kaken-pharmaceutical-announce-licensing-and-co-development-agreement-for-multispecific-antibody-nm81-in-inflammatory-bowel-disease-ibd/ 2025-11-13T13:31:22+00:00 https://forbion.com/fr/news-insights/news/financial-investigator-strategic-autonomy-begins-with-a-strong-home-market/ 2025-11-24T10:12:10+00:00 https://forbion.com/fr/news-insights/news/fierce-biotech-jefferies-london-conference-cements-reputation-as-jp-morgan-for-europe/ 2025-11-24T10:12:34+00:00 https://forbion.com/fr/news-insights/news/financial-times-the-looming-patent-cliff-facing-big-pharma/ 2025-11-24T10:03:27+00:00 https://forbion.com/fr/news-insights/news/financial-times-europe-s-plan-to-finally-make-its-single-market-work/ 2025-11-24T10:11:29+00:00 https://forbion.com/fr/news-insights/news/financial-times-rapid-trials-prompt-deals-rush-for-chinese-super-me-too-drugs/ 2025-11-24T10:17:57+00:00 https://forbion.com/fr/news-insights/news/fierce-biotech-people-are-getting-used-to-it-global-uncertainties-cant-dampen-upbeat-jefferies-conference/ 2025-11-25T16:38:48+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-oversubscribed-130-million-series-b-financing-in-protego-biopharma/ 2025-12-01T11:04:01+00:00 https://forbion.com/fr/news-insights/news/vectory-therapeutics-receives-fda-clearance-of-ind-to-proceed-with-the-pioneer-als-phase-12-trial-of-vtx-002-a-first-in-class-vectorized-antibody-targeting-tdp-43-pathology-in-als/ 2025-12-03T16:12:20+00:00 https://forbion.com/fr/news-insights/news/enterprise-therapeutics-publishes-results-of-phase-1-study-of-etd001-a-novel-inhaled-enac-blocker-for-treatment-of-cystic-fibrosis-in-the-journal-of-cystic-fibrosis/ 2025-12-09T17:25:39+00:00 https://forbion.com/fr/news-insights/news/vor-bio-announces-150-million-private-placement/ 2025-12-15T13:07:56+00:00 https://forbion.com/fr/news-insights/news/calluna-pharma-announces-the-appointment-of-gijs-van-den-brink-md-phd-as-independent-director/ 2025-12-16T13:34:19+00:00 https://forbion.com/fr/news-insights/news/rectify-and-boehringer-ingelheim-collaborate-to-advance-first-in-class-treatments-for-chronic-kidney-disease/ 2025-12-22T21:33:09+00:00 https://forbion.com/fr/news-insights/news/loqus23-therapeutics-nominates-lqt-23-as-first-in-class-oral-drug-candidate-for-huntington-s-disease/ 2026-01-06T12:24:25+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-80-million-series-a-financing-in-corsera-health/ 2026-01-07T13:08:40+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-announces-fda-fast-track-designation-for-ctx001-for-the-treatment-of-geographic-atrophy-secondary-to-amd/ 2026-01-08T07:53:59+00:00 https://forbion.com/fr/news-insights/news/vectory-therapeutics-receives-fda-fast-track-designation-for-vtx-002-a-first-in-class-vectorized-antibody-targeting-underlying-disease-biology-in-als/ 2026-01-08T12:04:15+00:00 https://forbion.com/fr/news-insights/news/beacon-therapeutics-announces-closing-of-oversubscribed-series-c-financing-for-over-75-million/ 2026-01-08T12:03:54+00:00 https://forbion.com/fr/news-insights/news/aavantgarde-completes-enrollment-in-luce-1-phase-12-clinical-trial-of-aavb-081-for-usher-syndrome-type-b-associated-retinitis-pigmentosa/ 2026-01-15T19:06:19+00:00 https://forbion.com/fr/news-insights/news/forbion-is-top-lead-investor-by-deal-count-in-2025-analysis/ 2026-01-19T16:17:31+00:00 https://forbion.com/fr/news-insights/news/forbion-announces-second-exit-from-forbion-growth-fund-iii-following-22-billion-acquisition-of-rapt-therapeutics-by-gsk/ 2026-01-21T12:34:49+00:00 https://forbion.com/fr/news-insights/news/seamless-therapeutics-announces-global-research-collaboration-with-lilly-to-develop-programmable-recombinase-based-therapeutics-for-hearing-loss/ 2026-01-28T12:25:01+00:00 https://forbion.com/fr/news-insights/news/sparrow-appoints-biopharmaceutical-industry-veteran-carlo-incerti-md-to-its-board-of-directors/ 2026-02-02T15:03:09+00:00 https://forbion.com/fr/news-insights/news/vectory-therapeutics-announces-first-participant-dosed-in-phase-12-pioneer-als-clinical-trial-of-vtx-002-in-people-with-amyotrophic-lateral-sclerosis-als/ 2026-02-09T12:04:08+00:00 https://forbion.com/fr/news-insights/news/forbion-joins-newly-launched-european-life-sciences-coalition/ 2026-02-12T14:45:05+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-oversubscribed-75-million-series-b-financing-in-altesa-biosciences-to-transform-the-treatment-of-chronic-lung-diseases/ 2026-02-19T12:05:50+00:00 https://forbion.com/fr/news-insights/news/forbion-co-leads-130-million-series-a-financing-in-slate-medicines-to-advance-anti-pacap-therapies-for-the-prevention-of-migraine-and-other-headache-disorders/ 2026-03-11T11:37:51+00:00 https://forbion.com/fr/news-insights/news/forbion-leads-105-million-series-c-in-tropic-to-scale-commercial-rollout-of-gene-edited-tropical-crops/ 2026-03-12T09:11:54+00:00 https://forbion.com/fr/news-insights/news/mestag-therapeutics-announces-40-million-financing-and-appoints-chief-medical-officer-and-chief-development-officer-in-preparation-for-clinic/ 2026-03-17T08:21:45+00:00 https://forbion.com/fr/news-insights/news/elevara-medicines-doses-first-patient-in-phase-2b-start-synergy-trial-of-elv001-in-rheumatoid-arthritis-patients-with-incomplete-response-to-tnfi/ 2026-03-16T13:23:57+00:00 https://forbion.com/fr/news-insights/news/amphista-therapeutics-appoints-louise-modis-as-ceo-and-patrick-kelly-md-as-cmo-and-provides-a-business-update-as-the-company-prepares-to-file-ind-application-for-amx-883/ 2026-03-19T16:39:02+00:00 https://forbion.com/fr/news-insights/news/anaveon-appoints-biotech-leader-thaminda-ramanayake-as-chief-executive-officer/ 2026-03-25T08:30:37+00:00 https://forbion.com/fr/news-insights/news/complement-therapeutics-announces-first-patient-dosed-with-ctx001-in-the-phase-iii-opti-gain-study-for-geographic-atrophy-secondary-to-amd/ 2026-03-25T08:59:58+00:00 https://forbion.com/fr/news-insights/news/prilenia-and-ferrer-announce-first-participant-enrolled-in-the-prevails-phase-3-study-of-pridopidine-in-als/ 2026-03-30T11:30:06+00:00 https://forbion.com/fr/news-insights/news/hengrui-pharma-and-braveheart-bio-announce-positive-phase-2-results-with-hrsbhb-1893-in-obstructive-hypertrophic-cardiomyopathy/ 2026-03-31T09:07:39+00:00 https://forbion.com/fr/news-insights/news/braveheart-bio-appoints-emil-degoma-md-as-chief-medical-officer/ 2026-03-31T09:11:22+00:00 https://forbion.com/fr/news-insights/news/cellcentric-initiates-dommino-1-a-pivotal-phase-2-clinical-trial-of-inobrodib-in-combination-with-pomalidomide-and-dexamethasone-inopd-in-relapsed-or-refractory-multiple-myeloma/ 2026-03-31T14:15:50+00:00 https://forbion.com/fr/news-insights/news/northsea-therapeutics-bolsters-board-as-orziloben-moves-into-late-stage-development/ 2026-03-31T15:42:58+00:00 https://forbion.com/fr/news-insights/insights/ 2025-09-10T09:35:06+00:00 https://forbion.com/fr/news-insights/insights/the-biotech-pulse-s1e1-the-manufacturing-of-complex-biologics/ 2025-08-08T14:16:14+00:00 https://forbion.com/fr/news-insights/insights/the-biotech-pulse-s1e2-navigating-the-ma-landscape-for-biotech-success/ 2025-08-08T14:16:05+00:00 https://forbion.com/fr/news-insights/insights/the-biotech-pulse-s1e3-empowering-womens-health-a-conversation-with-mary-kerr-ceo-of-nerre-therapeutics/ 2025-08-08T14:16:39+00:00 https://forbion.com/fr/news-insights/insights/the-biotech-pulse-s1e4-the-role-of-biotech-as-the-discovery-engine-for-pharma/ 2025-08-08T14:16:54+00:00 https://forbion.com/fr/news-insights/insights/the-biotech-pulse-s1e5-biotech-innovations-and-sustainability/ 2025-08-08T14:17:12+00:00 https://forbion.com/fr/news-insights/insights/the-biotech-pulse-s1e6-advancing-womens-health-bridging-gaps-in-innovation-and-action/ 2025-08-08T14:17:27+00:00 https://forbion.com/fr/news-insights/insights/the-biotech-pulse-s1e7-trust-translation-and-therapeutics-the-story-of-complement-therapeutics/ 2025-08-08T14:17:43+00:00 https://forbion.com/fr/news-insights/insights/get-to-know-forbion/ 2025-07-30T14:52:40+00:00 https://forbion.com/fr/news-insights/insights/our-role-in-the-rare-diseases-market/ 2025-08-21T14:07:20+00:00 https://forbion.com/fr/news-insights/insights/forbions-history-in-the-development-of-gene-therapies/ 2025-08-27T09:57:56+00:00 https://forbion.com/fr/news-insights/insights/our-investment-approach-for-companies-developing-precision-treatments-for-rare-diseases/ 2025-08-21T14:11:17+00:00 https://forbion.com/fr/news-insights/insights/special-event-with-the-cambridge-judge-business-school-smart-capital-leveraged-science-how-vcs-unlock-biotech-potential/ 2025-08-27T09:57:08+00:00 https://forbion.com/fr/news-insights/insights/the-biotech-pulse-s1e8-special-edition-with-cambridge-judge-business-school-smart-capital-leveraged-science-how-vcs-unlock-biotech-potential/ 2025-09-09T12:43:09+00:00 https://forbion.com/fr/news-insights/insights/bloomberg-vanguards-of-health-inside-forbion-s-ma-first-playbook-for-building-europe-s-biotech-winners/ 2025-09-09T19:34:30+00:00 https://forbion.com/fr/news-insights/insights/wxpress-interview-with-forbion-general-partner-marco-boorsma-phd/ 2025-11-14T09:43:09+00:00 https://forbion.com/fr/news-insights/insights/forbion-portfolio-company-calluna-pharma-highlighted-in-a-new-biocentury-ipf-article/ 2026-03-13T09:26:59+00:00 https://forbion.com/fr/news-insights/insights/20-years-of-forbion-investing-with-impact/ 2026-03-30T09:51:27+00:00 https://forbion.com/fr/news-insights/events/ 2026-03-16T10:04:03+00:00 https://forbion.com/fr/news-insights/events/the-2025-cell-gene-meeting-on-the-med/ 2025-08-15T11:29:39+00:00 https://forbion.com/fr/news-insights/events/invest-europe-sustainability-in-a-changing-geopolitical-landscape-what-you-need-to-know/ 2025-08-12T16:22:49+00:00 https://forbion.com/fr/news-insights/events/18th-annual-european-life-sciences-ceo-forum/ 2025-08-15T11:29:57+00:00 https://forbion.com/fr/news-insights/events/ipem/ 2025-08-13T09:44:53+00:00 https://forbion.com/fr/news-insights/events/sachs-associates-1st-biopharma-obesity-innovation-forum-for-science-drug-development-technology-and-investment/ 2025-08-15T11:30:13+00:00 https://forbion.com/fr/news-insights/events/dutch-life-sciences-conference-leiden/ 2025-08-15T11:30:30+00:00 https://forbion.com/fr/news-insights/events/world-agri-tech-innovation-summit/ 2025-08-15T11:30:46+00:00 https://forbion.com/fr/news-insights/events/nordic-life-science-days-nls-days-2024/ 2025-08-15T11:31:05+00:00 https://forbion.com/fr/news-insights/events/10th-lsx-world-congress/ 2025-08-15T11:31:24+00:00 https://forbion.com/fr/news-insights/events/swiss-biotech-day-2024/ 2025-08-15T11:31:39+00:00 https://forbion.com/fr/news-insights/events/anglonordic-life-science-conference/ 2025-08-15T11:31:56+00:00 https://forbion.com/fr/news-insights/events/0100-conference-europe-2024/ 2025-08-14T14:44:51+00:00 https://forbion.com/fr/news-insights/events/bio-europe-spring-2024/ 2025-08-15T11:36:40+00:00 https://forbion.com/fr/news-insights/events/17th-annual-european-life-sciences-ceo-forum-for-partnering-investment/ 2025-08-15T11:36:58+00:00 https://forbion.com/fr/news-insights/events/bio-neuroscience/ 2025-08-15T11:37:27+00:00 https://forbion.com/fr/news-insights/events/ipem-cannes-2024/ 2025-08-14T15:13:39+00:00 https://forbion.com/fr/news-insights/events/nordic-life-science-days/ 2025-08-15T11:38:18+00:00 https://forbion.com/fr/news-insights/events/jefferies-2023-london-healthcare-conference/ 2025-08-15T11:38:33+00:00 https://forbion.com/fr/news-insights/events/inv-tival-showcase/ 2025-08-15T11:39:02+00:00 https://forbion.com/fr/news-insights/events/bioeurope-fall/ 2025-08-15T11:39:30+00:00 https://forbion.com/fr/news-insights/events/the-esmo-conference/ 2025-08-15T11:39:58+00:00 https://forbion.com/fr/news-insights/events/international-partnering-strategy-investment-for-nordic-life-science-executive-leaders-lsx/ 2025-08-15T11:40:18+00:00 https://forbion.com/fr/news-insights/events/23rd-annual-biotech-in-europe-forum/ 2025-08-15T11:41:08+00:00 https://forbion.com/fr/news-insights/events/sachs-forum/ 2025-08-15T11:40:52+00:00 https://forbion.com/fr/news-insights/events/ipls-amsterdam-future-life-cycles/ 2025-08-14T15:50:59+00:00 https://forbion.com/fr/news-insights/events/lsx-congress-usa/ 2025-08-15T11:41:43+00:00 https://forbion.com/fr/news-insights/events/on-the-road-amsterdam-2023/ 2025-08-15T11:42:08+00:00 https://forbion.com/fr/news-insights/events/bio-quity-europe-2023/ 2025-08-15T11:42:23+00:00 https://forbion.com/fr/news-insights/events/lsx-world-congress-2023/ 2025-08-15T11:42:40+00:00 https://forbion.com/fr/news-insights/events/economist-impact-cell-and-gene-therapy-summit/ 2025-08-15T11:43:05+00:00 https://forbion.com/fr/news-insights/events/biovaria-munich/ 2025-08-15T11:43:40+00:00 https://forbion.com/fr/news-insights/events/swiss-biotech-day/ 2025-08-15T11:43:25+00:00 https://forbion.com/fr/news-insights/events/anglo-nordic-life-science-conference/ 2025-08-15T11:32:06+00:00 https://forbion.com/fr/news-insights/events/innovation-for-health-2023/ 2025-08-15T11:44:10+00:00 https://forbion.com/fr/news-insights/events/interact-2023-science-translation/ 2025-08-14T16:27:03+00:00 https://forbion.com/fr/news-insights/events/bio-europe-spring/ 2025-08-15T11:28:07+00:00 https://forbion.com/fr/news-insights/events/the-16th-annual-european-life-sciences-ceo-forum/ 2025-08-15T11:26:34+00:00 https://forbion.com/fr/news-insights/events/forbion-managing-partner-geert-jan-mulder-is-guest-speaker-at-the-talentmark-leiden-office-opening/ 2025-08-15T11:25:22+00:00 https://forbion.com/fr/news-insights/events/biofit/ 2025-08-15T11:23:03+00:00 https://forbion.com/fr/news-insights/events/dutch-life-sciences-conference/ 2025-08-15T11:20:05+00:00 https://forbion.com/fr/news-insights/events/world-orphan-drug-congress-2022/ 2025-08-15T11:14:28+00:00 https://forbion.com/fr/news-insights/events/inv-tival-showcase-2022/ 2025-08-15T11:16:17+00:00 https://forbion.com/fr/news-insights/events/nvp-seminar-vuca-world-volatility-uncertainty-complexity-ambiguity/ 2025-08-15T11:13:22+00:00 https://forbion.com/fr/news-insights/events/onco-cell-therapy-summit-europe-2022/ 2025-08-15T11:11:46+00:00 https://forbion.com/fr/news-insights/events/bioeurope/ 2025-08-15T11:10:18+00:00 https://forbion.com/fr/news-insights/events/high-tech-gruenderfonds-7th-life-science-pitch-day/ 2025-08-15T09:59:16+00:00 https://forbion.com/fr/news-insights/events/22nd-annual-biotech-in-europe-forum-for-global-partnering-investment/ 2025-08-15T09:57:25+00:00 https://forbion.com/fr/news-insights/events/ipem-2022/ 2025-08-15T09:52:43+00:00 https://forbion.com/fr/news-insights/events/european-forum/ 2025-08-15T09:50:49+00:00 https://forbion.com/fr/news-insights/events/lsx-nordic-congress/ 2025-08-15T09:48:42+00:00 https://forbion.com/fr/news-insights/events/retina-forum/ 2025-08-15T09:47:19+00:00 https://forbion.com/fr/news-insights/events/advanced-therapies-europe/ 2025-08-15T09:46:07+00:00 https://forbion.com/fr/news-insights/events/8th-annual-lsx-world-conference/ 2025-08-15T09:39:05+00:00 https://forbion.com/fr/news-insights/events/venture-challenge/ 2025-08-15T09:37:03+00:00 https://forbion.com/fr/news-insights/events/global-investor-forum-grow-present-connect/ 2025-08-15T09:35:30+00:00 https://forbion.com/fr/news-insights/events/5th-annual-neuroscience-innovation-forum-for-business-development-licensing-investment/ 2025-08-15T09:31:39+00:00 https://forbion.com/fr/news-insights/events/15th-annual-european-life-sciences-ceo-forum/ 2025-08-15T09:30:10+00:00 https://forbion.com/fr/news-insights/events/lsx-world-conference/ 2025-08-15T09:27:26+00:00 https://forbion.com/fr/news-insights/events/3rd-annual-goodwin-kpmg-jpmorgan-symposium/ 2025-08-15T09:05:42+00:00 https://forbion.com/fr/news-insights/events/the-next-frontiers-in-tackling-age-related-disorders/ 2025-08-15T09:01:25+00:00 https://forbion.com/fr/news-insights/events/redefining-early-stage-investments-resi-conference/ 2025-08-15T09:03:35+00:00 https://forbion.com/fr/news-insights/events/super-return-international/ 2025-08-15T08:58:17+00:00 https://forbion.com/fr/news-insights/events/life-sciences-tuesdays/ 2025-08-15T08:59:34+00:00 https://forbion.com/fr/news-insights/events/lsx-inv-tival-showcase/ 2025-08-15T08:57:05+00:00 https://forbion.com/fr/news-insights/events/venture-capital-forum-2021/ 2025-08-15T08:55:12+00:00 https://forbion.com/fr/news-insights/events/european-biopharma-summit/ 2025-08-15T08:53:25+00:00 https://forbion.com/fr/news-insights/events/bio-europe-2025/ 2025-08-27T12:49:11+00:00 https://forbion.com/fr/news-insights/events/women-s-private-equity-summit-europe-2025/ 2025-09-17T06:58:40+00:00 https://forbion.com/fr/news-insights/events/biocentury-grand-rounds-europe/ 2025-09-17T07:02:33+00:00 https://forbion.com/fr/news-insights/events/frame-2025/ 2025-09-17T06:59:25+00:00 https://forbion.com/fr/news-insights/events/ipem-paris-2025/ 2025-09-17T06:59:42+00:00 https://forbion.com/fr/news-insights/events/25th-annual-biotech-in-europe-forum/ 2025-09-17T07:00:07+00:00 https://forbion.com/fr/news-insights/events/venture-capital-forum-2025/ 2025-09-17T07:00:17+00:00 https://forbion.com/fr/news-insights/events/climate-week-nyc/ 2025-09-24T13:55:24+00:00 https://forbion.com/fr/news-insights/events/superreturn-cfocoo-2025/ 2025-09-26T09:53:10+00:00 https://forbion.com/fr/news-insights/events/nordic-life-science-nls-days-2025/ 2025-10-01T12:34:35+00:00 https://forbion.com/fr/news-insights/events/european-society-of-medical-oncology-esmo-2025/ 2025-10-01T12:34:11+00:00 https://forbion.com/fr/news-insights/events/ilpa-summit-2025/ 2025-10-01T12:36:17+00:00 https://forbion.com/fr/news-insights/events/super-return-europe-2025/ 2025-10-01T12:39:37+00:00 https://forbion.com/fr/news-insights/events/private-equity-insights-2025/ 2025-10-02T08:23:43+00:00 https://forbion.com/fr/news-insights/events/jp-morgan-health-conference-2026/ 2026-01-05T14:29:19+00:00 https://forbion.com/fr/news-insights/events/ipem-wealth-2026/ 2026-02-03T14:01:59+00:00 https://forbion.com/fr/news-insights/events/endpoints-events-2026-the-top-100-venture-investors-in-biotech/ 2026-02-26T08:51:25+00:00 https://forbion.com/fr/news-insights/events/lsx-world-congress-europe-2026/ 2026-03-13T12:51:00+00:00 https://forbion.com/fr/news-insights/events/adpd-2026/ 2026-03-13T14:47:45+00:00 https://forbion.com/fr/news-insights/events/46th-annual-td-cowen-health-care-conference/ 2026-03-16T09:54:17+00:00 https://forbion.com/fr/news-insights/events/biocapital-2026/ 2026-03-16T09:51:40+00:00 https://forbion.com/fr/news-insights/events/19th-annual-european-life-sciences-ceo-forum/ 2026-03-16T10:00:05+00:00 https://forbion.com/fr/news-insights/events/lsx-investival-showcase-usa-2026/ 2026-03-17T08:27:17+00:00 https://forbion.com/fr/news-insights/events/bioeurope-spring-2026/ 2026-03-20T15:24:20+00:00 https://forbion.com/fr/news-insights/events/anglonordic-life-science-conference-xxii/ 2026-03-26T10:59:48+00:00 https://forbion.com/fr/news-insights/events/biovaria-2026/ 2026-03-26T10:59:35+00:00 https://forbion.com/fr/news-insights/events/strengthening-european-biotechnology-policy-pathways-towards-the-biotech-act-ii/ 2026-03-27T11:42:01+00:00 https://forbion.com/fr/news-insights/events/investor-relations-network-new-york-forum/ 2026-03-27T11:47:35+00:00 https://forbion.com/fr/news-insights/events/rethinking-materials-innovation-and-investment-summit/ 2026-03-27T11:01:48+00:00 https://forbion.com/fr/news-insights/media-resources/ 2025-09-10T09:35:32+00:00 https://forbion.com/fr/news-insights/media-resources/the-biotech-pulse/ 2025-08-29T13:13:58+00:00 https://forbion.com/fr/news-insights/media-resources/icons/ 2025-08-29T10:23:20+00:00 https://forbion.com/fr/news-insights/media-resources/senior-team/ 2025-08-29T13:05:11+00:00 https://forbion.com/fr/news-insights/media-resources/logos/ 2025-08-29T13:08:37+00:00 https://forbion.com/fr/contact/ 2025-09-15T08:23:22+00:00 https://forbion.com/fr/grievances/ 2025-09-10T09:38:45+00:00 https://forbion.com/fr/page-not-found/ 2025-08-26T14:43:16+00:00 https://forbion.com/fr/search/ 2025-04-30T10:19:12+00:00 https://forbion.com/fr/rss/ 2025-04-30T10:19:12+00:00 https://forbion.com/fr/sitemap/ 2025-04-30T10:19:12+00:00 https://forbion.com/fr/sitemap-xml/ 2025-04-30T10:19:12+00:00